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   Abstract 
Abstract 
 
Within a number of industries, and particularly within the pharmaceutical industry, there is 
a desire for reliable, high yielding routes towards large numbers of valuable small 
molecules that allow a wide range of products to be synthesised. 
 
Heterocyclic compounds are particularly sought after as useful compounds, with an 
estimated 70% of pharmaceutical products being based on heterocyclic structures. A 
drawback of many traditional routes towards heterocyclic compounds is that the range of 
substituents that may be placed around the ring is limited. This is especially limiting if ring 
substituents have to be placed early in a synthesis, reducing the opportunities for 
elaboration at a late stage. 
 
Our approach is to take highly halogenated heterocyclic systems and use them as scaffolds 
for the synthesis of novel compounds by the sequential replacement of halogen atoms with 
other functionalities. 
 
This approach has led to the generation of a number of novel highly substituted 
heterocyclic species. 
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Chapter 1 
 
Introduction 
 
1.1 The Pharmaceutical Industry 
 
Historically, the birth of the pharmaceutical industry can be seen as being closely related to 
the growth of the synthetic dye industry, both of them being lent impetus by the burgeoning 
state of research into coal tar derivatives towards the end of the nineteenth century. Much 
of this research flowed from Liebig, lauded in Germany as the father of organic chemistry, 
and his seminal chemistry school at Giessen,1 through which passed such famous names as 
Erlenmeyer, Fehling, and Kekule.  
 
At the time, the great demand for quinine, and its resultant high cost, had led to attempts to 
produce it synthetically. Liebig had unsuccessfully turned his hand to the artificial 
generation of quinine,2 and this, coupled with the increasing recognition of the similarities 
between coal tar bases and the decomposition products of plant alkaloids, led Hofmann, 
himself a leading researcher of coal tar derivatives and a former pupil of Liebig, to consider 
the possibility of forming quinine via the introduction of the amine functionality to 
naphthalene. The proposed synthesis was unsuccessful, but research carried out by one of 
Hofmann’s students resulted in the discovery of mauveine, the first synthetic dye. An 
offshoot of the new chemical dye industry was the application of its products to biology. 
The existence of “chemoreceptors” in living systems was suggested by the medical student 
Paul Ehrlich, based upon the observation that dyes demonstrated selective affinities for 
biological tissues.3 It was argued that the chemoreceptors of certain parasites and microbes 
would differ from those found in the host and, as such, could be targeted. Ehrlich expressed 
this concept as the search for “magic bullets” that would specifically target the organisms at 
which they were aimed, and it forms the basis of modern chemotherapy.4 
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1.2 Modern Drug Discovery 
 
As far as drug discovery is concerned, until recently many lead structures were found by 
screening microbial broths, plant extracts, and existing compound collections.5 This 
changed with the advent of combinatorial chemistry, coupled with high throughput 
screening (HTS), whereby vast libraries of compounds were synthesised simultaneously, 
and then all screened to determine useful bioactivity and find ‘hits’.6 
 
While at first it was envisaged that these techniques would lead to a huge increase in the 
number of hit compounds found, it is coming to be acknowledged that investment in this 
technology has not provided the rewards imagined. To give some idea of the success rate of 
standard HTS, it has been suggested that in a screen for even a relatively “easy” target, 
typically one high quality lead compound may be found out of 100,000 molecules tested.7  
 
One explanation for this is that while combinatorial chemistry undoubtedly produces large 
numbers of compounds, the very fact that syntheses have been designed to give as much 
structural variety as possible means that a large proportion of the compounds produced for 
screening are not “drug-like”, and are therefore unlikely to possess the bioactivity 
necessary to be useful lead compounds. 
 
The primary problem in drug development is that a large proportion of hit compounds must 
be abandoned during clinical development because of unsuitable pharmacokinetic 
properties. Consequently, steps are being taken to recognise the properties that make a 
molecule drug-like, and to increase the drug-likeness during the lead optimisation process.8 
 
A major advance in this area was the publication of Lipinski’s “rules of five”,9 a set of 
guidelines which stated that orally available drug-like molecules: have a molecular weight 
less than or equal to 500; have a log P (where P is a partition coefficient) that is less than or 
equal to 5; have 5 or fewer H-bond donors (NH and OH); and have 10 or fewer H-bond 
acceptors (N and O). The rules do not apply to substrates of transporters and natural 
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products. It has been found that the rule of five is associated with 90% of orally active 
drugs that have achieved phase II status.10 More recent extensions to the rules include the 
observations that the polar surface area should be less than 140 Å2 (or that the sum of H-
bond donors and acceptors should be less than or equal to 12) and that there should be no 
more than 10 rotatable bonds.11 
 
As these concepts of drug-likeness are becoming understood and acted upon, a 
corresponding reduction in the attrition rate of new chemical entities (NCEs) during clinical 
development is being observed.12 Between 1991 and 2000 the percentage of projects 
involving NCEs failing due to bioavailability and pharmacokinetic reasons fell from 40% to 
10%,13 demonstrating the utility of drug-likeness considerations. 
 
1.3 Properties of Heterocyclic Systems 
 
Bearing in mind the points outlined above, it can be seen that appropriately functionalised 
low molecular weight heteroaromatic species may be excellent candidates exhibiting drug-
like properties. In fact, it has been estimated that 70% of pharmaceutical products are based 
upon heterocyclic structures.14 One of the major useful attributes of heterocyclic systems is 
the ability to hold given substituents in well-defined positions in three dimensional space, 
allowing far fewer degrees of conformational freedom than would be afforded by acyclic 
structures.15 In addition to this, the presence of heteroatoms gives greater scope for 
electronic interactions, potentially altering absorption, distribution, metabolism and 
excretion (ADME) properties.  
 
This thesis is concerned with the chemistry of highly halogenated pyridazines and 
thiophenes, two sub-classes of heterocyclic systems, and as such it seems appropriate to 
first give an overview of the typical chemistries of these heterocycles, followed by more 
detailed explorations of the idiosyncrasies of the aforementioned halogenated species. 
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1.4 Pyridazines in Medicinal Chemistry 
 
The relatively recent identification of the pyridazine moiety in Nature 
(hexahydropyridazines were first observed in natural products in 1971,16 and it was many 
more years before the first aromatic pyridazine was described17) has resulted in there 
traditionally being less interest in pyridazines than in the other diazines, however, with the 
freedom for generation of new intellectual property given by the previously sparse covering 
of the area, extensive expansion seems likely. 
 
A number of pharmaceuticals contain the pyridazine moiety, including, but by no means 
limited to, the antibacterials Cefozopran, Cinoxacin, Sulfamethoxypyridazine, and 
Nifurprazine, the antidepressant Minaprine, and the anti-inflammatory and analgesic 
Emorfazone (Figure 1.1).18-20 
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Figure 1.1 
 
1.5 Syntheses of Pyridazines 
 
1.5.1 By Formation of One Bond 
 
A well known method for the construction of pyridazine rings by formation of the inter-
heteroatom bond is the intramolecular oxidative coupling of two amino groups, an 
illustration of which is given below (Scheme 1.1).21 
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Scheme 1.1 
 
A similar process involves the trapping of a nitroso intermediate by a nucleophilic 
heterocycle, leading to the formation of ring fused polyheterocycles, such as the 
pyrrolocinnolineone system shown (Scheme 1.2).22 
 
O
N
H
NO2 N
H
N
O
Zn, NaOH
H2O, EtOH  
 
Scheme 1.2 
 
An alternative class of ring closure reactions, one particularly useful for the synthesis of 
cinnolines, is that involving bond formation adjacent to one of the heteroatoms.  
 
In the case of benzo-fused pyridazines, this bond forming reaction may be between the 
heteroatom and the benzene ring, or between the heteroatom and a carbon atom α- or β- to 
the ring. An example of the first scenario is the synthesis of cinnolin-3-ylio oxides by 
intramolecular nucleophilic aromatic substitution (Scheme 1.3).23 In the first stage, 
hydrazine is introduced to an acid chloride, and the resulting amine may be reacted with the 
aromatic ring, replacing the activated halogen. 
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O2N O2N O2NCOOH
F
O
NH
NF N
N
Oi) Cl2SO
ii) Me2NNH2
aq. NaHCO3
aq. K2CO3
 
Scheme 1.3 
 
An electrophilic carbon atom α- to the ring is utilised in the synthesis of pyrido[3,4-
d]pyridazine derivatives (Scheme 1.4) via an addition-elimination reaction yielding the 
fused heterocycle and hydrazine from the dicarboxhydrazide.24 
 
NMeO
MeO2C
CO2Me
NH2 NMeO
H2NHNOC
CONHNH2
NH2 NMeO NH2
H
N
HN
O
O
hydrazine
monohydrate
EtOH
H2O
 
 
Scheme 1.4 
 
Finally, the new bond may be formed between nitrogen and a carbon atom β- to the ring, 
often part of an alkynyl benzene parent system, as in the Richter cinnoline synthesis 
(Scheme 1.5).25 
 
 
C6H13
NH2
C6H13
N2+Cl- N
N
Cl C6H13NaNO2
HCl
ether/hexane  
 
Scheme 1.5 
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This approach has been extended to allow solid-supported chemistry to be performed.26 In 
this case (Scheme 1.6), treatment of the supported diazo compound with acid allows 
cleavage and cyclisation. 
 
PS
N
Br
N
Ph PS
N
N
Ph
NR
N R
Cl
H R
Pd(OAc)2
NEt3
DMF
HCl
acetone/water  
 
Scheme 1.6 
 
The remaining one bond forming step leading to pyridazines involves creation of a bond γ- 
to a heteroatom. One approach has been the base-induced cyclisation of ortho-
trifluoromethyl phenylhydrazides (Scheme 1.7), whereby initial deprotonation gives a 
quinine methide intermediate which cyclises to the difluoropyridazine, and then reacts 
further with the base to form the final amino pyridazine.27 
 
CF3
N
H
NH2
CF3
N
H
N H
N
N
NH2
C6H5CHO
toluene
NaHMDS
THF
 
Scheme 1.7 
 
A similar method was employed for the syntheses of 3-aroylcinnolines, in which the 
hydrazones were protonated to give a reactive intermediate susceptible to 
electrocyclisation, affording the target compounds after dehydration (Scheme 1.8).28 
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NMe2
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O H O
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Scheme 1.8 
 
Cyclisation may also be effected by an intramolecular reaction between a carbon 
nucleophile and a sufficiently activated electrophilic site, as in the synthesis of a range of 
tricyclic quinolones known to possess considerable antibacterial activity (Scheme 1.9).29 
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N
F
F
O
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N
CO2tBu
tBuO2C
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N
F
F
O
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Scheme 1.9 
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1.5.2 By Formation of Two Bonds 
 
Of the various two bond disconnections leading to fragments of four and two ring atoms, 
the most commonly applied is that which corresponds to the reaction between a four carbon 
motif with a dinitrogen compound, and the most straightforward subclasses of this category 
are the reactions of 1,4-dicarbonyl compounds with hydrazine. 
 
An example of this approach is shown in the synthesis of the kinase inhibitor FR180204, in 
which a pyrazolo-pyridazine motif is constructed by initial formation of a pyridazine-
containing intermediate (Scheme 1.10).30 
N N
O
N N
O
O
OEt
OEt
OOH
O
N+
NH2
I-
KOH
K2CO3
DMSO
O
EtO2C CO2Et
MW
hydrazine
EtOH
N N
N
HN
O
N N
N
HN
O
O
N
H
NH2
c. HCl
N N
N
HN
O
O
OH
O
Cl Oi)
base
ii) aq. NH3
O
NH2
POCl3
N N
N
N
Cl
N
hydrazine
EtOH
N N
N
N
NHN
NH2
FR180204  
 
Scheme 1.10 
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Examples are also known where a nitrile functionality replaces the carbonyl group, leading 
to a 3-aminopyridazine type compound (Scheme 1.11).31 
 
CN
CN
Cl
HO
Cl
Cl
O
CN
CN
Cl
HO
Cl
Cl
N NH2
CNCl
HO
Cl
Cl
N
N
NH2
hydrazine hydrate
EtOH
 
 
Scheme 1.11 
 
The alternative approach involving simultaneous formation of two bonds is the Diels-Alder 
type [4+2] cycloaddition, the most well-known example being the Carboni-Lindsey 
reaction, which involves reaction of a 1,2,4,5-tetrazine with either an alkene or alkyne 
(Scheme 1.12). The use of alkenes initially yields 1,4-dihydropyridazines, which must then 
be oxidised to pyridazines. Pyridazines are directly afforded through the reaction of 
alkynes, the utility of which are, however, lessened by their decreased reactivity and 
propensity to give lower yields.32 
 
N
N N
N
R1
R2
N
HN
R1
R2
N
N
R1
R2
N
N
R1
R2
H2C C CH2
R3
R3
R3
R3 [O]
 
Scheme 1.12 
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The less common type of [4+2] cycloaddition simply involves reaction of an azo dienophile 
with a conjugated diene. This method is especially appropriate for the synthesis of 1,2,3,6-
tetrahydropyridazines, as shown in the example below (Scheme 1.13).33 
 
N
N R
N
N
CF3
CF3
CF3
CF3
F3C CF3
F3C CF3
R
+
 
 
Scheme 1.13 
 
The final class of cycloaddition syntheses are the [3+3] cycloadditions. Cyclopropenes may 
be made to react with diazo compounds to give cycloadducts that upon rearrangement yield 
pyridazines (Scheme 1.14).34 
  
MeO2C
MeO2C
+ H2CN2
N
N
CO2Me
CO2Me
N
H
N
H+
 
 
Scheme 1.14 
 
Finally, a number of ring expansions that convert 5-membered heterocycles into 
pyridazines have been reported, including those of furans, thiophenes, 1-aminopyrrolidines, 
pyrrolidinediones and isoxazolines.35 The most important of these are probably the 
reactions of hydrazine with furans, in a process similar to the condensations between 
hydrazine and 1,4-dicarbonyls outlined above. 
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1.6 Functionalisation of Pyridazines 
 
A simple and versatile approach to substituted pyridazines is deprotonation of the parent 
heterocycle and subsequent trapping with an electrophile. The first factor to be taken into 
account for this method is the relative acidity of the protons in the starting material. A 
selection of informative examples whose pKa’s (in DMSO) have been recently calculated is 
shown below (Figure 1.2).36 
 
N N
N
N N
N
Me Me
39.6
44.7
34.9
40.7 39.6
40.3
41.0
43.6
44.7 31.1
37.9
 
 
Figure 1.2 
 
It can be seen that upon the change from benzene to pyridine, the acidity of the ring protons 
is increased as degree of conjugation in the pi system decreases. The 4-position of pyridine 
is the most susceptible to deprotonation, being furthest from the electronegative 
heteroatom. Addition of a second nitrogen atom increases acidity, and produces two acidic 
domains separated by a pKa difference of approximately 7 units. It is worth noting that the 
trend in acidities round the 6-membered heterocycles differs from that seen in the five-
membered cousins; the decreased external bond angles in the 6-membered cycles increase 
the electron repulsion felt by adjacent electron clouds. 
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This difference in acidity has been exploited using a strong, non-metallic organic base (tBu-
P4) to form the anion, followed by trapping with carbonyl compounds to give pyridazines 
substituted with a secondary or tertiary alcohol at the 4-position (Scheme 1.15).37 
 
N
N
N
N
OH
Ph Ph
Me2N P N P
N
N
N P NMe2
tBu
P
NMe2
NMe2
NMe2
NMe2
NMe2
Me2N NMe2
O
ZnI2
toluene  
 
Scheme 1.15 
 
Although reactions such as these appear simple enough, factors such as choice of base and 
the presence of ring substituents quickly complicate proceedings. The base employed in the 
previous example is fairly exotic, and the use of more common metallic bases changes the 
picture of reactivity. The electron deficient pyridazine ring, especially when one of the 
nitrogen atoms is coordinated to a cation, is susceptible to nucleophilic attack, meaning that 
commonly used strong bases such as butyllithium are unsuitable. More useful are hindered 
(and therefore less nucleophilic) lithium amide bases such as LDA or LiTMP, however, 
reactions can still tend towards oligomerisation as lithiated intermediates attack 
electrophilic pyridazines coordinated to metal. This can be alleviated to some extent by the 
formation of the anion using an excess of base and the trapping of the intermediate after a 
fairly short (minutes) reaction time (Scheme 1.16).38 
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N
N
N
N
i) 4 eq. LiTMP
ii) PhCHO
THF
Ph
OH  
 
Scheme 1.16 
 
It is interesting to note that in this case, the regioselectivity of the reaction is reversed, most 
probably due to the ring nitrogen atom interacting with the base and acting as a directing 
group.  
 
A similar procedure using a more stable organometallic intermediate allows fairly 
regioselective iodination of pyridazine, once again showing a propensity for reaction at the 
3-position (Scheme 1.17).39 
 
N
N
N
N
I
i) 1.5 eq. LiTMP
0.5 eq. ZnCl2TMEDA
ii) I2
THF/TMEDA N
N
N
N
I
I
I
+ +
N
N
+
11 74 8 7: : :  
Scheme 1.17 
 
Despite possessing an arguably attractive austerity, monosubstitutions of bare pyridazine 
are fairly removed from the desired goal of multifunctional heterocycles, and for further 
complexity to be achieved through deprotonation and trapping, the effects of other 
adornments around the ring must be taken into account. The use of directing groups in 
lithiation of pyridazine has a fairly short history, an early and facile example being the 4-
substitution of 3,6-dimethoxypyridazine using LiTMP and a variety of electrophiles.40 
 
A more useful reactivity is observed for pyridazine-3-carboxamide, where deprotonation 
occurs at the 4-position, ortho- to the directing group and away from the ring nitrogen 
15 
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(Scheme 1.18). Trapping with carbonyls gives 3,4-disubstituted products, while trapping 
with iodine leads to the “wrong” 3,5- substitution pattern, a result of the intermediate 
undergoing a halogen dance reaction.41 
 
N
NtBuHNOC N
NtBuLiNOC N
NtBuLiNOC
N
NtBuHNOCN
NtBuHNOC
i) 4 eq. LiTMP
ii) RCHO
THF
H2O
i) LiTMP
ii) I2
THF
LiTMP
I
I
I
Li
R
OH
 
 
Scheme 1.18 
 
The potential complexity increases further with the presence of multiple directing groups. 
In these cases competition between directing effects can lead to mixtures of products unless 
reaction conditions are carefully optimised.  
 
An example of a starting material possessing such conflicting influences is 3-chloro-6-
methoxypyridazine. Lithiations using standard dialkylamide bases followed by trapping 
with a range of electrophiles gave poor to moderate regioselectivities, while increasingly 
basic and hindered lithium amides gave selectivities approaching ninety nine percent in 
good yields (Scheme 1.19).42 
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Scheme 1.19 
 
The presence of a halogen atom in the previous example foreshadows the alternative 
common method for the regioselective functionalisation of pyridazine cores by metallation 
and then reaction with electrophiles: halogen-metal exchange. 
 
Although the literature contains fewer examples of metalation by halogen exchange than it 
does those performed via simple deprotonation, a couple of reactions are notable. The first 
procedure was developed in order to circumvent the necessity of performing lithiations of 
diazines at low temperatures. As noted above, lithiated pyridazine derivatives are highly 
reactive, and very low reaction temperatures, often combined with short reaction times, are 
required to prevent unwanted side reactions such as oligomerisation. In contrast, 
functionalisation of polysubstituted iodinated pyridazines could be achieved by sonicating 
the heterocycle at room temperature in the presence of lithium metal and an electrophile, 
which immediately captures the intermediate carbanion species upon formation (Scheme 
1.20).43  
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Scheme 1.20 
 
An alternative option that allows use of metalated pyridazine derivatives at room 
temperature is to use magnesated rather than lithiated species (Scheme 1.21). Dibrominated 
and diiodinated pyridazines have been shown to undergo exchange reactions with alkyl 
magnesium chlorides at room temperature to give heteroaryl Grignard compounds that 
could be trapped using a variety of electrophiles, allowing the formation of polyfunctional 
pyridazines still bearing a reactive halogen handle.44 
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Scheme 1.21 
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Halogenated pyridazines may also be functionalised via transition metal mediated cross 
coupling reactions. A variety of methodologies have been demonstrated, but all are united 
by the common themes of oxidative addition, transmetalation, and reductive elimination. 
 
One methodology that has been shown to be suitable for the selective reaction of 
symmetrically chlorinated pyridazines is the Negishi coupling. Reaction of 3,6-
dichloropyridazine with phenyl- and benzyl-zinc bromides gave almost exclusively 
monosubstituted products in moderate yields (Scheme 1.22).45 
 
N
N
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N
N
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R
+
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Pd(PPh3)4
THF  
 
Scheme 1.22 
 
The resulting monochloro derivatives could be reacted further at higher temperatures under 
similar conditions to give unsymmetrical 3,6-disubstituted products. 
 
Suzuki reaction conditions applied to the same substrate give less satisfactory results, as 
some degree of disubstitution seems unavoidable (Scheme 1.23).46, 47 
 
N
N
Cl
Cl
N
N
Cl
Ph
N
N
Ph
Ph
+
PhB(OH)2
(AdNC)2PdCl2
Cs2CO3
dioxane  
 
Scheme 1.23 
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The desired 3-chloro-6-aryl pyridazines could be accessed via Suzuki reaction if the 
molecule was first desymmetrised by selective replacement of a single chlorine atom by 
iodine, accomplished by warming the dichloro compound in hydroiodic acid and sodium 
iodide.48 The change in halogen atom considerably lowers the energy barrier to oxidative 
addition and allows monosubstitution to be smoothly realised, as has also been 
demonstrated for Sonogashira couplings on the same substrate. 
 
Exploitation of this difference in the susceptibility of aryl halogens to oxidative addition 
also allows synthesis of halogenated pyridazines bearing substituents at the 4- and 5-
positions, as shown in the following synthesis of a potential antihypertensive agent 
(Scheme 1.24). The specific synthetic scheme shown is an improvement on the previously 
established route to the target molecule, giving an increase in overall yield from 20 to 43%, 
but the key step is the Suzuki coupling, which may be performed in two successive 
regioselective steps to allow differing aryl groups to be arranged on the pyridazine 
scaffold.49 
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Scheme 1.24 
  
Halopyridazinones have also been shown to react under Buchwald-Hartwig amination 
conditions, as in the example below (Scheme 1.25).50 Formation of the biaryl ether 
analogue was possible using simple base-mediated nucleophilic aromatic substitution, but 
bromoaniline proved insufficiently reactive. Palladium catalysis gave straightforward 
access to the desired product. 
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Scheme 1.25 
 
The final major class of transformations that may be performed on halogenated pyridazines 
is that of nucleophilic aromatic substitution. This may in some way be considered as 
complementary to the functionalisations given above, as substitution generally requires 
chlorine, or even fluorine atoms to be present, as opposed to the metalations and cross 
coupling procedures which are better suited to the heavier halogens such as bromine and 
iodine. 
 
One relatively recent use of chloropyridazine as an electrophilic coupling partner was in the 
synthesis of some phenyl heteroaryl ketones (Scheme 1.26), an intermediate in whose 
production was diarylacetonitrile.51 
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NaHMDS
 
 
Scheme 1.26 
 
Pyridazines bearing multiple electron withdrawing groups are known to be excellent 
electrophiles, and may be used to trap particularly recalcitrant nucleophiles, as shown in the 
examples below (Scheme 1.27).52 
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Scheme 1.27 
 
1.7 Thiophenes in Medicinal Chemistry 
 
Thiophene is widely represented in medicinal chemistry, appearing in molecules with such 
diverse uses as antihypertensives, opioids, CNS drugs and anti-cancer agents. A small 
sample of such compounds is shown below (Figure 1.3).53-64 
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Figure 1.3 
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1.8 Syntheses of Thiophenes 
  
1.8.1 By Formation of One Bond 
  
Ring closures α- to the heteroatom are fairly uncommon, generally involving sulfur as a 
nucleophile. One interesting application is the synthesis of 2,3,5-trisubstituted thiophenes 
from aryl ketones, propargyl bromide, morpholine, and sulfur (Scheme 1.28).65 The first 
step is a Willgerodt-Kindler reaction giving the thiomorpholide, which can then be reacted 
with propargyl bromide in the presence of base. The resulting compound undergoes a 
Claisen rearrangement to give an allene, which is attacked intramolecularly by the sulfur 
atom to furnish the substituted thiophene. 
 
O
Ar
N
O
S
Br
N
Ar
OS
Ar
N
H
O
+ S
K2CO3
 
 
Scheme 1.28 
 
Ring closures β- to the heteroatom may be subdivided into Knoevenagel and Thorpe 
Ziegler type, depending on whether the intramolecular cyclisation is onto a carbonyl or 
nitrile functionality, respectively. The Thorpe-Ziegler class yields 3-aminothiophenes, such 
as in the example below (Scheme 1.29).66 
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Scheme 1.29 
 
The Knoevenagel type approach has been used for the synthesis of thienodolin, a natural 
product known to affect the growth of rice seedlings (Scheme 1.30).67 
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Scheme 1.30 
 
Ring syntheses where the final step is bond formation γ- to the heteroatom are a less 
common class, although one approach worthy of mention is the Nakayama procedure, 
which involves the zinc and titanium tetrachloride mediated cyclisation of diketo sulfides 
(Scheme 1.31).68 Symmetrically substituted sulfides may be prepared by the reaction 
between sodium sulfide and α-haloketones, while unsymmetrical compounds may be 
obtained from α-haloketones and α-mercaptoketones.69 
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Scheme 1.31 
 
1.8.2 By Formation of Two Bonds 
 
One of the more traditional approaches to thiophene systems is via two bond forming 
reactions between a sulfur atom and a four carbon component. Reactions of this sort may be 
further subdivided into two major groups: Gewald syntheses and Paal-Knorr syntheses. 
 
The Gewald reaction is a multi-component reaction, the first step of which is a 
Knoevenagel condensation between an α-cyanoester and an α-methylene carbonyl 
compound. Subsequent reaction with elemental sulfur leads to formation of 2-
aminothiophenes.  
 
This method has been employed for the production of polysubstituted thiophenes intended 
to act as templates for structural diversification and library synthesis.70 The resulting 
thiophenes were subsequently diversified by functionalisation of the amine and sequential 
deprotection and reaction of the two ester groups (Scheme 1.32). 
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Scheme 1.32 
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The Gewald reaction has also been used in the construction of a key intermediate for the 
total synthesis of 3-deazathiamine.71 Initial attempts to form the thiophene from the 
unhalogenated olefin led to a mixture of isomers, necessitating the synthesis of the 
chlorinated analogue, which could be cleanly cyclised to the desired intermediate (Scheme 
1.33). 
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Scheme 1.33 
 
The alternative [4C + S] approach is the Paal-Knorr synthesis (Scheme 1.34). This involves 
the condensation of a dicarbonyl compound using a sulfurising agent, such as Lawesson’s 
reagent. These cyclisations may be performed quickly in the absence of solvent under 
microwave irradiation.72 
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Scheme 1.34 
 
One of the limitations on the utility of Lawesson’s reagent is the ease with which it may be 
removed from the reaction mixture after use. A novel solution to this problem has been 
suggested in the form of fluorous technology (Scheme 1.35).73 
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Scheme 1.35 
 
The final class of important two bond forming reactions leading to thiophenes is that 
consisting of marriage between fragments of two and three atoms, the most important of 
which is the Hinsberg synthesis (Scheme 1.36), which gives 2,5-dicarboxylated thiophenes 
from thiodiacetates and α-diketones.74 
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Scheme 1.36 
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1.9 Functionalisation of Thiophenes 
 
Alkylation and acylation reactions of thiophenes are fairly few in number, largely due to 
the instability of thiophenes under traditional Friedel-Crafts reaction conditions. There are 
however, a handful of processes that allow these difficulties to be bypassed. For example, 
silica gel may be used in place of harsher Lewis acid catalysts such as aluminium 
trichloride. This methodology has been employed for the tert-butylation of the parent 
heterocycle (Scheme 1.37).75 
 
S S
t-BuBr
Na2CO3
SiO2
CCl4  
 
Scheme 1.37 
 
Thiophene may also be alkylated via the Mannich reaction (Scheme 1.38), although the 
process is considerably slower than that seen for pyrrole or furan, and generally requires the 
use of alkoxy substituted starting materials.76 
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Scheme 1.38 
 
In the above case, the two alkoxy substituents are tied back, reducing steric hindrance and 
increasing reactivity compared to similar non-cyclised dialkoxylated examples.77 
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Acylation reactions are also difficult. One alternative is lithiation of thiophene followed by 
trapping with DMF.78 In the example shown below (Scheme 1.39), this approach is 
complementary to Vilsmeier formylation, which results in functionalisation of the pyrrole 
ring. 
 
S
N
R
S
N
R
OHC
i) BuLi
ii) DMF
 
   
Scheme 1.39 
 
One of the more versatile strategies for the functionalisation of the thiophene scaffold is the 
employment of transition metal catalysis. A wide variety of such processes have been 
performed, and a few recent examples are given below. 
 
The Heck reaction is possibly the most straightforward approach of this type, as it enables 
direct C-H activation and corresponding increase in functionality. Although more 
traditional methods for the Heck coupling of unsubstituted thiophenes require harsh 
conditions,79 the use of the Jeffery method allows regioselective functionalisation of 
activated thiophenes in a relatively mild fashion (Scheme 1.40).80 
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Scheme 1.40 
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R is an electron withdrawing group such as nitro, cyano, or aldehyde, which, along with the 
sulfur atom, directs the reaction. 3-Substituted thiophenes react regioselectively at the 2-
position, although a competing reaction at the 5-position is observed, as well as some 2,5-
disubstitution. In contrast, 2-substituted starting materials give exclusively the 5-substituted 
product. Unfortunately, the reactivity of these systems is lower. Isolated yields are in the 
region of 30 – 80%, with the best results being observed for reactions of 2-cyanothiophene 
(77 – 81%). This methodology has been extended to the synthesis of arylated 
benzo[b]thiophenes (Scheme 1.41).81 
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Scheme 1.41 
 
Halogenated thiophenes are also useful coupling partners in palladium-mediated cross-
coupling processes. An early example of this is the Negishi coupling between 
iodothiophene and alkynylzinc reagents (Scheme 1.42).82 
 
S I S
ZnCl
THF
Pd(PPh3)4
 
 
Scheme 1.42 
 
Of more interest in the search for polysubstituted thiophenes is the regioselective reaction 
of multiply halogenated parent compounds.  
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Where thiophene is halogenated at two inequivalent positions, a degree of regioselectivity 
is made possible, but total selectivity may be hard to achieve. In the case of the Negishi 
coupling to 2,3-dibromothiophene (Scheme 1.43), clean reaction at the 2-position is found 
in good yield, allowing further functionalisation through the remaining bromine.83 
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Scheme 1.43 
 
The Suzuki reaction of 2,3-disubstituted thiophenes has also been observed to give 
preferential substitution at the 2-position, with excess boronic acid leading to both halogens 
being replaced.84 In certain cases, mixtures of products may be obtained, as seen, for 
example, in the following step (Scheme 1.44) taken from a synthesis of a liquid crystal, 
where the desired 2-substituted product is produced in 83% yield alongside 2% of the 
undesired isomer.85 
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Scheme 1.44 
 
The Stille coupling of 2,3-dibromothiophene has generally been found to lead to some 
degree of disubstitution, with the exact ratios depending on coupling partner and reaction 
conditions used (Scheme 1.45).86 Performed under the modified Farina conditions (AsPh3 
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as ligand in NMP)87 the desired monosubstitution product was obtained in 17 – 70% yield, 
with 4 – 12% of the disubstituted product observed. Use of the modified Fu conditions 
(PtBu as ligand, with CsF in dioxane)88 – a more reactive system – gave yields of 
monosubstituted product that were in the same range, 25 – 72%, but increased the level of 
disubstitution to 11 – 71%. 
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Scheme 1.45 
 
Just as the difference in reactivity between the two halogenated sites in 2,3-dibrominated 
thiophenes may be exploited to give regioselective processes, so may similar differences in 
the 2,4-dibrominated substrate. 2,4-Dihalogenated thiophene was used as the precursor in 
the synthesis of thio-enyne containing natural products found in various plants of the 
Anthemis genus (Scheme 1.46).89 The first step was conversion to 4-bromo-2-(1-
propynyl)thiophene, achieved in 70% yield by simple Negishi coupling with propynylzinc 
chloride (although further differentiation of the two sites by initial transhalogenation to 4-
bromo-2-iodo thiophene allows the coupling to be performed in 80% yield). 
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Pd(PPh3)4
THF  
 
Scheme 1.46 
 
This difference in reactivity was also exploited to allow an elegant synthesis of 3,4’-
dibromo-2,2’-bithiophene, via two separate functionalisations of 3-bromothiophene 
followed by regioselective Stille coupling of the products (Scheme 1.47).90 
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Scheme 1.47 
 
When thiophene bears multiple halogen atoms in equally reactive positions, selective 
monosubstitution becomes difficult, for example, based purely on statistical considerations, 
reaction of a symmetrically dihalogenated substrate with an equimolar amount of coupling 
partner should result in a 1:2:1 ratio of starting material:monosubstituted 
product:disubstituted product. Despite this, other factors may allow for increased selectivity 
through either steric or electronic means.  
 
In the case of 3,4-dihalogenated thiophenes, the most obvious effect is the former, as a 
sufficiently bulky substituent may interfere with the oxidative addition and transmetallation 
at the adjacent site. Reaction of 3,5-dibromothiophene with one equivalent of 
benzylzincbromide under palladium catalysis was shown to give 52% monosubstituted 
product along with 6% of the disubstituted species and 20% recovered starting material.91 
 
Attempts to synthesise a range of diheteroarylated thiophenes gave further insight into the 
activity of these 3,4-dihalogenated systems.92 Reaction of 3,4-dibromo-2,5-
dimethylthiophene with an excess of heteroaryl boronic acid resulted in an approximately 
equimolar mixture of starting material and mono- and di-coupled products, while use of the 
more reactive 3,4-diiodo-2,5-dimethylthiophene allowed synthesis of the desired dicoupled 
products in reasonable yields. Attempts to perform a dicoupling between the 
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diiodothiophene and a trimethylstannylthiazole gave only the monosubstituted product in 
16% yield, suggesting that the change from a boronic acid to an organo tin compound 
increased the steric demand involved in the reaction. 
 
Polyhalogenated parent compounds are probably the most widely applicable route towards 
polyfunctionalised thiophenes. Halogenation of thiophene is straightforward, and multiple 
reactions are made possible. A simple example is subsequent replacement of halogen atoms 
by nucleophilic aromatic substitution (Scheme 1.48). This approach is often limited by the 
requirement of a nitro group to activate ortho- substituents to substitution.93 
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Scheme 1.48 
 
Halogen atoms attached to the ring in the 3- or 4-positions may also undergo halogen metal 
exchange, allowing the generation of anions in positions other than those favoured by 
simple deprotonation (Scheme 1.49).94 This allows trapping with electrophiles from 
positions not allowed by the methods outlined at the start of this section. 
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Scheme 1.49 
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1.10 Conclusions 
 
The literature outlined above has demonstrated the need for methodology tailored to the 
reliable exploration of chemical space with particular regard to drug-like molecules 
containing heterocyclic motifs, namely pyridazine and thiophene. A variety of pyridazine- 
and thiophene- containing drug molecules has been exhibited, and currently favoured 
methods for the synthesis and functionalisation of these desired species have been briefly 
reviewed to provide an overview of the types of chemistry possible for the synthesis of 
functionalised pyridazine and thiophene derivatives. The majority of the rest of this work 
will examine approaches to the realisation of diverse ranges of these drug-like heterocyclic 
compounds. 
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Chapter 2 
 
Nucleophilic Aromatic Substitution Reactions of Polyfluoropyridazines 
 
2.1 Background 
 
The aim of this thesis is to describe advances that have been made concerning the synthesis 
of new and diversely substituted heterocycles, namely pyridazine and thiophene. The bulk 
of the following work concerns transformations performed using tetrafluoropyridazine as a 
starting material. 
 
As discussed in chapter 1, functionalised pyridazines are potentially valuable molecules 
possessing a range of desirable pharmaceutical properties. Routes towards these targets are 
numerous, including various ring-closing procedures, such as cycloadditions or 
condensations of dicarbonyls, and functionalisations of the parent heterocycle by such 
means as transition metal mediated reactions, metallations, and nucleophilic substitutions. 
 
Our approach was to utilise the chemistry of perhalogenated heterocycles to allow us to 
produce a diverse range of desirable polyfunctional pyridazine and thiophene molecules. 
For our explorations of the reactions of pyridazine, we used the perfluorinated derivative as 
our starting material, the choice of which requires some explanation.  
 
The chemistry of fluorocarbon systems differs notably from that of hydrocarbon systems 
due to the disparity in electronic properties between hydrogen and fluorine. While the C-H 
bond in aromatic systems is relatively non-polar, the extreme electronegativity of fluorine 
causes polarisation of the C-F bond, leading, in the case of polyfluorinated aromatic 
systems, to electron deficient rings susceptible to nucleophilic, rather than the more usual 
electrophilic, attack. Additionally, fluorine is able to act as a leaving group, as F-, while 
hydrogen tends to be abstracted as H+.1 
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For these reasons, perfluorinated aromatic systems exhibit reactivity that may be viewed as 
complementary to that of their hydrocarbon counterparts. While the chemistry of benzene is 
dominated by electrophilic aromatic substitution, proceeding via a Wheland intermediate, 
the reactions of hexafluorobenzene are predominantly nucleophilic aromatic substitution 
processes, which pass through a conceptually similar Meisenheimer intermediate, for the 
reasons outlined above (Scheme 2.1).2, 3 This dichotomy leads some to describe the 
reactions of perfluorinated species as ‘mirror image’ chemistry with respect to the more 
familiar hydrocarbon behaviour. 
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Scheme 2.1 
 
This same reactivity holds true for perfluorinated heterocyclic compounds, and the insertion 
of electronegative nitrogen atoms into the ring system serves to activate the remaining ring 
carbon atoms, further facilitating substitution. Pentafluoropyridine has previously been 
used as a scaffold for drug discovery purposes, and a few words about its use as such 
appear appropriate here. 
 
The first thing that becomes obvious when examining the nucleophilic aromatic 
substitution chemistry of pentafluoropyridine as opposed to hexafluorobenzene is that the 
molecule has become less symmetrical; six identical potential sites of attack have given 
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way to five sites, one of which is unique, and four of which are paired into two symmetrical 
domains. This situation leads in effect to three possible sites of attack, namely ortho-,  
meta-, and para- to ring nitrogen. Experimentally, nucleophilic substitution reactions of 
pentafluoropyridine generally proceed with replacement of the fluorine atom at the 4- 
position, giving 2,3,5,6-tetrafluorinated systems as products (Scheme 2.2).4 
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Scheme 2.2 
 
To understand the regioselectivity of the reaction, it is necessary to examine the 
intermediates resultant from the potential sites of reaction (Scheme 2.3). 
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Scheme 2.3 
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It can be observed that in the case of nucleophilic attack meta- to the ring nitrogen, the 
negative charge is delocalised over three carbon atoms, each bearing a fluorine atom, while 
attack ortho- or para- to ring nitrogen allows one third of the resonance canonicals to 
involve delocalisation onto nitrogen. It is known that delocalisation onto electronegative 
nitrogen is preferable to delocalisation onto an sp2 hybridised CF centre, as the latter case 
leads to unfavourable interactions between the charge and the lone pairs on fluorine, and as 
such meta- substitution should be disfavoured. This turns out to be the case, and 
pentafluoropyridine may be employed as an electrophile undergoing substitution at the 2-, 
4-, and 6- positions. 
 
This reactivity was exploited to allow the synthesis of a range of compounds showing 
potential as antithrombotic agents.5 A representative synthesis is shown below (Scheme 
2.4).  
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Scheme 2.4 
 
Several similar syntheses utilising reactions of highly fluorinated pyridine scaffolds have 
been published by the Durham group, and it has been demonstrated that sequential reaction 
with a variety of nucleophiles produces novel compounds with good to excellent levels of 
regiocontrol, potentially making these processes suitable for use in diversity-oriented 
parallel synthesis targeted towards the discovery of new pharmaceutical agents.6-8 
 
In light of this precedent, we have turned to investigating the merits of employing a similar 
approach to the diversification of other perhalogenated heterocyclic cores, and the 
following chapters will be concerned with our findings regarding the reactions of 
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tetrafluoropyridazine; consequently, a brief review of the chemistry of tetrafluoropyridazine 
follows. 
 
Previous studies of the reactions of tetrafluoropyridazine have been limited and, as would 
be expected, have been in the main confined to its behaviour towards nucleophiles. The few 
nucleophilic species explored thus far have shown differing degrees of reactivity and 
regioselectivity. 
 
Simple amines appear to be most easily controlled, with ammonia giving the 4-substituted 
product in good yield, while the more reactive potassium phthalimide gave a poor yield of 
the 4,5-disubstituted derivative.9 Similarly, sodium thiophenoxide was found to be 
unsuitable for the purposes of selective substitution, with a single equivalent giving 
disubstitution, and three equivalents giving a mixture of di-, tri-, and tetra-substituted 
products. 
 
Versatile routes to the synthesis of methyl ethers have been described, with the addition of 
successive equivalents of sodium methoxide leading sequentially to 4-, 4,5-, 4,5,6- and 
tetra-methoxy derivatives, while treatment of tetrafluoropyridazine with methanol and 
sulfuric acid gives substitution at the 3-position (Scheme 2.5).10  
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Scheme 2.5 
 
Reaction with sulfuric acid in water leads to pyridazinone, while the action of hydrochloric 
acid converts tetrafluoropyridazine to the tetrachloro equivalent from which it is usually 
synthesised (Scheme 2.6). 
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Scheme 2.6 
 
Trifluoropyridazinone has been utilised as a potential scaffold for sequential nucleophilic 
aromatic substitution processes, with disubstituted products formed in variable selectivities 
and yields (Scheme 2.7).11 
 
 
 
47 
Chapter 2: Nucleophilic Aromatic Substitution Reactions of Polyfluoropyridazines 
N
NH
F
F
F
O
N
NH
F
Nuc2
Nuc1
ONuc1
Nuc2  
 
Scheme 2.7 
 
Finally, a number of papers have described the reactions of tetrafluoropyridazine with 
various perfluorinated nucleophiles which, although of some interest due to their unusual 
electronic and steric properties, are of little importance in the pursuit of drug-like 
compounds.12-15 
 
As can be seen, prior work has confirmed the suitability of the heterocycle as an 
electrophile, but fallen short of giving a picture of the degree of suitability for 
polyfunctionalisation by a series of selective, clean, and high yielding nucleophilic 
substitutions. What may be ascertained with certainty is that tetrafluoropyridazine readily 
undergoes substitution with a number of nucleophiles, and, at least in certain cases, shows a 
degree of regioselectivity. We chose to extend the known chemistry of this species in the 
hope that selective and clean routes could be found to exciting new chemical entities. 
 
2.2 Aims and Approach 
 
Given that previous studies had shown a bias towards reaction at the 4- and 5-positions, it 
was hoped that at least certain nucleophiles or conditions would lead to clean reaction at a 
single site. If this could be achieved, further selective reactions were desired, relying upon 
the properties imparted by existing substituents to guide subsequent reactions. It was 
envisaged that understanding the interplay between the electronic and steric properties of 
the electrophilic substrate and the incoming nucleophile could give ready access to a 
powerful methodology for the synthesis of a wide range of variously substituted 
heterocycles, as outlined in the following scheme (Scheme 2.8). 
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Scheme 2.8 
 
 2.3 Nucleophilic Aromatic Substitution Reactions of Tetrafluoropyridazine 
 
Our first desire was to ascertain the applicability of the substitution reactions, so to this end, 
we decided to carry out a number of reactions between tetrafluoropyridazine and a variety 
of nucleophiles, hoping to observe clean, selective monosubstitutions and assess the scope 
of reactions of this species. To aid comparison, all reactions were carried out in the same 
solvent, and using a non-nucleophilic tertiary amine as base to neutralize the hydrofluoric 
acid liberated during the process of substitution. Reactions were performed between 
equimolar quantities of electrophile and nucleophile, and carried out at relatively low 
temperatures where feasible. 
 
Nucleophilic species employed included amines, alcohols, thiols, and selected carbon 
nucleophiles, and the results of these experiments are outlined in the following sections. A 
range of steric and electronic properties was desired among the nucleophilic coupling 
partners, to allow observation of trends in reactivities and regioselectivities, to see if a 
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variety of reactants would be tolerated, and assess the suitability of this scaffold for parallel 
synthesis. 
 
2.3.1 Reactions with Amines 
 
Reactions of tetrafluoropyridazine with morpholine, diethylamine, N-methylallylamine, and 
aniline gave regioselective monosubstitution products in good yield upon stirring with 
DIPEA in THF for a few hours at 0 °C (Table 2.1). The products 1, 2, 3 and 4 were isolated 
and purified by means of column chromatography. 
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RR'NH Product o C Yield (%)
N
H
O
N
N
F
F
N
F
O
1
0 81
N
H
N
N
F
F
N
F
2
0 82
N
H
N
N
F
F
N
F
3
0 82
H2N
N
N
HN
FF
F 4
0 78
Br
N
H
N
N
F
F
N
F
Br
5
25a 65
N
H
O
O
.HCl
N
N
F
F
N
F
OO
6
25b 50
N
N
F
F
F
F
RR'NH
DIPEA
THF N
N
F
F
NRR'
F
a Reaction run overnight
b Reaction run for three days  
Table 2.1 
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The orientation of substitution was determined by analysis of the NMR spectra obtained, a 
brief discussion of which will follow. 
 
Proton NMR spectroscopy, as would be expected, gives little information about 
regiochemistry in these examples, as the hydrogen atoms in the molecules occupy sites on 
the nucleophile rather than around the ring. 
 
A more useful structural probe is fluorine NMR spectroscopy, which may be analysed at 
various depths to interrogate the molecule. Tetrafluoropyridazine displays two signals, at -
91 and -145 ppm relative to chlorotrifluoromethane in deuterated chloroform.10 The more 
deshielded signal, at -91 ppm, corresponds to the fluorine atoms at the 3- and 6-positions, 
ortho- to ring nitrogen, while the less deshielded signal, at -145 ppm, corresponds to the 
remaining two fluorines, situated further from the electronegative nitrogen atoms.  
 
A simple approach to structure confirmation consists of qualitative comparison between the 
spectrum of tetrafluoropyridazine and that of the entity in question. As an example, the 
product of reaction between tetrafluoropyridazine and diethylamine shows signals at -81, -
101, and -147 ppm. Two of these shifts are close to the figure of -91 observed for fluorines 
adjacent to ring nitrogen in tetrafluoropyridazine, while only one is similar to the value of -
145 seen for the fluorines in the 4- and 5-positions. This immediately suggests that 
substitution has taken place at the position para- to ring nitrogen. 
 
A more rigorous approach involves consideration of the influence of substituents on nearby 
shifts to rationalise the spectrum. A simple example was alluded to earlier, while 
mentioning the deshielding effects of electronegative nitrogen on adjacent nuclei. It is 
obvious in the case of a perfluorinated system that replacing a fluorine atom with a 
different substituent will alter the resonance frequencies of the remaining fluorines to a 
greater or lesser extent. The degree of change for a few representative substituents seen in 
the context of pentafluorobenzene is illustrated below (Table 2.2).16 
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R F-2/F-6 F-3/F-5 F-4
F -162.9 -162.9 -162.9
H -139.2 -162.7 -154.5
CH3 -144.1 -164.4 -159.7
NH2 -162.9 -165.5 -173.9
OH -164.1 -164.3 -169.2
OCH3 -158.4 -164.8 -164.8
R
F
F
F
F
F
 
 
Table 2.2 
 
These values can be used to determine the shift differences that a given substituent causes 
at the ortho-, meta-, and para-positions. These substituent chemical shift (scs) differences 
are tabulated below (Table 2.3). 
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R ortho meta para
H +23.7 +0.2 +8.4
CH3 +18.8 -1.5 +3.2
NH2 0 -2.6 -11
OH -1.2 -1.4 -6.3
OCH3 +4.5 -1.9 -1.9
R
F
F
F
F
F
 
 
Table 2.3 
 
It is possible to use these values to predict the NMR spectra of other compounds; for 
example, pentafluoroethylbenzene would be expected to have a very similar fluorine 
spectrum to pentafluoromethylbenzene. A slightly more profound use would be the 
combination of chemical shift differences to predict the spectra of disubstituted 
tetrafluorobenzenes in an additive fashion. For our purposes, it is necessary to apply these 
ideas to non-benzenoid species. A convenient stepping stone is the NMR behaviour of 
polyfluorinated pyridines, which has been studied in some depth. 
 
The observed shifts of a number of substituted tetrafluoropyridines are shown below (Table 
2.4). Of note is the fact that there are now two parameters changing – the relative position 
of the substituent with respect to the fluorine in question, and the position of the substituent 
on the pyridine ring. 
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Compound F-2 F-3 F-4 F-5 F-6
NF
F
F
F
F R
-87.6 -162.0 -134.1 -162.0 -87.6
NF
F
F
F
R
OCH3 - -164.5 -140.9 -171.9 -91.4
NF
F
F
F
R
OH - -164.7 -141.3 -173.6 -91.6
NF
F
F
R
F
OH -88.2 - -133.8 -164.8 -96.6
NF
F
R
F
F
NH2 -95.0 -165.0 - -165.0 -95.0
NF
F
R
F
F
OH -95.5 -164.6 - -164.6 -95.5
NF
F
R
F
F
OCH3 -92.9 -161.7 - -161.7 -92.9
 
 
Table 2.4 
 
With the shifts for each isomer of tetrafluorohydroxypyridine tabulated, it is possible to 
discern its effects on the fluorine nuclei from each position. When averaged, the chemical 
shift differences for the hydroxy substituent in pyridine are -1.1 to ortho- fluorines, -5.5 to 
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meta- fluorines, and -10.3 to para- fluorines. These values compare moderately well with 
the values observed in the fluorobenzene case, suggesting some commonality over different 
ring systems. Furthermore, despite limited data, amino- and methoxy- substituents 
demonstrate the same trends as seen in benzenoid examples. 
 
It is now possible to apply these principles to our diethylamino substituted pyridazine. The 
ortho-, meta-, and para- shift differences elicited by the similar dimethylamino substituent 
in benzene have been reported as +9.69, -0.75, and -0.97 respectively.17 By combining 
these values with the known shifts of tetrafluoropyridazine, as discussed above, it is 
possible to predict the expected spectra for both of the possible substitution products, which 
are as follows (Figure 2.1). 
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Figure 2.1 
 
Clearly, the values predicted by the situation on the left hand side are considerably closer to 
the experimental values of -81, -110, and -147 ppm than those predicted by the alternative 
substitution, and also provide a distinction between the two more deshielded environments, 
something that was lacking in the previous crude analysis. Theoretical values are improved 
further by the use of chemical shift differences calculated for the diethylamino substituent 
on polyfluoropyridine,18 which predicts the fluorine shifts in the 4-substituted isomer to be 
-87, -100, and -140 ppm. A similar approach was taken for the other products of reaction 
between tetrafluoropyridazine and amines, and all products were identified as being the 
result of substitution at the 4-position. 
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With the identity of the product confirmed, the necessity to explain the observed 
regioselectivity remains. This may be achieved by the same means used to rationalise the 
selectivity observed in reactions with pentafluoropyridine, with a few refinements. The 
addition of a second ring nitrogen reduces the number of possible sites of attack to two, 
each having a symmetrically identical counterpart. The two possible Meisenheimer 
intermediates are shown below (Scheme 2.9). 
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Scheme 2.9 
 
It is immediately obvious that, unlike in the case of substitution in pentafluoropyridine, the 
two sets of resonance canonical forms are statistically the same, in that both contain one 
structure bearing the negative charge on ring nitrogen, and two structures bearing negative 
charges on fluorinated carbon. A further factor is required to account for the observed 
selectivity. 
 
It has long been suggested that the three canonical forms involved in the intermediate are 
not of equal importance, as indicated by the preponderance of substitution para- rather than 
ortho- to the substituent in pentafluorobenzenes.19 LCAO MO calculations performed to 
investigate the behaviour of aromatic systems undergoing reduction also imply that the 
charge density in the Meisenheimer intermediate will be greatest at the atom opposite the 
tetrahedral carbon, as shown below (Figure 2.2).20 
 
57 
Chapter 2: Nucleophilic Aromatic Substitution Reactions of Polyfluoropyridazines 
R R'
1.368
1.000
1.3161.316
1.000
 
 
Figure 2.2 
 
With this borne in mind, the observed selectivity of the reaction may be rationalised by 
considering that the negative charge present in the intermediate is better localised on the 
electronegative nitrogen atom, which is flanked by a further electronegative heteroatom and 
a sigma withdrawing C-F group, than on a carbon atom where it will be destabilised by 
unfavourable interactions with the non-bonding lone pairs on fluorine. 
 
While the reactions of these first simple amines with tetrafluoropyridazine were complete 
within a matter of hours at 0 °C, giving good yields, a couple of other amines gave less 
satisfactory results. 1-(4-Bromophenyl)-N-methylmethanamine required stirring at room 
temperature overnight, due to its increased steric demand, while methyl 2-
(methylamino)acetate, even after stirring at room temperature for several days, gave a 
disappointingly low yield of 6. Part of this may be attributed to the poor solubility of the 
nucleophile in the reaction mixture. 
 
Overall, it seems that the reactions of amines with tetrafluoropyridazine proceed with high 
regioselectivity in moderate to good yield, a promising first step towards selective 
polyfunctionalisation. 
 
2.3.2 Reactions with Alcohols 
 
After seeing encouraging results for the reactions of amines with tetrafluoropyridazine, we 
moved on to investigate the reactions of a selection of alcohols, a summary of which is 
shown below (Table 2.5). 
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ROH Product T Yield (%)
HO
N
N
F
F
O
F
7
RT 61
HO
N
N
F
F
O
F
8
RTa 63
HO
N
N
F
F
O
F
9
reflux 73
HO
N
N
F
F
O
F
10
reflux 72
N
N
F
F
F
F DIPEA
THF N
N
F
F
OR
F
ROH
a Reaction run for six days  
 
Table 2.5 
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The first example tested was para-cresol, which reacted fairly rapidly at room temperature 
to give the corresponding 4-substituted product 7. The regioselectivity of the reaction was 
again confirmed by substituent chemical shift calculations. The separation of the product 
from traces of disubstituted material was not achieved using simple column 
chromatography, and HPLC was required to obtain analytically pure material. 
 
The use of aliphatic alcohols resulted in a considerably reduced rate of reaction. This is 
probably best rationalised by comparing the acidities of the nucleophiles in question, which 
suggest that the aromatic alcohol is more likely to be deprotonated, and able to attack as a 
relatively reactive negatively charged species. 
 
After the observation of the considerably increased reaction times necessary when using 
aliphatic alcohols, subsequent reactions with alcohols were performed at elevated 
temperature, allowing reactions to reach completion in good yield within a far more useful 
timescale. The regiochemistries of the reaction products were confirmed using NMR 
spectroscopy procedures as described above.  
 
Once again, reactions of tetrafluoropyridazine with nucleophiles, in this case alcohols, have 
been shown to be high yielding and able to proceed with good regioselectivity. 
 
2.3.3 Reactions with Carbon Nucleophiles 
 
With successful substitution reactions involving nitrogen- and oxygen-centred nucleophiles 
in hand, we began to investigate reactions of tetrafluoropyridazine with a number of carbon 
nucleophiles. Firstly, in contrast to the nucleophiles already employed, phenylmagnesium 
bromide failed to give a clean and selective monosubstitution. Although the major product 
of the reaction was again monosubstitution at the 4- position, analysis of the reaction 
mixture by 19F NMR spectroscopy also showed the presence of the 3-substituted product, 
along with traces of a disubstituted product (Scheme 2.10). The reaction of 
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phenylmagnesium bromide with a slight excess of tetrafluoropyridazine leads to 4-
substitution, 3-substition, and a disubstituted isomer in an approximately 32:6:1 ratio by 19F 
NMR spectral analysis of the reaction mixture. Increased quantities of nucleophile, while 
improving conversion, serve to bring about ever greater quantities of disubstituted material, 
whose removal by recrystallisation dramatically lowers the isolable yield of 
monosubstituted product. 
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Scheme 2.10 
 
The reason for this loss of selectivity may once again be explained by examination of the 
mechanism of reaction. As already outlined, nucleophilic substitution processes such as 
these proceed via a reactive intermediate, which then loses fluoride to give the final 
product. The substitution reaction can therefore be seen as a two-step reaction, the first step 
of which is rate determining, and dictates the regioselectivity of the reaction. Thus far, we 
have assumed that the regioselectivity is determined purely by the relative stabilities of the 
various intermediates possible, and this has, in all cases up to this point, been entirely in 
favour of substitution para- to ring nitrogen. Other factors, however, have been 
disregarded, the most relevant here being the initial electronic charge densities.  
 
The free energy profile of the nucleophilic substitution reaction is represented 
schematically below (Figure 2.3), and shows the relative free energies of the starting 
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material, product, and the intermediate. It can be seen that upon forming the intermediate, 
the regioselectivity is already determined, and one can imagine a similar free energy profile 
for the reaction resulting in substitution ortho- to the ring nitrogen. The intermediate is 
higher in energy than the starting material, and as such we assume a late transition state for 
the first step of the reaction. With that in mind, we can describe the transition state as being 
similar to the intermediate, or at least more similar to the intermediate than to the starting 
material. This bears out our assertion that regioselectivity should be predictable by 
considering the various reactive intermediates possible and recognising which electronic 
configurations are most stabilised by the molecular structure of the ring.  
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Figure 2.3 
 
While this method has thus far adequately explained our findings, with the move to carbon 
nucleophiles we have observed products resulting from a competing pathway. This can be 
understood to be a result of the use of a far more reactive nucleophile than has been 
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employed up until this stage. While in former cases the transition state could be assumed to 
be late, with increasingly energetic starting materials the transition state will become 
earlier, and as such more like the starting material, so that regioselectivity is determined 
less by stabilising factors present in the intermediate, and more by factors present in the 
starting material, namely the electrophilicity of the various ring carbon atoms. These two 
considerations work in opposite directions for this reaction, with attack at the 3-position 
favoured by an early transition state, and attack at the 4-position favoured by a late 
transition state. As we increase the reactivity of the starting materials, we would expect to 
see an increase in 3-substitution, which is indeed observed. 
 
The next carbon nucleophile to be employed was methylmagnesium bromide, which we 
expected to behave similarly to phenylmagnesium bromide, with possibly a slightly greater 
ratio of 3- to 4-substitution, due to the marginally higher instability of methyl, as opposed 
to phenyl carbanions. In fact, it was found that the reaction of tetrafluoropyridazine with 
methylmagnesium bromide leads to a complex mixture of products, consisting largely of 
intractable, tarry material. The marked contrast between this reaction and the relatively well 
behaved reaction with phenylmagnesium bromide is due to the presence, or absence, of an 
acidic proton in the initial product, which may be abstracted under the highly basic reaction 
conditions, leading to further nucleophilic substitution processes (Scheme 2.11). 
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Scheme 2.11 
 
Having established the unsuitability of strongly basic alkyl nucleophiles for use in the first 
functionalisation of tetrafluoropyridazine, we examined the use of a rather milder carbon 
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nucleophile. Ethyl acetoacetate may be deprotonated under fairly mild conditions, and as 
such we could avoid the harsh basic media inevitable during reactions with Grignard 
reagents. Initial experiments with ethyl acetoacetate, using a single equivalent of base, led 
to a mixture of fused compounds (Scheme 2.12), rather than the monosubstituted product 
that might have been expected. This would again appear to be due to the enhanced acidity 
of a proton alpha- to the fluorinated pyridazine ring system. While the methylene protons 
borne by the acetoacetate moiety are reasonably acidic, the remaining proton in that 
position subsequent to initial substitution is even more so, suggesting that ring closing 
reactions should start to occur even before complete consumption of starting material.  
 
N
N
F
F F
OEt
O O
OEt
O- O
N
N
F
F
F
F
O
OEt
O
N
N
F
F F
O-
OEt
O
N
N
FN
N
F
OO FF
O
OEt
O
EtO
DIPEA
THF
DIPEA
+
 
 
Scheme 2.12 
 
Evidently, if using one equivalent each of base and nucleophile, all base will have been 
consumed by the time the reaction is halfway towards complete disubstitution. Beyond this 
point, base induced cyclisation is no longer driving the reaction, and substitution becomes 
promoted by the HF formed during conversion (Scheme 2.13). 
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Scheme 2.13 
 
Although reactions were performed in dry THF, this autocatalytic production of 
hydrofluoric acid was undesirable, not least because the presence of acid during and after 
aqueous work-up led to hydrolysis of the product, leading to further liberation of acid. 
Subsequently, reactions between tetrafluoropyridazine and ethyl acetoacetate were 
performed in the presence of an excess of base, leading not only to the cessation of the 
generation of hydrofluoric acid, but also noticeably cleaner reactions, with only one isomer 
of the ring fused system isolated (Scheme 2.14). 
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Scheme 2.14 
 
As far as confirmation of regiochemistry is concerned, it will be noticed that only two of 
four possible regioisomers are shown in the preceding two diagrams, both resulting from 
cyclisation through the ketone, rather than carboxyl, oxygen atom. Theoretically, four 
regioisomers are possible, and their structures are shown below (Figure 2.4). 
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Figure 2.4 
 
Although distinguishing between the first two structures and the second two is trivial with 
the aid of 19F NMR spectroscopy, using processes similar to those described earlier in this 
chapter, it is not as straightforward to ascertain through which of the oxygen atoms 
cyclisation has occurred. Once analysis of the 19F NMR spectrum has indicated to which 
side of the pyridazine ring the furan has been fused, consideration of proton and carbon 
NMR spectra give indications of the orientation of the substituents on the furan ring, with 
good evidence being provided by 2D NMR experiments. 
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In the case of the major product isolated from the reaction, 19F NMR spectral shifts of -
76.46 and -98.48 ppm suggest that the fluorine atoms are in the 3- and 6- positions, with 
both substitutions occurring para- to ring nitrogen, meaning that the product is one of the 
first two structures shown above. The two carbons, each bearing a fluorine atom, are easily 
located in the 13C NMR spectrum, owing to their large 1JCF coupling constants. Equally, the 
other two carbons constituting the pyridazine ring may be readily identified by their 
splitting patterns. Proton NMR spectroscopy gives little information in isolation, but HSQC 
(Figure 2.5) allows assignment of the two methyl carbons by correlation with the readily 
assigned proton peaks. HMBC (Figure 2.6) shows connectivity between methylene protons 
and a carbon with a shift of 161 ppm, while the singlet methyl protons show connectivity to 
the carbon that was originally the methylene of ethyl acetoacetate, with a shift of 109 ppm, 
and another carbon nucleus resonating at 168 ppm, too low a value to be a ketone and 
therefore the β-carbon in the furan ring, suggesting that the resonance at 161 ppm is that of 
the ester carbon shown in the first of the four diagrams above. 
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Figure 2.5 
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Figure 2.6 
 
While the nucleophiles employed in previous sections of this chapter have behaved fairly 
predictably, the use of carbon nucleophiles has added some complicating factors. The 
presence of acidic protons in initial substitution products has been shown to lead to 
instability, and perhaps more interestingly the use of reactive nucleophiles has led to a 
decrease in the regioselectivity of the substitution process, with factors other than the 
stability of the Meisenheimer intermediate having to be considered. 
 
2.3.4 Reactions with Thiols 
 
The final set of reactions investigated for monosubstitution of tetrafluoropyridazine was 
that involving sulfur nucleophiles. The first nucleophile used was thiophenol, one 
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equivalent of which was found to give exclusively the disubstituted product 15, with 50% 
conversion of starting material (Scheme 2.15).  
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Scheme 2.15 
 
This observation may be explained by considering again the Meisenheimer intermediate 
involved in the reaction (Scheme 2.16). While the initial substitution reaction proceeds via 
the three resonance canonicals described earlier, the product of the initial substitution is 
able to undergo further reaction, in which the intermediate consists of four possible 
resonance canonicals, further stabilising the intermediate and making the product of initial 
substitution more reactive than the tetrafluorinated starting material, consistent with the 
known para- activating influence of thiophenolic substituents in reactions of 
polyfluorinated benzenes.21 
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Scheme 2.16 
 
Subsequently, alternative sulfur nucleophiles were employed in an attempt to ascertain 
whether monosubstitution was possible (Table 2.6). It was hoped that by altering the 
nucleophilicity, or the charge-stabilising properties of the thiol, the substitution could be 
halted after the first reaction, allowing synthesis of trifluorinated sulfur-substituted 
pyridazines.  
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RSH % a % b
HS
Cl
0 50
HS
OMe
39 61
HS
100 0
N
N
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THF N
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N
N
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F
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a b
 
 
Table 2.6 
 
Two substituted thiophenols were investigated, one being the less nucleophilic 4-
chlorothiophenol, the other the relatively electron rich 4-methoxythiophenol. While 
reaction with the chlorothiophenol again led to pure disubstitution in fifty percent 
conversion, reaction with one equivalent of 4-methoxythiophenol gave a reaction mixture 
containing approximately two parts disubstituted material for every one part of 
monofunctionalised product. We next increased the electron donating character of the 
nucleophile by moving to ethanethiol (Scheme 2.17).  
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Scheme 2.17 
 
It was found that 4-ethylthio-2,3,5-trifluoropyridazine 16 could be obtained in good 
conversion from tetrafluoropyridazine, allowing selective monosubstitution with a sulfur 
centred nucleophile, and providing a further example of a substituted trifluorinated 
pyridazine on which to perform further investigative substitutions. 
 
2.4 Nucleophilic Aromatic Substitution Reactions of Trifluoropyridazines 
 
Having completed reactions of tetrafluoropyridazine with a number of nucleophiles, we 
observed that a range of nitrogen-, oxygen-, carbon-, and sulfur- centred substituents may 
be introduced to the pyridazine core by this method. In general, we have noted that the 
reactions give good selectivities and reasonable yields, and the instances where over-
reaction has occurred give hope that further substitution of the trifluoropyridazine scaffold 
should be possible. 
 
Our next suite of experiments was aimed at exploring the behaviour of a number of 
substituted trifluoropyridazines towards further nucleophilic attack. Of interest was not 
only the fact that our new electrophiles had four inequivalent sites of potential nucleophilic 
attack (displacement of any of the three fluorine atoms, or replacement of the substituent), 
but also that we expected to see some influence borne by the ring substituent already in 
place.  
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As we have already seen, simple consideration of the perhalogenated ring generally 
predicts substitution para- to the ring nitrogens, but there is room for complicating steric 
and electronic effects from substituents, with substituent ortho-, meta-, and para- directing 
effects, such as those observed for sulfur nucleophiles in the previous section, being of 
particular interest. 
 
For the following experiments we took four representative products prepared in the 
previous sections, namely the products of reactions with morpholine (4-(3,5,6-trifluoro-
pyridazin-4-yl)morpholine 1), isopropyl alcohol (3,4,6-trifluoro-5-[(1-
methylethyl)oxy]pyridazine 10), phenylmagnesium bromide (3,4,6-trifluoro-5-
phenylpyridazine 11), and ethanethiol (4-(ethylthio)-3,5,6-trifluoropyridazine 16), and 
reacted each with a further equivalent of a different nucleophile. In this fashion we hoped to 
explore the possibilities of a second nucleophilic substitution, the compatibility of existing 
substituents with incoming nucleophiles, and any unexpected trends in the behaviour of the 
reactions not discussed previously in the literature. 
 
To aid comparability, all reactions were again performed under similar conditions with 
respect to solvents and concentrations as far as was reasonable. 
 
2.4.1 Reactions with Amines and Thiols 
 
The first nucleophiles to be applied were morpholine and thiophenol, and the results are 
summarised in the following table (Table 2.7). 
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Table 2.7 
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Reactions of morpholine with trifluoropyridazines bearing phenyl, isopropoxy, and 
thioethoxy groups in the 4-position gave uniform good results, with clean monosubstitution 
occurring at the fluorinated position para- to ring nitrogen, as might have been expected 
from our earlier results. 4,5-Substitution was confirmed by the 19F NMR spectra showing 
two peaks with shifts of around -85 ppm for each compound, consistent with fluorine 
ortho- to ring nitrogen. Reactions were noticeably slower for the trifluorinated materials 
than for the perfluorinated equivalent, with thioethoxy trifluoropyridazine taking a little 
over twenty four hours to react completely with morpholine at room temperature, and the 
phenyl and isopropoxy compounds taking several days at the same temperature. 
 
Following these results, we next investigated the reactions of thiols with substituted 
trifluoropyridazines. Phenyl, isopropoxy, and morpholino substituted trifluoropyridazines 
were each reacted with a single equivalent of thiophenol. The high nucleophilicity of 
thiophenol is amply demonstrated in these examples, as the reactions all reached 
completion within one hour at 0 °C, a considerable reduction in reaction time compared to 
the reactions of morpholine with the same electrophiles. 
 
Once again, all reactions went in good yield and gave, possibly surprisingly, clean 
monosubstitution at the remaining fluorinated position para- to ring nitrogen. In these 
examples, unlike the previously mentioned case of reaction of thiophenol with 
tetrafluoropyridazine, initial substitution did not then lead to preferential second 
substitution ortho- to the first sulfur substituent under the conditions employed. This may 
be rationalised by considering the uneven charge density in the intermediate, with differing 
importance attached to ortho- and meta- positions. The two cases are represented below 
(Figure 2.7). 
 
76 
Chapter 2: Nucleophilic Aromatic Substitution Reactions of Polyfluoropyridazines 
N
N
F
F
F
F
N
N
F
F
S
F
N
N
F
F
R
F
N
N
F
S
R
FPhSH
PhSH
 
 
Figure 2.7 
 
In the former reaction, as discussed earlier, initial substitution takes place at the arrowed 4- 
position, followed by rapid second substitution at the 5- position, arrowed on the right hand 
side of the diagram. The intermediate involved in the first reaction may be described as 
having the majority of the negative charge delocalised over two fluorine-bearing carbons 
and the ring nitrogen, with the greatest concentration on the heteroatom which, as noted 
before, is the preferred site for the charge, as it lacks the destabilising interactions found 
between charges on carbon and the fluorine lone pairs. Second substitution is more highly 
favoured still, as in this case the greatest component of the charge may still be located on a 
ring nitrogen, while a slightly destabilising interaction with fluorine is removed to be 
replaced by an electronegative but poorly overlapping sulfur atom, which also allows 
further delocalisation and therefore stabilisation of the charge. 
 
In the latter reaction, initial substitution once again takes place para- to the available 
heteroatom, but further reaction ortho- to the thiophenol group requires substitution at the 
3-position. While varying R groups will cause subtle differences, some general 
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observations can be made about the differences in the resulting intermediates. Both 
intermediates contain a ring nitrogen meta- to the position of substitution, while the other 
meta- position bears the R- group in the second step, as opposed to an inductively 
stabilising fluorine atom. The other factor opposing a second substitution is the interchange 
of the remaining heteroatom and C-F group – the first step involves an intermediate with 
ortho- C-F and para- nitrogen, while in the second step the positions are reversed, reducing 
stabilisation, and seemingly providing sufficient barrier to reaction to prevent 
oversubstitution. 
 
In general, it appears that nucleophilic aromatic substitution reactions of functionalised 
trifluoropyridazines with amines and thiols may be performed to give good yields of 
difunctionalised difluorinated pyridazines with excellent levels of regioselectivity. The 
orientation of substitution is readily rationalised, and oversubstitution does not appear to be 
a problem when using activating sulfur nucleophiles. 
 
2.4.2 Reactions with Alkoxides and Carbon Nucleophiles 
 
Encouraged by our successful disubstitution reactions thus far, we moved on to assess 
reactions involving further classes of nucleophiles, namely oxygen- and carbon- centred 
species. The first to be employed was isopropyl alcohol. After four days at reflux, a mixture 
of 4-(3,5,6-trifluoro-4-pyridazinyl)morpholine 1, isopropyl alcohol, and Hünig’s base in 
tetrahydrofuran showed no conversion from starting material. As an extreme example, the 
theoretically most reactive trifluoropyridazine synthesised thus far, 4-(ethylthio)-3,5,6-
trifluoropyridazine 16, was dissolved in tetrahydrofuran with excess isopropyl alcohol and 
base, and microwave irradiated to a temperature of one hundred and eighty centigrade for 
ten minutes. Even under these forcing conditions, no conversion of the starting material 
was observed, so we moved to carry out reactions using the more reactive lithium 
isopropoxide. Our new nucleophile was reacted with phenyl-, morpholino-, and ethylthio- 
substituted trifluoropyridazines 11, 1 and 16, with addition of the nucleophile to the 
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reaction mixture occurring at -78 °C, followed by slow warming to room temperature 
(Table 2.8). 
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Table 2.8 
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The reaction of 4-(ethylthio)-3,5,6-trifluoropyridazine 16 with lithium isopropoxide gave 
the expected 4,5-disubstituted product 23 in good yield, following the trend thus far 
established for second substitutions, with the regiochemistry of the product again confirmed 
by the methods discussed previously. Reaction of our nucleophile with the morpholino- 
substituted trifluoropyridazine 1, however, gave traces of an isomeric byproduct, which 
proved difficult to separate from the major product, causing a significant reduction in 
isolated yield of 18. This appears once again to be due to the use of a more reactive 
nucleophile reducing the importance of stabilisation of the intermediate, and pushing 
regioselectivity away from the expected site, although the consideration of steric effects 
gives further suggestion of disincentive to reaction at the 5-position. Reaction of lithium 
isopropoxide with the phenyl- substituted pyridazine 11 also leads to the formation of small 
amounts of byproducts, but in this case, we were unable to separate the regioisomeric 
byproducts from the major product 24. 
 
With regioselective reactions of trifluoropyridazines with nitrogen-, sulfur-, and oxygen-
centred nucleophiles established, the final area we wanted to explore involved the 
behaviour of these electrophiles with carbon nucleophiles. 
 
It is worth noting that the pyridazine ring is still highly electron deficient, and attempts to 
react methylmagnesium bromide with monosubstituted trifluoropyridazines still result in 
extensive decomposition and the formation of intractable product mixtures, as per previous 
explorations. As such, the carbon nucleophile we chose to employ was again 
phenylmagnesium bromide, for direct comparison with the previous results, and the 
desirable lack of α- hydrogen atoms. Reactions were performed with morpholino-, 
isopropoxy-, and thioethoxy- substituted trifluoropyridazines 1, 10, and 16, with 
temperatures gradually being raised from -78 °C to room temperature over the course of the 
reaction (Table 2.9). 
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Table 2.9 
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The reaction of phenylmagnesium bromide with the morpholino- substituted 
trifluoropyridazine 1 provided two unusual results; not only was the major product the 
unexpected 6- substituted compound 25, but a small quantity of the third possible 
substitution pathway was visible by 19F NMR spectroscopy. Analysis of the spectral peaks 
suggested a pair of compounds each bearing a phenyl group ortho- to ring nitrogen, and 
each possessing one ortho- and one para- fluorine. Comparison with the previously 
acquired spectrum of the 4,5- difunctionalised compound 17 suggested that none of this 
expected isomer was present in the reaction mixture. Confirmation of the structure of the 
major product was provided by a 1H-19F heteronuclear nOe experiment (Figure 2.9), 
showing the proximity of the morpholine protons to the more deshielded fluorine nucleus. 
 
 
Figure 2.8 
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Figure 2.9 
 
Reaction of the Grignard with the isopropoxy- substituted trifluoropyridazine 10 also 
showed a mixture of products, and although separation was not achieved, analysis of NMR 
spectra again suggested that the products were the result of reaction at the two sites 
adjacent to ring nitrogen. 
 
Finally, reaction of the phenyl nucleophile with the 4-thioethoxy trifluoropyridazine 16 was 
performed. In this case, 4,5-disubstitution did appear to take place, but was the minor 
product of the reaction, with the majority of material produced again being the result of 
nucleophilic attack at one of the positions ortho- to ring nitrogen. 
 
It is clear that the regioselectivity of reactions with phenylmagnesium bromide differs 
considerably from that seen in the reactions of amines and thiols. This can again be 
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attributed to the increased reactivity of the nucleophile and resultant alteration of the 
importances of electronic effects in the intermediate and initial state. 
 
As far as the generation of polyfunctionalised pyridazine systems is concerned, the results 
discussed in this section indicate that the order of application of nucleophiles to the scaffold 
may be critical – for example, while alcohols are readily and regioselectively attached to 
the pyridazine core by reaction with tetrafluoropyridazine, reactions of alkoxide with 4- 
substituted 3,5,6-trifluoropyridazine systems seem to give rise to lower yielding and less 
regioselective processes. 
 
2.5 Nucleophilic Aromatic Substitution Reactions of Difluoropyridazines 
 
Having observed some examples of regioselective second substitutions, we wanted to 
ascertain whether or not a selective third substitution would be possible. Reasonable routes 
to 4,5-disubstituted difluorinated pyridazines having been found, the next functionalisation 
should lead to a trisubstituted pyridazine scaffold bearing a single fluorine atom ortho- to 
ring nitrogen. In going from reactions of the tetrafluorinated to the trifluorinated systems, 
we noted a distinct reduction in reactivity, which one would expect to be even greater over 
the transition from trifluorinated to difluorinated materials. Also, we observed that the 
major directing effect, among a number of contributory factors, up until this point has been 
a propensity for reaction para- to the ring nitrogens. With this influence removed, control 
of selectivity falls entirely to the properties of the two previously introduced substituents. 
With a view to maximising the disparity between reactivities at our fluorinated sites, the 
obvious choice of electrophile that we already had in hand was 4-(3,6-difluoro-5-
(phenylthio)pyridazin-4-yl)morpholine 22, bearing a thiophenoxy group, which we have 
already seen to be ortho- activating to some extent, and a morpholino group, which should 
be deactivating and therefore also somewhat meta- directing. 
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Reaction of our chosen electrophile with lithium isopropoxide gave moderate success, 
going to completion without the need for heating, and giving a five to one ratio of products 
by 19F NMR spectroscopic analysis (Scheme 2.18). 
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Scheme 2.18 
 
Unfortunately, these isomers proved resistant to separation, and we have been unable to 
characterise them individually. 
 
It was hoped that the use of a less reactive nucleophile might allow for a cleaner product 
distribution, and enhanced ease of separation. With this intention, we performed the 
reaction between our chosen electrophile and morpholine. The reaction was sluggish, as 
might have been expected from past trends, but after microwave irradiation at 150 °C for 
90 minutes, conversion of the starting material was complete, and 19F NMR spectroscopy 
showed fairly clean transformation to a single major product 33 (Scheme 2.19). 
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Scheme 2.19 
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In this case, purification by column chromatography was fairly straightforward, and the 
trisubstituted fluoropyridazine could be isolated in 71% yield. X-ray crystallography 
determined the structure of the product as that shown (Figure 2.10). 
 
 
 
Figure 2.10 
 
Confirmation of the structure demonstrates that a third regioselective substitution is 
possible, with the orientation determined by the directing effects of the previously 
introduced substituent. 
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2.6 Conclusions 
 
The aims of this chapter were to explore the reactions of a number of variously fluorinated 
pyridazine systems with a range of nucleophilic species, with the intention of gaining a 
better understanding of the behaviour of electron deficient heterocyclic cores, and 
determine the suitability of tetrafluoropyridazine as a potential scaffold for the generation 
of multiply substituted new chemical entities. A number of routes towards highly 
functionalised pyridazine systems have been demonstrated, and several results of interest 
highlighted. 
 
It has been shown that tetrafluoropyridazine will tolerate reaction with a wide variety of 
nucleophiles, giving encouraging yields of monosubstituted products, and that excellent 
selectivity for reaction at the 4- position is possible. It seems that the regioselectivity of 
substitution depends largely upon the ability of the reactive intermediate produced to 
stabilise the charge generated, but initial state considerations also bear non-negligible 
weight, with significant quantities of by-products formed when reactive nucleophiles are 
employed. 
 
Second functionalisations showed a greater variety of selectivities; while amines and thiols 
behaved in a controlled fashion and reacted at the expected site to give good yields of 
difunctionalised products, more reactive nucleophiles gave less predictable results. Having 
established the unsuitability of alcohols for the second substitution, the use of alkoxides 
gave, in certain cases, mixtures of products, with the expected reaction pathway competing 
against substitution at the harder sites. The use of Grignard reagents pushes selectivity well 
away from that seen for amines and thiols, with considerable replacement of fluorine atoms 
ortho- to ring nitrogen. This variance in behaviour necessitates the careful sequencing of 
reactions in order to synthesise certain difunctionalised pyridazines, an illuminating 
example being the disparity in reaction products observed when reacting morpholine and 
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phenylmagnesium bromide with tetrafluoropyridazine, depending upon the order of 
application (Scheme 2.20). 
 
N
N
F
F
F
F
N
N
F
F
F
F
N
N
F
N
F
O
N
N
F
N
F
O
i) morpholine
i) PhMgBr
ii) morpholine
ii) PhMgBr
17
25  
 
Scheme 2.20 
 
By the third step, the reactivity of the electrophile is greatly reduced, and fairly forcing 
conditions are required. The directing effects available for differentiation of the two 
reactive sites are minimal, and even with optimal substituents for regioselectivity 
employed, selective substitutions are not guaranteed. While successful trifunctionalisation 
has been demonstrated, the example seems far from general. 
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Chapter 3 
 
Reactions of Trifluoropyridazines with Binucleophiles 
 
3.1 Aims and Approach 
  
While the preceding chapter concerned itself with the reactions of polyfluoropyridazine 
derivatives with monofunctional nucleophiles, we were also interested in the possibility of 
reacting polyfluoropyridazines with bifunctional nucleophiles. The most obvious reason for 
this interest is in the nature of the products obtained, which will be fused polycyclic 
systems similar to some of those seen in chapter 1, allowing what will hopefully be a 
general approach to a wide range of functionalised pyridazine ring fused systems in the 
manner shown below (Scheme 3.1). 
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Scheme 3.1 
 
Depending on the nature of the tether between the two ends of the binucleophile, a range of 
fused structures, including those containing the skeletal forms represented below (Figure 
3.1), should be accessible. Frameworks such as these have been shown to be highly 
prevalent among pharmaceutical compounds, and as such similar structures might 
reasonably be expected to possess drug-like properties.1 
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Figure 3.1 
 
The other attractive possibility of reactions with binucleophiles is the level of regiocontrol 
that may be offered. As discussed at the end of the previous chapter, selective reactions of 
difluorinated pyridazines appear at present to be challenging. While some regiocontrol is 
possible, the major directing effect in reactions of tetra- and tri-fluoropyridazines, that of 
orientation with respect to ring nitrogens, will generally be absent in difluoropyridazines, 
with control of regiochemistry ceded to the rather more nebulous influences of the 
substituents. If, after introduction of the first substituent, a binucleophile is introduced to 
the fluoropyridazine, our prior results would indicate a reasonable likelihood of initial 
reaction ortho- to the first substituent, after which the tethered nature of binucleophile 
should direct subsequent attack to only one of the two available sites, encouraging clean 
generation of a single isomer of a functionalised, ring-fused pyridazine. 
 
With these objectives in mind, the reactions described in this chapter will involve the 
combination of previously synthesised functionalised trifluoropyridazines with a number of 
binucleophiles. This should give an indication of the applicability of our general method to 
the generation of ring fused heterocyclic systems, and also establish the regioselectivity of 
reactions when employing asymmetrical binucleophiles. 
 
3.2 Reactions of 4-(3,5,6-Trifluoropyridazin-4-yl)morpholine 
 
For our initial experiments involving the reactions of functionalised fluorinated pyridazines 
with binucleophiles, we chose 4-(3,5,6-trifluoropyridazin-4-yl)morpholine as a model 
substrate, as it was relatively accessible and was expected to show chemistry representative 
of a number of our previously prepared compounds without possessing any functionality 
likely to interfere in subsequent nucleophilic aromatic substitution reactions. 
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The first reaction performed was between 4-(3,5,6-trifluoropyridazin-4-yl)morpholine 1 
and N,N’-dimethylethylene diamine, a symmetrical binucleophile the reactivity of which 
has previously been demonstrated in its reactions with other polyfluorinated heterocycles.2 
While we were confident that initial nucleophilic attack would be successful, our previous 
experiments with sequential monosubstitutions suggested that the ring closure might be 
difficult. Happily, the desired fused product, 3-fluoro-5,8-dimethyl-4-morpholin-4-yl-
5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 34, was produced in good yield after stirring 
the reagents together in THF at room temperature (Scheme 3.2). The apparent ease of 
reaction in this case, in contrast to what might have been expected, can be attributed to the 
increase in reaction rate afforded by the fact that the final step is intramolecular, the 
rapidity of ring closing further emphasised by the good yield, and absence of ethylene 
diamine bridged bipyridazines.  
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Scheme 3.2 
 
Encouraged by our successful reaction of a substituted trifluoropyridazine with a 
bifunctional nucleophile, we next investigated the use of some other dinitrogen 
nucleophiles, namely benzamidine and two aminopyridines. In these cases, the formation of 
the desired fused ring systems was not achieved, despite the use of vigorous conditions and 
strong bases such as alkyl lithiums and sodium hydride. 
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The final set of experiments performed on 4-(3,5,6-trifluoropyridazin-4-yl)morpholine 1 
was that involving reaction with a range of asymmetrically disubstituted benzenes, the 
object of which was to produce a number of fused tricyclic systems. 
 
The nucleophiles employed were 2-mercaptophenol, 2-aminophenol, and 2-
aminobenzenethiol. Reaction with 2-mercaptophenol gave a tricyclic product after a few 
hours stirring at room temperature, the structure of which is presumed to be that shown 
below (Scheme 3.3), by analogy with the similar reactions outlined later in this chapter. 
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Scheme 3.3 
 
In contrast to the above, reactions with various aniline derivatives failed to effect the 
desired results, even after extended periods of heating, reflecting the difference in 
activating ability of sulfur- and nitrogen- centred substituents. 
 
As we have already seen, a sulfur substituent activates the pyridazine ring to further attack, 
particularly ortho- and para- to itself, while a nitrogen substituent is deactivating, and 
should have a tendency to direct subsequent substitution to the meta- position (Figure 3.2). 
It is possible that a further factor is the presence of the hydrogen atom on the bridging 
nitrogen, which is potentially capable of hydrogen bonding to the second nucleophilic 
centre, orienting it away from the electrophilic diazine site. 
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Figure 3.2 
 
While a couple of syntheses of fused systems from 4-(3,5,6-trifluoropyridazin-4-
yl)morpholine 1 have been demonstrated, it was disappointing that the procedure was not as 
general as might have been hoped, and we moved on to consider other monofunctionalised 
systems. 
 
3.3 Reactions of 3,5,6-Trifluoropyridazin-4-amine 
 
In our prior experiments, we observed the deactivating effect of a nitrogen substituent, and 
we were conscious that this effect may be a factor in the difficulties outlined in section 3.2. 
Another consideration is that the introduction of a secondary amine, while potentially 
useful as a route to increased diversity, is essentially irreversible and of little use for further 
synthetic transformations. 
 
With this in mind, we turned to the investigation of the reactions of 4-amino-3,5,6-
trifluoropyridazine 36. It was hoped that this scaffold would present us with two valuable 
characteristics: of immediate interest was the possibility of reducing the deactivating 
influence of the nitrogen atom by oxidation to a nitro group, but we were also aware that 
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the amino group is in itself a useful synthetic handle, possibly allowing further 
functionalisation or even complete removal and replacement with a different group 
(Scheme 3.4). 
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Scheme 3.4 
 
The known3 aminopyridazine was synthesised from tetrafluoropyridazine in moderate yield 
by straightforward reaction with ammonia (Scheme 3.5).  
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Scheme 3.5 
 
Before any attempts were made to modify the amino group, we investigated the reactions of 
the amino pyridazine 36 with binucleophiles, to compare its behaviour with that of the 
morpholino- substituted pyridazine 1. 
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Perhaps unsurprisingly, the reactivity of both substrates was found to be similar; reactions 
with aminopyridines again proved unsuccessful, while of the reactions attempted with 
disubstituted benzenes only that involving 2-mercaptophenol led to the isolation of a fused 
tricyclic product 37 (Scheme 3.6), most probably due to the reasons given above. 
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Scheme 3.6 
 
With the reactivity of the parent amine established, we looked towards methods of 
increasing reactivity by lessening the electron-donating properties of the amino group. Our 
first investigations in this area involved attempting to acylate the amino group, hopefully 
increasing the electrophilicity of the diazine (Scheme 3.7). 
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Scheme 3.7 
 
Unfortunately, attempts to acylate our amine under various conditions failed to produce the 
desired product, demonstrating the very low nucleophilicity of the exocyclic nitrogen atom. 
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An alternative method of activation envisaged was the conversion of the amino group to a 
nitro functionality. The analogous reaction has previously been performed on 4-
aminotetrafluoropyridine, using peroxytrifluoroacetic acid as the oxidising agent. Recent 
work at Durham has shown that the reaction may be performed more cleanly by using the 
powerful oxidising agent hypofluorous acid (Scheme 3.8).  
 
N
F
F
F
F
NH2
N
F
F
F
F
NO2
HOF.MeCN
 
 
Scheme 3.8 
 
Given the apparently low reactivity of our aminopyridazine and the ready availability of the 
necessary equipment for the generation and use of hypofluorous acid, we decided that the 
latter method was worth investigating. While reaction of 4-amino-3,5,6-trifluoropyridazine 
36 with the oxidising agent showed gratifyingly high levels of conversion from the starting 
material, none of the desired trifluorinated nitro compound could be isolated from the 
reaction mixture. It seems likely that the initial product is highly unstable and rapidly 
undergoes further reaction, most probably with water, to form more stable species. 
 
No further investigation of the reactions of the amino trifluoropyridazine was undertaken. It 
would appear that the scaffold is of limited use as a coupling partner for binucleophiles, and 
conversion to the nitro compound increases reactivity of the heterocycle to a point where 
storage and handling become very difficult. 
 
3.4 Reactions of 4-(Ethylthio)-3,5,6-trifluoropyridazine 
 
Having previously observed the activating effect of a sulfur substituent with respect to 
nucleophilic aromatic substitutions of polyfluoropyridazines, we hoped that such starting 
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materials would be the most likely to undergo successful reactions with binucleophiles to 
form the ring fused compounds we desired. 
 
4-(Ethylthio)-3,5,6-trifluoropyridazine 16, as synthesised in chapter 2, was chosen as the 
starting material for the following reactions in light of its ease of preparation and 
purification, and expected higher reactivity towards nucleophiles. 
 
Reaction with N,N’-dimethylethylene diamine once again proceeded quickly and cleanly to 
give the expected fused bicyclic product 38 in good yield (Scheme 3.9). 
 
N
N
S
FF
F N
N
S
FN
N
N
H
H
N
DIPEA
THF
16 38 77%  
 
Scheme 3.9 
 
Reactions with the three disubstituted benzenes described above were then performed, in 
the hope that the increased reactivity towards nucleophiles bestowed on the heterocyclic 
ring by the thioethoxy group might allow all three adducts to be prepared. The first 
nucleophile employed was 2-mercaptophenol, which, unsurprisingly, reacted well to give 
the fused bicyclic product 39 (Scheme 3.10).  
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Scheme 3.10 
 
It was possible to grow crystals of the product that were suitable for analysis by X-ray 
crystallography, which confirmed the structure as shown below (Figure 3.3). It would 
appear that the initial attack is performed by the sulfur atom, further activating the 
intermediate to nucleophilic attack by the oxygen atom. 
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Figure 3.3 
 
Reaction of 4-(ethylthio)-3,5,6-trifluoropyridazine 16 with 2-aminophenol at room 
temperature led to what appeared, by 19F NMR spectroscopy, to be a difluorinated 
pyridazine, presumably the uncyclised intermediate. Microwave irradiation of the reaction 
mixture to an indicated temperature of 100 °C for a period of five minutes effected 
conversion to the tricyclic product 40 (Scheme 3.11). 
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Scheme 3.11 
 
Once again it was possible to grow crystals suitable for X-ray crystallography, which 
demonstrated that the major product was 4-ethylsulfanyl-3-fluoro-10H-9-oxa-1,2,10-triaza-
anthracene (Figure 3.4), formed via initial attack by nitrogen followed by cyclisation 
through oxygen, rather than the isomeric 4-ethylsulfanyl-3-fluoro-9H-10-oxa-1,2,9-triaza-
anthracene. 
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Figure 3.4 
 
By comparing the structures of the two products above, it may be seen that the difference in 
reactivities may be rationalised by appreciating the differing effects of the substituents in 
the intermediate, as discussed in section 3.2. Also of note is the difference in reactivity 
between 4-(ethylthio)-3,5,6-trifluoropyridazine 16 and 4-(3,5,6-trifluoropyridazin-4-
yl)morpholine 1; while the former affords a ring fused product after reaction with 2-
aminophenol, the deactivating character of the morpholino substituent in the latter made 
synthesis of the desired fused system impractical. 
 
The third disubstituted benzene, 2-aminobenzenethiol, was also found to lead to the 
formation of a tricyclic product after microwave irradiation (Scheme 3.12). Although X-ray 
quality crystals could not be grown, analogy would suggest that the product is likely to be 
the result of initial attack by nitrogen, followed by cyclisation through sulfur, particularly 
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as initial attack by sulfur would be activating, giving reactivity similar to that seen for 2-
mercaptophenol, and unlikely to require irradiation, as in the case of 2-aminophenol. 
 
N
N
S
FF
F N
N
S
F
H
N
S
DIPEA
THF
NH2
SH
16 41 63%  
 
Scheme 3.12 
 
Encouraged by the increased reactivity shown by the thioethoxy- substituted 
trifluoropyridazine, we turned our attention back to the aminopyridines which had proved 
unsuitable for reaction with the nitrogen- substituted trifluoropyridazines. 
 
Reaction of 4-(ethylthio)-3,5,6-trifluoropyridazine 16 with 2-aminopyridine, after 
microwave irradiation to an indicated temperature of 150 °C for thirty minutes, gave a 
moderate quantity of the aza-fluorene, assigned as 4-ethylsulfanyl-3-fluoro-1,2,4b,9-
tetraaza-fluorene 42 as shown below (Scheme 3.13). 
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Scheme 3.13 
 
103 
Chapter 3: Reactions of Trifluoropyridazines with Binucleophiles 
This regiochemistry is suggested by prior reactions between aminopyridines and 
perfluoropyridine derivatives, which have been shown to lead to products in which sp3 
hybridised nitrogen is attached to the site of initial nucleophilic attack.4 
 
The slightly more nucleophilic 2-amino-3-picoline was also used, and in this case, although 
microwave irradiation proves useful in increasing the rate of reaction, complete conversion 
of starting material is observed after one week of stirring at room temperature (Scheme 
3.14). 
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Scheme 3.14 
 
Recrystallisation of the product allowed elucidation of the structure by means of X-ray 
crystallography, confirming the geometry as shown (Figure 3.5). 
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Figure 3.5 
 
The final binucleophile employed was ethyl acetoacetate (Scheme 3.15). In contrast to its 
behaviour when combined with tetrafluoropyridazine, the reaction with 4-(ethylthio)-3,5,6-
trifluoropyridazine 16 was very sluggish, requiring extended microwave irradiation to push 
the reaction to completion. 
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Scheme 3.15 
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The structure of the product may be inferred by analogy with the behaviour observed when 
combining the nucleophile with tetrafluoropyridazine, as discussed in chapter 2, and from 
the known reactions of ethyl acetoacetate with similar polyfluorinated systems.5  
 
3.5 Conclusions 
 
In undertaking the work detailed in this chapter we set out to demonstrate the applicability 
of our synthetic approach to the formation of selectively functionalised fused heterocyclic 
systems. By combining binucleophiles with the class of trifluoropyridazines synthesised in 
chapter 2, we hoped to show that a variety of fused systems could be produced in a 
regiochemically controlled manner.  
 
All the trifluoropyridazines used proved suitable for further derivatisation with at least 
some binucleophilic species, although there appears to be a considerable difference in 
reactivity depending on the nature of the substituent already in place, with electron 
donating substituents causing a marked decrease in the electrophilicity of the heterocycle. 
 
A number of asymmetrical binucleophiles have been employed, and reactions have tended 
to lead to a single isolated product in reasonable to good yield, demonstrating not only 
good selectivity between the electrophilic sites of the pyridazine, but also the nucleophilic 
sites of difunctional attacking species. 
 
While the number of reactions covered in this chapter is relatively small, the principle by 
which we envisioned creating a library of fused systems has been demonstrated. 
Combination of suitable examples of trifluoropyridazines and binucleophiles will allow 
generation of diverse families of fused fluoroheterocycles, which may in themselves be of 
interest as potential drug candidates, or be amenable to further derivatisation. 
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Chapter 4 
 
Reactions of Tetrabromothiophene 
 
4.1 Background 
 
While the previous two chapters of this thesis have been concerned with the reactions of 
highly halogenated pyridazines, we were also interested in applying the methodology 
already laid out to five-membered heterocyclic systems, particularly thiophene. In contrast 
to prior efforts, this chapter will focus on the chemistry of perbrominated systems, for two 
reasons. Firstly, perfluorinated examples of the five-membered heterocycles are either 
unknown, or difficult to synthesise and unstable.1 Secondly, by moving from perfluorinated 
to perbrominated systems, the possibilities of performing metal-halogen exchange reactions 
and metal-mediated cross-couplings are introduced, widening the range of products 
potentially available. 
 
A survey of the literature concerning perbrominated five-membered heterocycles reveals 
the paucity of published reactions. Tetrabromopyrrole has been N-methylated,2 and the 
only reactions of tetrabromofuran recorded are oxidations, such as its solid-state photo-
oxidation to a γ-lactone and its photo-oxidation to dibromomaleic anhydride in benzene.3, 4 
 
There is a little more information about perbromothiophene and its reactions. It is 
synthesised in good yield by action of elemental bromine on thiophene.5 The stability and 
relative ease of handling of thiophenes has meant that they have seen a variety of uses. 
Perbromothiophene is often encountered as a precursor of polycyclic compounds such as 
porphyrins,6 dithienothiophenes,7, 8 and TTF-type compounds.9  
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Porphyrin synthesis involves conversion of the tetrabromothiophene into 3,4-
dibromothiophene, which can be arylated using a Grignard reagent, and then lithiated 
before undergoing a series of couplings and condensations to yield the porphyrin product, 
giving an indication of how this system can be used for the synthesis of polyfunctional 
species by sequential displacement of the four bromine atoms (Scheme 4.1). 
 
 
S
Br Br
Br Br S
Br Br
S
SLi Li S
CHO
OH OH
H H
Zn
AcOH/H2O
PhMgBr
THF
S
OH OH
H H
+
N
H
BF3 OEt2
CH2Cl2, RT, DDQ
N
S N
S
+
 
 
Scheme 4.1 
 
Conceptually, syntheses of other large polycyclic molecules follow the same pattern: 
reaction with one reagent at the favoured 2- and 5-positions, followed by further reaction at 
the 3- and 4-positions, and then often some kind of condensation or ring closing reaction to 
generate the desired target. 
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Finally, tetrabromothiophene has also been used in palladium coupling reactions, both 
Sonogashira10 and Suzuki-Miyaura11 type. As in previous reactions, the 2- and 5-positions 
are substituted first, and the 3- and 4-positions can subsequently be functionalised with a 
different side group (Scheme 4.2). 
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Scheme 4.2 
 
In summary, it has been seen that tetrabromothiophene is a good substrate for metal-
mediated cross-coupling reactions, although relatively few examples of its use as such 
appear in the literature. With the addition of lithium-halogen exchange reactions and the 
possibility of nucleophilic aromatic substitution chemistry, tetrabromothiophene seems a 
promising substrate on which to conduct investigation into sequential substitution for the 
purpose of synthesis of polyfunctional systems. 
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4.2 Aims and Approach 
 
As discussed in previous chapters, this thesis is concerned with developing versatile, 
general methodology for the synthesis of a wide range of polyfunctionalised and selectively 
fluorinated heterocyclic systems from perhalogenated starting materials. This chapter will 
focus on our attempts to apply our approach to the functionalisation of the perbrominated 
thiophene scaffold.  
 
By applying nucleophilic aromatic substitution conditions, as demonstrated in the 
preceding chapters, alongside metal-mediated coupling reactions and debromolithiations 
followed by trapping with suitable electrophiles, we hope to be able to gain access to 
diverse multi-substituted heterocycles. 
 
For example, the scheme below (Scheme 4.3) shows a few examples of the molecules that 
may be prepared in this way. Included are three simple processes: nucleophilic substitution; 
Suzuki-Miyaura cross-coupling; and lithium-halogen exchange followed by reaction with 
F+ or other suitable electrophiles. 
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Scheme 4.3 
 
By altering the order in which these processes are performed, it should be possible to create 
a range of substituted five-membered heterocycles, and also establish a mechanistic 
rationale for the substitution pattern. 
 
4.3 Fluorination of Bromothiophenes 
 
Among the processes we wanted to perform on tetrabromothiophene was the exchange of 
bromine for fluorine, and we envisaged this transformation taking place by way of lithium 
halogen exchange followed by trapping with a source of electrophilic fluorine, such as 
Selectfluor®. 
 
Before performing this reaction on tetrabromothiophene, we wanted to establish its 
applicability, and as such we carried the process out on various mono-brominated 
thiophene derivatives. 
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Initial experiments, utilising n-butyllithium as the lithiating agent in THF, and Selectfluor® 
as the source of “F+”, proved unsuccessful, most probably due to the insolubility of the 
fluorinating agent in the reaction medium. 
 
Changing the fluorinating agent to N-fluorobenzenesulfonimide (NFSI), which is readily 
soluble in THF, allowed encouraging results to be obtained (Table 4.1). Both 2- and 3-
bromothiophene could be converted to the corresponding fluoroheterocycles by treatment 
with n-butyllithium and then addition of a solution of fluorinating agent in THF, followed 
by slow warming to room temperature from -78 °C. 
 
113 
Chapter 4: Reactions of Tetrabromothiophene 
S
Br
S
F
i) BuLi
Solvent A
ii) NFSI
THF
a By 19F NMR spectroscopy
Starting
material Solvent A Product Yield
a (%)
S Br
THF S
F
45
80
S Br
ether S
F
45
85
S
Br
THF S
F
46
36
S
Br
ether S
F
46
50
 
 
Table 4.1 
 
With the entire process conducted in THF, 2-bromothiophene could be converted to the 
fluorothiophene 45 in 80% yield (determined by 19F NMR spectroscopy of the reaction 
mixture with respect to an internal reference). However, isolation of the appreciably 
volatile fluorinated product from the reaction medium proved difficult. Similarly, 3-
bromothiophene was converted to its fluorinated counterpart 46 in 36% yield. Performing 
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the lithiation in diethyl ether (in which NFSI is only sparingly soluble) increases the yields 
to 85 and 50% respectively. 
 
With conversion from bromothiophene to fluorothiophene successfully achieved, we next 
turned to the investigation of the reactions of some substituted bromothiophenes. Our first 
substrate was 2-bromo-5-nitrothiophene, the reaction of which (Scheme 4.4) failed to 
produce any of the desired product, with a large volume of tarry, intractable material 
produced. 
 
S SBr NO2 F NO2
X
i) BuLi
ii) NFSI
THF  
 
Scheme 4.4 
 
Subsequently, a selection of substituted bromothiophenes were subjected to the fluorination 
conditions described above, and found to give the desired fluoroheterocycles in moderate to 
good yields, as shown in the table below (Table 4.2). 
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Starting material Product Yielda (%)
S Br
S F
47
88
S Br
S F
48
78
S BrCl
S FCl
49
43
S Br
Br
S F
Br
50
65
S
R
S
R
i) BuLi
ether
ii) NFSI
THF
Br Br
a By 19F NMR spectroscopy  
 
Table 4.2 
 
The two methylated bromothiophene materials gave similar results to those observed for 
the 2-bromothiophene example. In the case of 2-bromo-5-methylthiophene, the presence of 
the methyl group raises the yield of fluorinated product from 80 to 88%, which may be 
rationalised by the increased electron density of the thienyl anion improving reactivity 
towards the electrophile. With the methyl group in the 3-position, the yield is slightly lower 
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than that observed for the unmethylated 2-bromothiophene, at 78%, most likely due to 
steric hindrance to reaction. 
 
In contrast to the addition of methyl groups, the presence of electron-withdrawing halogen 
substituents leads to a marked decrease in yields. The fluorination of 2-bromo-5-
chlorothiophene led to the formation of a single fluorinated heterocycle 49 in low yield, 
indicating the effect of electron-withdrawing substituents, but also demonstrating the 
selectivity possible when performing lithium halogen exchange on a substrate bearing 
different halogen atoms.  
 
Finally, fluorination of 2,3-dibromothiophene afforded the fluorinated product 50 in 65% 
yield, which when compared to the yield achieved in the fluorination of 2-bromothiophene, 
demonstrates a reduction which may be attributed to both steric and electronic effects. Once 
again, only a single fluorinated thiophene product was observed, showing the excellent 
regioselectivity possible in these situations. 
 
4.4 Reactions of Perbromothiophene 
 
Having confirmed possibilities for functionalisation afforded by lithiation of 
bromothiophenes, we moved our focus to the chemistry of perhalogenated systems, in 
keeping with the theme of this thesis. Perbromothiophene 51 was readily prepared from the 
parent heterocycle by simple bromination, following literature procedure (Scheme 4.5).5 
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Scheme 4.5 
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With our perhalogenated substrate in hand, we undertook a series of experiments aimed at 
establishing the viability of a number of methods for producing functionalised compounds. 
 
4.4.1 Debromolithiations 
 
Bearing in mind our previous results indicating the reduced yields encountered when 
lithiating and then fluorinating bromothiophenes bearing electron-withdrawing or sterically 
hindering groups, we anticipated potential problems with our perbrominated species, and as 
such initial experiments with the perbrominated thiophene involved trapping with H+, as we 
expected the proton to be particularly readily attacked by our nucleophilic intermediate. 
 
Lithium halogen exchange followed by the addition of dilute hydrochloric acid gave the 
desired 2,3,4-tribromothiophene 52 in reasonable yield (Scheme 4.6). 
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Scheme 4.6 
 
Encouraged by confirmation that lithiation of the perhalogenated heterocycle and 
subsequent trapping with an electrophile was possible in our hands, we expanded the range 
of electrophiles employed in order to further explore the tolerances of the process. Our 
results are shown in the following table (Table 4.3). 
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Electrophile Product Yield (%)
iodomethane SBr
Br Br
53
53
1-iodoheptane
SBr
Br Br
trace
benzyl bromide
SBr
Br Br
trace
NFSI
SBr
Br Br
F
0
SBr
Br Br
Br SBr
Br Br
1) BuLi
2) Electrophile
THF R
 
 
Table 4.3 
 
The reaction of the thienyllithium lithium species with iodomethane gives the 2-methyl 
substituted tribromothiophene 53 in sufficient yield for it to be recrystallised from the 
organic extract of the crude reaction mixture. The structure of the product was confirmed 
by X-ray crystallography (Figure 4.1). 
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Figure 4.1 
 
Moving from the unhindered iodomethane to the considerably bulkier 1-iodoheptane 
resulted in a marked decrease in the amount of product formed, and while the presence of 
the desired product could be surmised from GC-MS analysis of the reaction mixture, 
isolation of the product from the highly complex mixture was not achieved. 
 
A similar result was observed when the electrophile employed was benzyl bromide. Once 
again, although GC-MS indicated that small quantities of the desired product were present, 
isolation of the pure compound could not be accomplished. 
 
The final electrophile listed in the above table, NFSI, proved less reactive still. The reaction 
resulted in the formation of a highly complex mixture of products, within which the desired 
compound was not observed by either GC-MS or 19F NMR spectroscopic analysis. 
 
In conclusion, it would appear that the low yields of products arising from 
debromolithiation and trapping with electrophiles, coupled with the difficulties encountered 
during product isolation, make this approach unsuitable for, for example, parallel synthesis 
techniques. 
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4.4.2 Reactions with Nucleophiles 
 
The next class of reactions that we wanted to explore, in keeping with the procedures 
described in the preceding chapters, was that involving the behaviour of 
tetrabromothiophene with nucleophiles. While bromothiophenes do not at first look as 
promising as fluoropyridazines for the purposes of functionalisation by nucleophilic 
aromatic substitution, there are some precedents in the literature, involving nucleophilic 
attack on electron deficient bromothiophenes (Scheme 4.7).12 
 
SBr NO2 SN NO2
N
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Scheme 4.7 
 
It was envisaged that our perhalogenated substrates may act as electrophiles (Scheme 4.8), 
allowing the preparation of multiply substituted products by a series of nucleophilic 
aromatic substitutions. 
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Scheme 4.8 
 
Initial reactions were performed with sodium alkoxides, and reactions under reflux led to 
the formation of tribromothiophene 52, rather than the desired ethers, most probably as a 
result of bromophilic attack on the substrate (Scheme 4.9).13 
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Scheme 4.9 
 
Similar results were observed for the reactions of tetrabromothiophene with sodium 
thioethoxides, while reflux in the presence of amine nucleophiles failed to give conversion 
from starting materials. 
 
It would appear that tetrabromothiophene is an unsuitable scaffold for the purposes of 
generating libraries of polyfunctionalised heterocyclic systems via sequential nucleophilic 
aromatic substitutions, and no further nucleophilic substitutions were attempted. 
 
4.4.3 Buchwald-Hartwig and Ullmann-Type Reactions 
 
Following the disappointing results of our investigation into the reactions of 
tetrabromothiophene with nucleophiles, we turned to possible alternative routes to the 
desired target compounds. Two obvious contenders were the Buchwald-Hartwig and 
Ullmann reactions, which allow the synthesis of bifunctional ethers and amines from a 
variety of bromo-aromatic starting materials. 
 
The Buchwald-Hartwig amination was explored for perbromothiophene using both primary 
and secondary amines, and various bases, but no conversion to the desired products was 
observed under any of the reaction conditions (Scheme 4.10). 
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Scheme 4.10 
 
The alternative approach, the copper-catalysed Ullmann reaction, was also attempted and 
again, we failed to observe any of the desired products in the reaction mixture (Scheme 
4.11). 
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Scheme 4.11 
 
With these approaches appearing unsuitable, it is apparent that the formation of thiophene-
heteroatom bonds remains elusive, certainly compared to the slightly more readily 
achievable carbon-carbon bond forming processes. 
 
4.4.4 Suzuki-Miyaura Reactions 
 
Having touched upon metal-catalysed coupling reactions in the previous section, we also 
wanted to explore the Suzuki-Miyaura cross-coupling of tetrabromothiophene, with the 
intention of forming new carbon-carbon bonds for functionalisation purposes. 
123 
Chapter 4: Reactions of Tetrabromothiophene 
 
As outlined at the beginning of this chapter, Suzuki couplings of tetrabromothiophenes 
have been reported, but generally with the purpose of producing symmetrically 
disubstituted products. As elsewhere in this thesis, we were primarily concerned with 
achieving selective monosubstitution, and as such we performed the coupling reaction 
between tetrabromothiophene 51 and a single equivalent of phenylboronic acid in the 
presence of five molar % Pd(PPh3)4 and a variety of solvents and bases, in order to 
determine the optimum conditions for reaction. The results of this screening process, with 
conversion from starting material and yield of monosubstituted product 54 as determined 
by GC-MS analysis, are tabulated below (Table 4.4). 
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Base Solvent Conversion (%) Yield (%)
K2CO3 toluene 93 81
K2CO3 DMF 93 72
K2CO3 THF 32 21
K2CO3 IPA 100 45
K2CO3 MeCN 57 57
KF toluene 63 60
KF DMF 81 64
KF THF 0 0
KF IPA 56 56
KF MeCN 28 28
Na3PO4 toluene 86 74
Na3PO4 DMF 100 62
Na3PO4 THF 67 43
Na3PO4 IPA 84 62
Na3PO4 MeCN 74 74
Ba(OH)2 toluene 3 3
Ba(OH)2 DMF 84 54
Ba(OH)2 THF 20 20
Ba(OH)2 IPA 100 0
Ba(OH)2 MeCN 0 0
SBr
Br Br
Br SBr
Br Br
Pd(PPh3)4
PhB(OH)2
base
solvent
51 54
 
Table 4.4 
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It will be noted that the best results were seen when potassium carbonate was used as the 
base, in a medium of toluene. Although in some cases reasonable yields were achieved, 
isolation of the products was arduous. The persistent presence of tetrabromothiophene and 
disubstituted products alongside the desired monosubstituted product, coupled with the 
low, and similar, affinity all three show towards stationary phases during chromatography, 
makes separation of the products impractical, and this approach, certainly for 
symmetrically halogenated thiophenes, does not seem suitable for our purposes. 
 
4.5 Conclusions 
 
At the start of this chapter we set out our aims in the area of the chemistry of 
bromothiophenes, which were to investigate the feasibility of nucleophilic substitutions, 
metal-catalysed cross-couplings, and debromolithiations followed by trapping with 
electrophiles. Despite some encouraging results, tetrabromothiophene seems a far less 
accommodating scaffold than tetrafluoropyridazine. 
  
Debromolithiation of tetrabromothiophene has been demonstrated, and the thienyllithium 
anion has been trapped using a number of electrophiles, with varying degrees of success. 
While tribromothienyllithium requires the application of fairly reactive non sterically 
hindered electrophiles, reactions of less highly halogenated bromothiophenes have proved 
successful even with the comparatively unreactive NFSI, and trends in reactivity and 
regioselectivity of mono- and di-brominated thiophenes have been shown. 
 
Reactions with nucleophiles have been disappointing, in contrast to our earlier studies of 
the reactions of perfluorinated systems, and nucleophilic aromatic substitution of 
tetrabromothiophene does not seem feasible due to competing bromophilic attack. 
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Finally, metal-mediated couplings have shown mixed results. While Buchwald-Hartwig 
and Ullmann-type reactions have thus far proved unsuccessful, Suzuki-Miyaura cross-
couplings have allowed us to produce mono-arylated thiophenes in moderate yields. 
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Conclusions 
 
This thesis has described the synthesis of a number of functionalised heterocyclic systems 
from halogenated heterocyclic precursors. As described in the introduction, versatile routes 
towards multiply functionalised heterocyclic cores are potentially valuable tools for the 
rapid exploration of new regions of chemical space, with particular emphasis on the 
discovery of medicinal molecules by rapid analogue synthesis of large numbers of drug-like 
compounds. 
 
Tetrafluoropyridazine has been shown to be an excellent scaffold for the generation of 
highly functionalised species by sequential nucleophilic aromatic substitution processes. 
Reactions with a wide range of mononucleophiles have been demonstrated, the majority of 
which give good yields and high levels of regioselectivity (Scheme 5.1). 
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Scheme 5.1 
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The effects directing nucleophilic aromatic substitutions in tetrafluoropyridazine have been 
discussed, and toleration of a number of nucleophilic species has been demonstrated. 
 
After the first functionalisation is performed, some of the resultant trifluoropyridazine 
systems may be reacted again to further diversify the range of possible products. Reactions 
of ethylsulfanyl- substituted trifluoropyridazines with tethered difunctional nucleophiles 
give rise to ring-fused pyridazine systems, whose skeletal forms suggest pharmacological 
potential (Scheme 5.2). 
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Scheme 5.2 
 
Alternatively, second substitutions may be performed using another mononucleophile to 
produce a difunctionalised difluoropyridazine system (Scheme 5.3). In this case, both the 
directing effect of the first substituent, and the character of the incoming nucleophile need 
to be understood to rationalise the results of reactions, with different substitution patterns 
being the potential result of changing the order in which nucleophiles are applied to the 
fluoropyridazine core. For example, to produce a pyridazine substituted at the 4- and 5- 
positions with ether and thioether functionalities, the various directing effects suggest that 
the first reaction should be with an alcohol, followed by second substitution using a thiol. 
The behaviour described in chapter 3 suggests that a wide range of difunctionalised 
difluoropyridazines should be accessible through these simple nucleophilic aromatic 
substitution processes. 
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Scheme 5.3 
 
Third substitutions of fluoropyridazines have also been demonstrated, leading to highly 
functionalised monofluorinated pyridazine systems. In these cases, reactions become more 
difficult as the less electrophilic pyridazine ring becomes decreasingly susceptible to 
nucleophilic attack, and the regioselectivity of the reaction suffers. Despite this, a 
regioselective substitution reaction of a difluoropyridazine system has been demonstrated, 
showing not only that tetrafluoropyridazine is amenable to at least three sequential 
functionalisation reactions (Scheme 5.4), but also that high regioselectivity can be carried 
through this process. 
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Scheme 5.4 
 
The ready reactivity of tetrafluoropyridazine with both monofunctional and tethered 
bifunctional nucleophilic species suggests that it could be an excellent scaffold from which 
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to build libraries of highly functionalised heterocyclic compounds, which could be of 
particular use to the pharmaceutical industry. 
 
We have also applied our approach to the generation of a range of highly functionalised 
heterocyclic compounds from a halogenated scaffold to tetrabromothiophene. As yet, our 
results are comparatively disappointing. The nucleophilic aromatic substitution processes 
which work so well for tetrafluoropyridazine do not seem applicable to 
tetrabromothiophene, due to the lower electrophilicity of the system, and competing 
bromophilic attack. 
 
Attempts to synthesise the desired products via metal-mediated coupling chemistry have 
proved unsuccessful, although carbon-carbon bond forming processes proceed well. 
Monofunctionalisation by this route is hampered by the formation of intractable product 
mixtures, the result of statistical attack on a symmetrical substrate. 
 
Finally, lithiations of bromothiophenes produce encouraging results, with mono- and di- 
bromo thiophenes being lithiated and trapped in good yields. Lithiation of 
tetrabromothiophene goes similarly smoothly, but the thienyl anion has proven resistant to 
trapping by electrophiles, requiring reactive, sterically undemanding species with which to 
react. 
 
While the apparent obstacles to the use of tetrabromothiophene as a scaffold for the 
synthesis of libraries of highly functionalised heterocycles may not be insurmountable, it is 
clear that the possibilities offered by tetrafluoropyridazine are far more promising, having 
demonstrated that a multitude of heterocyclic systems of potential biological interest can be 
produced using simple and readily rationalised nucleophilic aromatic substitution 
processes. 
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Chapter 6 
 
Experimental 
 
6.1 Technical Details 
 
All starting materials were obtained commercially (ABCR, Alfa-Aesar, Fluorochem, 
Lancaster, Sigma-Aldrich) or from GlaxoSmithKline’s chemical stores, Stevenage. 
Solvents were dried using either literature procedures or via the Innovative Technology 
solvent purification system. 
 
Microwave reactions were performed on a Biotage Initiator 60 EXP. Mass directed HPLC 
was performed on a Supelco LCABZ++ column using MicroMass MassLynx v4.0 
software. 
 
Melting points were recorded using a Gallenkamp melting point apparatus at atmospheric 
pressure and are uncorrected. 
 
IR spectra were recorded using a Perkin Elmer 1600 Series FTIR using a Golden Gate 
attachment and analysed using GRAMS Analyst software. 
 
NMR spectra were recorded in deuterated chloroform, unless otherwise stated, using 
tetramethylsilane and trichlorofluoromethane as internal references on a Varian Mercury 
400, Bruker Avance 400, or Bruker DPX400 operating at 400 MHz (1H NMR), 376 MHz 
(19F NMR), and 100 MHz (13C NMR), or a Varian Inova 500 operating at 500 MHz (1H 
NMR), 470 MHz (19F NMR), and 125 MHz (13C NMR), or a Varian VNMRS-700 
operating at 700 MHz (1H NMR), 658 MHz (19F NMR), and 175 MHz (13C NMR). 
Chemical shifts are given in ppm and coupling constants are recorded in Hz. 
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Mass spectra were recorded on a Thermo-Finnigan Trace GCMS spectrometer, a 
Micromass LCT LC-MS spectrometer, a Waters Xevo QTOF spectrometer, or a Waters ZQ 
mass spectrometer coupled to a Waters Acquity HPLC system. Exact mass measurements 
were performed on a Thermo-Finnigan LTQ-FT spectrometer, a Bruker Daltonics 7T 
FTICR-MS or a Micromass Q-TOF hybrid quadrupole mass spectrometer. 
 
Elemental analyses were obtained using an Exeter Analytical E-440 Elemental Analyser, or 
by Butterworth Laboratories Ltd. Teddington, UK. 
 
All crystallographic data were collected on a Bruker SMART-6000 CCD (λMoKα, ω-scan, 
0.3° / frame) at T = 120K. The structures were solved using direct methods and refined by 
full-matrix least squares on F2 for all data using SHELXTL software. All non-hydrogen 
atoms were refined with anisotropic displacement parameters, H-atoms were located on the 
difference map and refined isotropically. 
 
6.2 Experimental to Chapter 2 
 
4-(3,5,6-Trifluoro-pyridazin-4-yl)morpholine 1 
 
N
N
F
F
F
F
N
N
F
F
N
F
O
N
H
O
DIPEA
THF
1  
 
DIPEA (1.35 mL, 7.73 mmol) and morpholine (0.45 mL, 5.17 mmol) were added to a 
stirred solution of tetrafluoropyridazine (781 mg, 5.14 mmol) in THF (10 mL) at 0 °C 
under nitrogen, and the clear solution was stirred at 0 °C for 2 hours. The mixture was then 
concentrated in vacuo, partitioned between EtOAc and water, the phases were separated 
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and the aqueous phase was extracted with EtOAc. The combined organic phases were 
concentrated in vacuo to give approx. 1.4g of a light yellow oil. TLC (of the crude reaction 
NMR sample) showed Rf = 0.34 in 1:1 EtOAc / cyclohexane. Purification by Biotage SP4, 
12+M SiO2 column (initial solvent - cyclohexane (2 column volumes), then a gradient 
elution over 10 CV's (cyclohexane to 80% EtOAc in cyclohexane)) gave 4-(3,5,6-trifluoro-
4-pyridazinyl)morpholine 1 (908 mg, 81%) as white crystals; mp 34.5 – 36.1 °C (Found: 
[MH]+, 220.06923. C8H8F3N3O requires: [MH]+, 220.06922); νmax(film)/cm-1 2970.3, 
2902.1, 2860.8 and 1595.1; δH 3.54 (4 H, br s, CH2N), 3.80 – 3.86 (4 H, m, CH2O); δC 
50.12 (t, 4JCF 4.4, CH2N), 66.71 (s, CH2O), 129.29 (ddd, 2JCF 24.8, 3.2, 3JCF 3.2, C-4), 
139.72 (ddd, 1JCF 270.8, 2JCF 28.8, 3JCF 9.6, C-5), 156.85 (dd, 1JCF 240.5, 3JCF 12.0, C-3), 
157.98 (dd, 1JCF 240.5, 2JCF 3.2, C-6); δF -143.82 – -143.35 (1F, m, F-5), -98.62 (1 F, dd, 
3JFF 31.0, 5JFF 26.4, F-6), -80.82 (1 F, dd, 4JFF 28.7, 5JFF 26.4 F-3); m/z (ES+) 220 ([MH]+, 
100%). 
 
N,N-diethyl-3,5,6-trifluoro-4-pyridazinamine 2 
 
N
N
F
F
F
F
N
N
F
F
N
F
N
H
DIPEA
THF
2  
 
DIPEA (1.33 mL, 7.64 mmol) and diethylamine (0.53 mL, 5.09 mmol) were added to a 
stirred solution of tetrafluoropyridazine (774 mg, 5.09 mmol) in THF (10 mL) at 0 °C 
under nitrogen, and the clear solution was stirred at 0 °C for 4 hours. The mixture was then 
concentrated in vacuo, partitioned between EtOAc and water, the phases were separated 
and the aqueous phase was extracted with EtOAc. The combined organic phases were 
concentrated in vacuo to give approx. 1.2 g of a yellow oil. TLC (of the crude reaction 
NMR sample) showed Rf = 0.2 in 1:9 EtOAc / cyclohexane. Purification by Biotage SP4, 
25+S SiO2 column (initial solvent – 3% EtOAc in cyclohexane (2 column volumes), then a 
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gradient elution over 10 CV's (3% EtOAc in cyclohexane to 15% EtOAc in cyclohexane), 
then 15% EtOAc in cyclohexane for 5 CV’s) gave N,N-diethyl-3,5,6-trifluoro-4-
pyridazinamine1 2 (852 mg, 82%) as a yellow oil; (Found: [MH]+, 206.08973. C8H8F3N3O 
requires: 206.08996); νmax(film)/cm-1 2983.8, 2940.5 and 1587.1; δH 1.28 (6 H, t, 3JHH 7.1, 
CH3), 3.47 (4 H, qt, 3JHH 7.1, 5JHF 1.5, CH2); δC 13.91 (s, CH3), 46.79 (t, 4JCF 5.2, CH2), 
129.17 (ddd, 2JCF 25.6, 4.8, 3JCF 4.8, C-4), 137.86 (ddd, 1JCF 266.8, 2JCF 28.8, 3JCF 11.2, C-
5), 156.97 (dd, 1JCF 238.1, 3JCF 2.4, C-3), 157.05 (dd, 1JCF 238.9, 2JCF 4.0, C-6); δF -146.75 
(1 F, dd, 4JFF 28.1, 3JFF 24.7, F-5), -100.65 (1 F, dd, 5JFF 28.7, 3JFF 24.7, F-6), -81.44 (1 F, 
dd, 5JFF 28.7, 4JFF 28.1 F-3); m/z (ES+) 206 ([MH]+, 100%). 
 
N-Allyl-3,5,6-trifluoro-N-methylpyridazin-4-amine 3 
 
N
N
F
F
F
F
N
N
F
F
N
F
N
H
DIPEA
THF
3  
 
DIPEA (1.35 mL, 7.73 mmol) and N-methylallylamine (0.50 mL, 5.16 mmol) were added 
to a stirred solution of tetrafluoropyridazine (785 mg, 5.16 mmol) in THF (10 mL) at 0 °C 
under nitrogen, and the clear solution was stirred at 0 °C for 3.5 hours. The mixture was 
then concentrated in vacuo, partitioned between EtOAc and water, the phases were 
separated and the aqueous phase was extracted with EtOAc. The combined organic phases 
were concentrated in vacuo to give approx. 1.3 g of a light yellow oil. TLC (of the crude 
reaction NMR sample) showed Rf = 0.36 in 1:3 EtOAc / cyclohexane. Purification by 
Biotage SP4, 25+M SiO2 column (initial solvent – 6% EtOAc in cyclohexane (2 column 
volumes), then a gradient elution over 10 CV's (6% EtOAc in cyclohexane to 30% EtOAc 
in cyclohexane), then 30% EtOAc in cyclohexane for 5 CV’s) gave N-allyl-3,5,6-trifluoro-
N-methylpyridazin-4-amine 3 (861 mg, 82%) as a light-yellow oil; (Found: [M]+, 
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204.07433. C8H8F3N3O requires:  [M]+, 204.07431); νmax(film)/cm-1 2908.1, 1644.4 and 
1593.8; δH 3.14 (3 H, t, 5JHF 3.2, CH3), 3.97 (2 H, d, 3JHH 5.9, CH2), 5.29 (1 H, dd, 3JHH 
16.9, 2JHH 1.2, HCH), 5.32 (1 H, dd, 3JHH 10.3, 2JHH 1.2, HCH), 5.82 - 5.94 (1 H, m, CH); 
δC 39.60 (t, 4JCF 5.6, CH3), 57.28 (t, 4JCF 4.8, CH2), 119.06 (s, =CH2), 130.09 (ddd, 2JCF 
25.6, 4.8, 3JCF 4.8, C-4), 132.20 (s, CH), 138.36 (ddd, 1JCF 267.6, 2JCF 28.0, 3JCF 9.6, C-5), 
156.94 (dd, 1JCF 239.7, 3JCF 12.8, C-3), 157.18 (dd, 1JCF 238.9, 2JCF 4.8, C-6); δF -145.60 (1 
F, dd, 4JFF 28.1, 3JFF 26.4, F-5), -100.02 (1 F, dd, 5JFF 28.7, 3JFF 26.4, F-6), -80.87 (1 F, dd, 
5JFF 28.7, 4JFF 28.1, F-3); m/z (ES+) 204 ([M]+, 100%). 
 
3,5,6-Trifluoro-N-phenylpyridazin-4-amine 4 
 
N
N
F
F
F
F
N
N
F
F
HN
F
H2N
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THF
4  
 
DIPEA (1.35 mL, 7.73 mmol) and aniline (0.46 mL, 5.10 mmol) were added to a stirred 
solution of tetrafluoropyridazine (776 mg, 5.10 mmol) in THF (10 mL) at 0 °C under 
nitrogen, and the clear solution was stirred at 0 °C for 4 hours. The mixture was then 
concentrated in vacuo, partitioned between EtOAc and water, the phases were separated 
and the aqueous phase was extracted with EtOAc. The combined organic phases were 
concentrated in vacuo to give approx. 1.2 g of a yellow oil. Purification by column 
chromatography (silica, ethyl acetate:hexane) gave 3,5,6-trifluoro-N-phenylpyridazin-4-
amine 4 (895 mg, 78%) as a white solid, mp 123.2 – 124.0 °C (Found: C, 53.61%, H, 
2.81%, N, 18.74%. C10H6F3N3 requires C, 53.34%, H, 2.69%, N, 18.66%); δH 6.47 (1 H, br. 
s, NH), 7.15 – 7.40 (5 H, m, ArH); δC 122.7 (d, 5JCF 2.6, C-2’), 124.2 – 124.3 (m, C-4), 
126.5 (s, C-4’), 129.4 (s, C-3’), 136.5 (ddd, 1JCF 272.3, 2JCF 29.9, 3JCF 6.9, C-5), 137.1 (s, 
C-1’), 156.8 (dd, 1JCF 238.2, 2JCF 3.3, C-6), 156.9 (d, 1JCF 237.7, C-3); δF -141.5 (1 F, dd, 
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4JFF 25.4, 3JFF 24.5, F-5), -98.92 (1 F, dd, 5JFF 29.5, 3JFF 24.5, F-6), -88.96 (1 F, dd, 5JFF 
29.5, 3JFF 25.4, F-3); m/z (ES+) 224.9 ([MH]+, 100%). 
 
N-[(4-bromophenyl)methyl]-3,5,6-trifluoro-N-methyl-4-pyridazinamine 5 
 
N
N
F
F
F
F
N
N
F
F
N
F
N
H
DIPEA
THF
Br Br
5  
 
DIPEA (1.3 mL, 7.46 mmol) and 1-(4-bromophenyl)-N-methylmethanamine (1.05 mL, 
5.26 mmol) were added to a stirred solution of tetrafluoropyridazine (786 mg, 5.17 mmol) 
in THF (10 mL) under nitrogen, and the solution was stirred for 24 hours. The mixture was 
then concentrated in vacuo, partitioned between EtOAc and water, the phases were 
separated and the aqueous phase was extracted with EtOAc. The combined organic phases 
were concentrated in vacuo to give approx. 2.3 g of a yellow oil. TLC (of the crude reaction 
NMR sample) showed Rf = 0.10 in 1:9 EtOAc / cyclohexane. Purification by Biotage SP4, 
40+M SiO2 column (initial solvent – 3% EtOAc in cyclohexane (2 column volumes), then 
a gradient elution over 10 CV's (3% EtOAc in cyclohexane to 15% EtOAc in cyclohexane), 
then 15% EtOAc in cyclohexane for 5 CV’s) gave N-[(4-bromophenyl)methyl]-3,5,6-
trifluoro-N-methyl-4-pyridazinamine 5 (1122 mg, 65%) as white crystals, mp 77.1-78.5 °C 
(Found: C, 43.39%, H, 2.70%, N, 12.41%. C12H9BrF3N3 requires C, 43.40%, H, 2.73%, N, 
12.65%); νmax(film)/cm-1 2940.9, 1601.9, 1573.9 and 1560.8; δH 3.09 (3 H, dd, 5JHF 3.8, 2.7, 
CH3), 4.53 (2 H, s, CH2), 7.15 (2 H, d, 3JHH 8.5, ArH), 7.49 (2 H, d, 3JHH 8.5, ArH); δC 
39.96 (t, 4JCF 5.2, CH3), 57.65 (t, 4JCF 4.8, CH2), 121.90 (s, C-4’), 128.98 (s, C-2’), 130.18 
(ddd, 2JCF 24.8, 4.8, 3JCF 3.2, C-4), 131.99 (s, C-3’), 134.92 (br s, C-1’), 139.00 (ddd, 1JCF 
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270.8, 2JCF 29.6, 3JCF 10.4, C-5), 156.90 (dd, 1JCF 240.5, 3JCF 12.0, C-3), 157.43 (dd, 1JCF 
239.7, 2JCF 4.0, C-6); δF -144.25 (1 F, dd, 4JFF 28.1, 3JFF, 25.8, F-5), -99.35 (1 F, dd, 5JFF 
28.7, 3JFF 25.8, F-6), -80.58 (1 F, dd, 5JFF 28.7, 4JFF 28.1, F-3); m/z (ES+) 334.1 ([MH]+, 
100%). 
 
Methyl N-methyl-N-(3,5,6-trifluoro-4-pyridazinyl)glycinate 6 
 
N
N
F
F
F
F
N
N
F
F
N
F
N
H
DIPEA
THF
OO OO
.HCl
6  
 
DIPEA (2.29 mL, 13.17 mmol) and tetrafluoropyridazine (801 mg, 5.27 mmol) were added 
to a stirred solution of sarcosine methyl ester hydrochloride (735 mg, 5.27 mmol) in THF 
(10 mL) under nitrogen, and the solution was stirred for 3 days. The mixture was then 
concentrated in vacuo, partitioned between EtOAc and water, the phases were separated 
and the aqueous phase was extracted with EtOAc. The combined organic phases were 
concentrated in vacuo to give approx. 0.8 g of a light yellow oil. TLC (of the crude reaction 
NMR sample) showed Rf = 0.24 in 1:2 EtOAc : cyclohexane. Purification by Biotage SP4, 
25+M SiO2 column (initial solvent – 8% EtOAc in cyclohexane (2 column volumes), then 
a gradient elution over 10 CV's (8% EtOAc in cyclohexane to 40% EtOAc in cyclohexane), 
then 40% EtOAc in cyclohexane for 5 CV’s) gave methyl N-methyl-N-(3,5,6-trifluoro-4-
pyridazinyl)glycinate 6 (616 mg, 50%) as a light-yellow oil; (Found: C, 40.55; H, 3.34; N, 
17.70. C8H8F3N3O requires C, 40.86; H, 3.43; N, 17.87%); νmax(film)/cm-1 2958.4, 1747.1 
and 1597.2; δH 3.27 (3 H, dd, 5JHF 3.4, 2.7, NCH3), 3.81 (3 H, s, OCH3), 4.14 (2 H, s, CH2); 
δC 42.12 (t, 4JCF 5.6, NCH3), 52.50 (s, OCH3), 55.34 (dd, 4JCF 6.4, 4.8, CH2), 129.62 (ddd, 
2JCF 25.6, 4.8, 3JCF 3.2, C-4), 138.77 (ddd, 1JCF 269.2, 2JCF 28.8, 3JCF 9.6, C-5), 156.86 (d, 
1JCF 240.0, C-3), 156.95 (dd, 1JCF 238.9, 2JCF 4.0, C-6), 169.31 (s, C=O); δF -144.62 (1 F, t, 
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4JFF 27.5, 3JFF 25.2, F-5), -99.30 (1 F, dd, 5JFF 28.7, 3JFF 25.2, F-6), -81.00 (1 F, t, 5JFF 28.7, 
4JFF 27.5, F-3); m/z (ES+) 236.1 ([MH]+, 100%). 
 
3,4,6-Trifluoro-5-[(4-methylphenyl)oxy]pyridazine 7 
 
N
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F
F
F
F
N
N
F
F
O
FDIPEA
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HO
7  
 
DIPEA (1.3 mL, 7.46 mmol) and p-cresol (0.53 mL, 5.07 mmol) were added to a stirred 
solution of tetrafluoropyridazine (768 mg, 5.05 mmol) in THF (10 mL) under nitrogen, and 
the solution was stirred for 26 hours. The mixture was then concentrated in vacuo, 
partitioned between EtOAc and water, the phases were separated and the aqueous phase 
was extracted with EtOAc. The combined organic phases were concentrated in vacuo to 
give approx. 1.1 g of a yellow oil. TLC (of the crude reaction NMR sample) showed Rf = 
0.2 in cyclohexane. Purification by Biotage SP4 failed to remove traces of disubstituted 
product, so 90 mg of sample were removed from 899 mg of impure product and after 
purification by HPLC gave 3,4,6-trifluoro-5-[(4-methylphenyl)oxy]pyridazine 7 (74 mg, 
6%) as a colourless oil (Found: C, 54.93%, H, 2.86%, N, 11.40%. C11H7F3N2O requires C, 
55.01%, H, 2.94%, N, 11.66%); νmax(film)/cm-1 2928.0, 1614.9, 1606.0 and 1570.9; δH 2.38 
(3 H, s, CH3), 6.97 (2 H, d, 3JHH 8.7, ArH), 7.21 (2 H, dd, 3JHH 8.7, 4JHH 0.7, ArH); δC 20.73 
(s, CH3), 116.97 (s, C-2’), 130.56 (s, C-3’), 134.67 (ddd, 2JCF 27.2, 5.6, 3JCF 5.6, C-5), 
135.75 (s, C-4’), 141.86 (ddd, 1JCF 282.8, 2JCF 28.0, 3JCF 7.2, C-4), 153.05 (s, C-1’), 156.77 
(ddd, 1JCF 243.6, 2JCF 10.0, 4JCF 2.4, C-3), 159.24 (d, 1JCF 246.9, C-6); δF -140.35 (1 F, dd, 
3JFF 24.1, 4JFF 24.1, F-4), -93.95 (1 F, dd, 5JFF 30.4, 3JFF 24.1, F-3), -85.54 (1 F, dd, 5JFF 
30.4, 4JFF 24.1, F-6); m/z (ES+) 241.2 ([MH]+, 100%). 
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4-(Cyclohexyloxy)-3,5,6-trifluoropyridazine 8 
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DIPEA (1.3 mL, 7.46 mmol) and cyclohexanol (0.55 mL, 5.29 mmol) were added to a 
stirred solution of tetrafluoropyridazine (777 mg, 5.11 mmol) in THF (10 mL) under 
nitrogen, and the clear solution was stirred for 6 days. The mixture was then concentrated 
in vacuo, partitioned between EtOAc and water, the phases were separated and the aqueous 
phase was extracted with EtOAc. The combined organic phases were concentrated in vacuo 
to give approx. 0.9 g of a yellow oil. TLC (of the crude reaction NMR sample) showed Rf 
= 0.24 in 1:49 EtOAc / cyclohexane. Purification by Biotage SP4, 25+S SiO2 column 
(initial solvent – 1% EtOAc in cyclohexane (2 column volumes), then a gradient elution 
over 10 CV's (1% EtOAc in cyclohexane to 5% EtOAc in cyclohexane), then 5% EtOAc in 
cyclohexane for 5 CV’s) gave 4-(cyclohexyloxy)-3,5,6-trifluoropyridazine 8 (752 mg, 63%) 
as a colourless oil; (Found: C, 51.70%, H, 4.54%, N, 11.77%. C10H11F3N2O requires C, 
51.75%, H, 4.78%, N, 12.07%); νmax(film)/cm-1 2940.4, 2863.4 and 1607.3; δH 1.02 - 2.37 
(10 H, m, CH2), 4.80 (1 H, br s, CH); δC 23.04 (s, C-3’, C-5’), 24.93 (s, C-4’), 32.05 (s, C-
2’, C-6’), 83.30 (d, 4JCF 4.0, C-1’), 135.98 (ddd, 2JCF 27.2, 4.8, 3JCF 4.8, C-4), 140.24 (ddd, 
1JCF 275.6, 2JCF 28.0, 4JCF 8.0, C-5), 156.73 (ddd, 1JCF 242.1, 3JCF 11.2, 4JCF 1.6, C-3), 
159.32 (dd, 1JCF 244.5, 2JCF 2.4, C-6); δF -146.29 (1 F, dd, 4JFF 27.5, 3JFF 26.4, F-5), -95.77 
(1 F, dd, 5JFF 29.3, 3JFF 26.4, F-6), -87.45 (1 F, dd, 5JFF 29.3, 4JFF 27.5, F-3); m/z (ES+) 
233.2 ([MH]+, 100%). 
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3,4,6-Trifluoro-5-(2-propen-1-yloxy)pyridazine 9 
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DIPEA (1.3 mL, 7.46 mmol) and allyl alcohol (0.36 mL, 5.26 mmol) were added to a 
stirred solution of tetrafluoropyridazine (780 mg, 5.13 mmol) in THF (10 mL) under 
nitrogen, and the solution was stirred at reflux for 24 hours. The mixture was then 
concentrated in vacuo, partitioned between EtOAc and water, the phases were separated 
and the aqueous phase was extracted with EtOAc. The combined organic phases were 
concentrated in vacuo to give approx. 1 g of a yellow oil. TLC (of the crude reaction NMR 
sample) showed Rf = 0.24 in 1:9 EtOAc / cyclohexane. Purification by Biotage SP4, 25+S 
SiO2 column (initial solvent – 3% EtOAc in cyclohexane (2 column volumes), then a 
gradient elution over 10 CV's (3% EtOAc in cyclohexane to 15% EtOAc in cyclohexane), 
then 15% EtOAc in cyclohexane for 5 CV’s) gave 3,4,6-trifluoro-5-(2-propen-1-
yloxy)pyridazine 9 (716 mg, 73%) as a colourless oil (Found: [MH]+, 191.04277. 
C7H5F3N2O requires:  [MH]+, 191.04267); νmax/cm-1 2898.8, 1648.2 and 1611.8; δH 5.03 (2 
H, dd, 3JHH 6.0, 5JHF 0.9, O-CH2), 5.44 (1 H, dd, 3JHH 10.5, 2JHH 1.0, CHH), 5.51 (1 H, dd, 
3JHH 16.9, 2JHH 1.0, CHH), 5.96 - 6.09 (1H, ddd, 3JHH 16.9, 3JHH 10.5, 3JHH 6.0, CH); δC 
74.65 (dd, 4JCF 5.6, 1.6, O-CH2), 121.37 (s, CH2), 130.50 (s, CH), 136.18 (ddd, 2JCF 27.2, 
4.8, 3JCF 4.8, C-5), 140.07 (ddd, 1JCF 277.2, 2JCF 28.8, 3JCF 8.0, C-4), 156.69 (ddd, 1JCF 
242.1, 3JCF 11.2, 4JCF 1.6, C-6), 158.68 (d, 1JCF 242.9, C-3); δF -146.60 (1 F, dd, 4JFF 26.4, 
3JFF 25.8, F-4), -95.79 (1 F, dd, 5JFF 28.7, 3JFF 25.8, F-3), -87.60 (1 F, dd, 5JFF 28.7, 4JFF 
26.4, F-6); m/z (ES+) 191.0 ([MH]+, 100%). 
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3,4,6-Trifluoro-5-[(1-methylethyl)oxy]pyridazine 10 
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DIPEA (1.3 mL, 7.46 mmol) and isopropanol (0.41 mL, 5.26 mmol) were added to a stirred 
solution of tetrafluoropyridazine (780 mg, 5.13 mmol) in THF (10 mL) under nitrogen, and 
the solution was stirred at reflux for 24 hours. The mixture was then concentrated in vacuo, 
partitioned between EtOAc and water, the phases were separated and the aqueous phase 
was extracted with EtOAc. The combined organic phases were concentrated in vacuo to 
give approx. 0.9 g of a yellow oil. TLC (of the crude reaction NMR sample) showed Rf = 
0.28 in 1:9 EtOAc / cyclohexane. Purification by Biotage SP4, 25+S SiO2 column (initial 
solvent – 3% EtOAc in cyclohexane (2 column volumes), then a gradient elution over 10 
CV's (3% EtOAc in cyclohexane to 15% EtOAc in cyclohexane), then 15% EtOAc in 
cyclohexane for 5 CV’s) gave 3,4,6-trifluoro-5-[(1-methylethyl)oxy]pyridazine 10 (713 mg, 
72%) as a colourless oil (Found: [MH]+, 193.05830. C7H7F3N2O requires:  [MH]+, 
193.05832); νmax/cm-1 2990.8, 2941.6 and 1608.2; δH 1.47 (6 H, dd, 3JHH 6.1, 6JHF 0.8, 
CH3), 5.02 - 5.14 (1 H, m, CH); δC 22.47 (s, CH3), 78.85 (d, 4JCF 4.0, CH), 136.01 (ddd, 
2JCF 27.1, 5.2, 3JCF 5.2, C-5), 140.00 (ddd, 1JCF 275.8, 2JCF 28.6, 3JCF 7.8, C-4), 156.76 (ddd, 
1JCF 239.7, 3JCF 11.2, 4JCF 1.6, C-6), 159.14 (ddd, 1JCF 246.1, 2JCF 8.8, 4JCF 2.4, C-3); δF -
147.01 (1 F, dd, 4JFF 27.0, 3JFF 25.8, F-4), -96.10 (1 F, dd, 5JFF 28.7, 3JFF 25.8, F-3), -87.87 
(1 F, dd, 5JFF 28.7, 4JFF 27.0, F-6); m/z (ES+) 193.2 ([MH]+, 100%). 
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3,4,6-Trifluoro-5-phenylpyridazine 11, 3,4,5-trifluoro-6-phenylpyridazine 12, and 3,5-
difluoro-4,6-diphenylpyridazine 13 
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Phenylmagnesium bromide (1M solution in THF, 5.13 mL, 5.13 mmol) was added to a 
stirred solution of tetrafluoropyridazine (780 mg, 5.13 mmol) in THF (10 mL) under 
nitrogen at -78 °C. The reaction was allowed to come to RT overnight, at which point 19F 
NMR spectroscopic analysis showed the presence of the major product, a regioisomer of 
the major product, and a disubstituted species. The reaction was quenched by addition of 
wet THF, and then concentrated, partitioned between EtOAc and water, and extracted with 
two further portions of EtOAc. The combined organic phases were dried and concentrated 
in vacuo to give approx. 1 g of crude product. TLC (of the crude reaction NMR sample) 
showed Rf = 0.25 in 1:19 EtOAc : cyclohexane. Purification by Biotage SP4, 40+M SiO2 
column (gradient elution over 15 CV's (cyclohexane to 4% EtOAc in cyclohexane), then 4-
20% EtOAc in cyclohexane over 5 CV's) gave 624 mg of material, recrystallisation of 
which (from cyclohexane) gave 3,4,6-trifluoro-5-phenylpyridazine 11 (501 mg, 47%) as 
white crystals, mp 82.7-83.4 °C (Found: C, 57.15%, H, 2.41%, N, 13.22%. C10H5F3N2 
requires C, 57.15%, H, 2.40%, N, 13.33%); νmax/cm-1 1580.6, 1558.1, 1457.9 and 1444.6; 
δH 7.56 - 7.62 (5 H, m, CH); δC 121.27 (ddd, 2JCF 31.9, 8.8, 3JCF 4.0, C-5), 123.65 (br s, C-
4’), 129.08 (s, C-2’, C-6’), 129.77 (br s, C-3’, C-5’), 131.11 (s, C-1’), 147.86 (ddd, 1JCF 
281.2, 2JCF 27.2, 3JCF 8.0, C-4), 156.58 (ddd, 1JCF 243.7, 3JCF 12.8, 4JCF 2.4, C-6), 162.30 (d, 
1JCF 245.3, C-3); δF -129.26 (1 F, dd, 3JFF 26.4, 4JFF 21.8, F-4), -97.63 (1 F, dd, 5JFF 31.0, 
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3JFF 26.4, F-3), -79.61 (1 F, dd, 5JFF 31.0, 4JFF 21.8, F-6); m/z (ES+) 211.2 ([MH]+, 100%). 
Minor products were identified by 19F NMR spectroscopic analysis of the reaction mixture, 
but were not isolated: 3,4,5-trifluoro-6-phenylpyridazine 12; δF -156.68 (1 F, dd, 3JFF 25.3, 
3JFF 18.7, F-4), -136.49 (1 F, dd, 4JFF 24.5, 3JFF 18.7, F-5), -96.08 (1 F, dd, 3JFF 25.3, 4JFF 
24.5, F-3); 3,5-difluoro-4,6-diphenylpyridazine 13; δF -117.11 (1 F, d, 4JFF 23.4, F-5), -
83.00 (1 F, d, 4JFF 23.4, F-3). 
 
4,7-Difluoro-2-methyl-furo[2,3-d]pyridazine-3-carboxylic acid ethyl ester 14 
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DIPEA (0.9 ml, 5.17 mmol) and ethyl acetoacetate (0.25 ml, 1.96 mmol) were added to a 
stirred solution of tetrafluoropyridazine (0.312 mg, 2.05 mmol) in THF (10 ml). After four 
days at room temperature, the mixture was concentrated and partitioned between DCM (3 × 
10 ml) and water. The combined organic phases were dried and concentrated, giving 617 
mg of crude product, and purification by column chromatography (silica, ethyl 
acetate:hexane) gave 4,7-difluoro-2-methyl-furo[2,3-d]pyridazine-3-carboxylic acid ethyl 
ester 14 (0.192 g, 40%) as a colourless oil (Found: C, 49.6%; H, 3.4%; N, 11.9%. 
C10H8F2N2O3 requires: C, 49.6%; H, 3.3%; N, 11.6%); νmax / cm-1 2987.8, 1719.5, 1615.1 
and 1586.7; δH 1.44 (3H, t, 3JHH 7.1, CH2CH3), 2.92 (3H, s, CCH3), 4.44 (2H, q, 3JHH 7.1, 
CH2); δC 14.20 (s, CH2CH3), 14.73 (s, CCH3), 62.05 (s, CH2), 109.09 (d, 3JCF 3.6, C-3), 
119.06 (dd, 2JCF 35.4, 3JCF 5.9, C-3a), 141.82 (dd, 2JCF 28.6, 3JCF 10.1, C-7a), 152.25 (dd, 
1JCF 241.0, 4JCF 3.9, C-4), 158.73 (dd, 1JCF 247.7, 4JCF 2.3, C-7), 160.95 (s, C=O), 168.25 (s, 
C-2); δF  -98.48 (1 F, d, 5JFF 33.5, F-4), -76.46 (1 F, d, 5JFF 33.5, F-7); m/z (EI+) 242 ([M]+, 
49%), 214 (62), 197 (100), 170 (32). 
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3,6-Difluoro-4,5-bis(phenylthio)pyridazine 15 
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DIPEA (2.6 mL, 14.8 mmol) and thiophenol (1 mL, 9.7 mmol) were added to a stirred 
solution of tetrafluoropyridazine (780 mg, 5.13 mmol) in THF (10 mL) at 0 °C under 
nitrogen. Addition was performed in two separate 0.5 ml quantities. An hour after the first 
addition, 50% conversion to bis-substituted product was confirmed by LCMS and NMR 
spectroscopy, and the remaining thiophenol was added to the stirred solution. The mixture 
was then allowed to come to RT overnight. Aqueous sodium hydroxide was added to the 
flask, and the product was extracted into EtOAc. The aqueous phase was extracted with two 
further portions of EtOAc and the combined organic phases were combined, dried and 
concentrated to give approx. 1.6 g of crude product. Purification by Biotage SP4, 40+M 
SiO2 column (inital solvent - 1% EtOAc in cyclohexane (2 column volumes), then a 
gradient elution over 10 CV's (1% EtOAc in cyclohexane to 7% EtOAc in cyclohexane), 
then 7% EtOAc in cyclohexane for 5 CV's) gave 3,6-difluoro-4,5-
bis(phenylthio)pyridazine1 15 (1.31 g, 77%) as yellow crystals, mp 99.1-100.3 °C (lit. mp 
97-99 °C) (Found: C, 57.73%, H, 3.00%, N, 8.34%. C16H10F2N2S2 requires C, 57.82%, H, 
3.03%, N, 8.43%); νmax/cm-1 1578.7, 1500.4 and 1377.8; δH 7.34 - 7.47 (10 H, m, ArH); δC 
129.29 (s, C-4’, C-4’’) 129.65 (s, C-3’, C-5’, C-3’’, C-5’’) 130.26 (s, C-1’, C-1’’) 132.22 
(s, C-2’, C-6’, C-2’’, C-6’’) 133.56 (dd, 2JCF 17.6, 3JCF 16.0, C-4, C-5) 162.59 (dd, 1JCF 
249.3, 4JCF 6.4, C-3, C-6); δF -75.76 (2 F, br s,); m/z (ES+) 333.2 ([MH]+, 100%). 
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4-(Ethylthio)-3,5,6-trifluoropyridazine 16 
 
N
N
F
F
F
F DIPEA
THF N
N
F
F
S
F
EtSH
16  
 
DIPEA (1.35 mL, 7.73 mmol) and ethanethiol (0.30 mL, 4.1 mmol) were added to a stirred 
solution of tetrafluoropyridazine (780 mg, 5.13 mmol) in THF (10 mL) at 0 °C under 
nitrogen, and the clear solution was stirred at 0 °C for 1 hour. The mixture was then 
concentrated in vacuo, partitioned between EtOAc and water, the phases were separated 
and the aqueous phase was extracted with EtOAc. The combined organic phases were 
concentrated in vacuo to give approx. 1.2 g of a brown oil. Purification by column 
chromatography (silica, hexane:ethyl acetate) gave 4-(ethylthio)-3,5,6-trifluoropyridazine 
16 (514 mg, 65%) as a colourless oil (Found: [MH]+, 195.0210. C6H5N2F3S requires 
[MH]+, 195.0204); δH 3.27 (2 H, qt, 3JHH 7.4, 5JHF 1.1, CH2), 1.40 (3 H, t, 3JHH 7.4, CH3); δC 
15.14 (s, CH3), 27.37 (dd, 4JCF 5.5, 4JCF 4.0, CH2), 121.65 (ddd, 2JCF 35.6, 2JCF 11.9, 3JCF 
3.2, C-4), 149.29 (ddd, 1JCF 276.5, 2JCF 28.1, 3JCF 7.5, C-5), 155.76 (ddd, 1JCF 244.0, 4JCF 
13.2, 3JCF 2.7, C-3), 162.65 (d, 1JCF 241.1, C-6); δF -74.55 (1F, dd, 3JFF 30.2, 4JFF 21.0, F-5), 
-99.36 (1 F, dd, 3JFF 30.2, 5JFF 26.4, F-6), -124.83 (1 F, dd, 5JFF 26.4, 4JFF 21.0, F-3); m/z 
(ES+) 195.0 ([MH]+, 100%). 
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4-(3,6-Difluoro-5-phenyl-4-pyridazinyl)morpholine 17 
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DIPEA (0.18 mL, 1.03 mmol) and morpholine (0.06 mL, 0.68 mmol) were added to a 
stirred solution of 3,4,6-trifluoro-5-phenylpyridazine 11 (143 mg, 0.680 mmol) in THF (10 
mL) under nitrogen, and the solution was stirred at RT for 4 days. The mixture was then 
concentrated in vacuo, partitioned between EtOAc and water, the phases were separated 
and the aqueous phase was extracted with EtOAc. The combined organic phases were 
concentrated in vacuo to give approx. 0.2 g of crude product. Purification by Biotage SP4, 
40+M SiO2 column (initial solvent – 5% THF in cyclohexane (2 column volumes), then a 
gradient elution over 10 CV's (5% THF in cyclohexane to 25% THF in cyclohexane), then 
25% THF in cyclohexane for 5 CV’s) gave 203 mg of product of approx. 93% purity 
(LCMS). 77 mg of material were further purified by RP-HPLC, and gave 4-(3,6-difluoro-5-
phenyl-4-pyridazinyl)morpholine 17 (61 mg, 32%) as white crystals, mp 180.6-182.0 °C 
(Found: C, 60.54%, H, 4.69%, N, 15.01%. C10H5F3N2 requires C, 60.64%, H, 4.72%, N, 
15.15%); νmax/cm-1 2977.1, 2857.3 and 1543.8; δH 3.04 (4 H, td, 3JHH 4.7, 5JHF 1.6, NCH2), 
3.61 (4 H, dd, 3JHH 4.8, 4.6, OCH2), 7.31 - 7.38 (2 H, m, CH), 7.42 - 7.57 (3 H, m, CH); δC 
50.55 (d, 4JCF 4.8, NCH2), 66.54 (s, OCH2), 120.42 (dd, 2JCF 31.2, 3JCF 6.4, C-5), 128.95 (s, 
C-2’, C-6’), 129.49 (s, C-3’, C-5’), 129.53 (br s, C-4’), 129.64 (t, 3JCF 2.4, C-1’), 139.21 
(dd, 2JCF 22.4, 3JCF 6.4, C-4), 159.38 (d, 1JCF 240.5, C-3), 163.36 (d, 1JCF 239.7, C-6); δF -
86.89 (1 F, d, 5JFF 31.6, F-3), -83.96 (1 F, d, 5JFF 31.6, F-6); m/z (ES+) 278.2 ([MH]+, 
100%). 
 
 
147 
Chapter 6: Experimental 
4-{3,6-Difluoro-5-[(1-methylethyl)oxy]-4-pyridazinyl}morpholine 18 
Method A: 
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DIPEA (0.20 mL, 1.15 mmol) and morpholine (0.07 mL, 0.80 mmol) were added to a 
stirred solution of 3,4,6-trifluoro-5-[(1-methylethyl)oxy]pyridazine 10 (153 mg, 0.796 
mmol) in THF (10 mL) under nitrogen, and the solution was stirred at RT for 4 days. The 
mixture was then concentrated in vacuo, partitioned between EtOAc and water, the phases 
were separated and the aqueous phase was extracted with EtOAc. The combined organic 
phases were concentrated in vacuo to give approx. 0.2 g of crude product. TLC (of the 
crude reaction NMR sample) showed Rf = 0.24 in 1:4 THF / cyclohexane. Purification by 
Biotage SP4, 40+M SiO2 column (initial solvent – 5% THF in cyclohexane (2 column 
volumes), then a gradient elution over 10 CV's (5% THF in cyclohexane to 25% THF in 
cyclohexane), then 25% THF in cyclohexane for 5 CV’s) gave 4-{3,6-difluoro-5-[(1-
methylethyl)oxy]-4-pyridazinyl}morpholine 18 (163 mg, 79%) as white crystals, mp 73.9-
75.4 °C (Found: [MH]+, 260.12041. C11H15F2N3O2 requires:  [MH]+, 260.12051); νmax/cm-1 
2980.8, 2861.6 and 1566.9; δH 1.33 (6 H, d, 3JHH 6.2, CH3), 3.39 (4 H, dd, 3JHH 4.4, 5JHF 
3.3, NCH2), 3.76 (4 H, t, 3JHH 4.4, OCH2), 4.63 - 4.76 (1 H, m, 3JHH 6.2, 5JHF 1.4, CH); δC 
22.37 (s, CH3), 50.17 (d, 4JCF 4.8, NCH2), 66.95 (s, OCH2), 77.13 (d, 4JCF 5.6, CH), 133.26 
(dd, 2JCF 23.2, 3JCF 8.0, C-4), 137.06 (dd, 2JCF 24.8, 3JCF 8.8, C-5), 159.57 (d, 1JCF 239.7, C-
3), 160.46 (d, 1JCF 240.5, C-6); δF -93.19 (1 F, d, 5JFF 29.8, F-6), -86.19 (1 F, d, 5JFF 29.8, F-
3); m/z (ES+) 260.3 ([MH]+, 100%). 
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Method B: 
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Lithium isopropoxide (2 M in THF, 0.45 mL, 0.90 mmol) was added to a stirred solution of 
4-(3,5,6-trifluoro-4-pyridazinyl)morpholine 1 (195 mg, 0.89 mmol) in THF (10 mL) under 
nitrogen at -78 °C, and the solution was allowed to come to RT overnight. The reaction was 
quenched by the addition of wet THF, then concentrated in vacuo, partitioned between 
EtOAc and water, the phases were separated and the aqueous phase was extracted with 
EtOAc. The combined organic phases were concentrated in vacuo to give approx. 237 mg 
of crude product. TLC (of the crude reaction NMR sample) showed Rf = 0.16 in 1:9 EtOAc 
/ toluene. Purification by Biotage SP4, 40+M SiO2 column (initial solvent – 2% EtOAc in 
toluene (2 column volumes), then a gradient elution over 10 CV's (2% EtOAc in toluene to 
13% EtOAc in toluene), then 13% EtOAc in toluene for 5 CV’s) gave 126 mg of product of 
approximately 97% purity. Further purification by RP-HPLC gave 4-{3,6-difluoro-5-[(1-
methylethyl)oxy]-4-pyridazinyl}morpholine 18 (94 mg, 41%) as white crystals, mp 73.8-
75.0 °C (Found: C, 50.93%, H, 5.80%, N, 16.26%. C11H15F2N3O2 requires C, 50.96%, H, 
5.83%, N, 16.21%); νmax/cm-1 2981.6, 2861.6 and 1566.8; δH 1.37 (6 H, dd, 3JHH 6.2, 6JHF 
0.7, CH3), 3.43 (4 H, td, 3JHH 4.7, 5JHF 1.8, NCH2), 3.81 (4 H, dd, 3JHH 4.7, 4.6, OCH2), 4.69 
- 4.80 (1 H, m, 3JHH 6.2, 5JHF 1.6, CH); δC 22.47 (s, CH3), 50.28 (d, 4JCF 4.8, NCH2), 67.05 
(s, OCH2), 77.21 (d, 4JCF 6.4, CH), 133.34 (dd, 2JCF 23.2, 3JCF 8.0, C-4), 137.18 (dd, 2JCF 
24.8, 3JCF 8.8, C-5), 158.33 - 161.05 (m, 1JCF 240.5, C-3), 160.55 (d, 1JCF 239.7, C-6); δF -
92.89 (1 F, d, 5JFF 30.4, F-6), -86.04 (1 F, d, 5JFF 30.4, F-3); m/z (ES+) 260.2 ([MH]+, 
100%). 
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4-(5-(Ethylthio)-3,6-difluoropyridazin-4-yl)morpholine 19 
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DIPEA (0.27 mL, 1.5 mmol) and morpholine (0.09 mL, 1.03 mmol) were added to a stirred 
solution of 4-(ethylthio)-3,5,6-trifluoropyridazine 16 (200 mg, 1.03 mmol) in THF (10 mL) 
at 0 °C under nitrogen, and the clear solution was stirred at RT overnight. The mixture was 
then concentrated in vacuo, partitioned between EtOAc and water, the phases were 
separated and the aqueous phase was extracted with EtOAc. The combined organic phases 
were concentrated in vacuo to give approx. 0.2 g of a light yellow oil. Purification by 
column chromatography gave 4-(5-(ethylthio)-3,6-difluoropyridazin-4-yl)morpholine 19 
(197 mg, 73%) as a yellow oil (Found: C, 45.63%, H, 5.06%, N, 16.16%. C10H13F2N3OS 
requires C, 45.97%, H, 5.01%, N, 16.08%); νmax/cm-1 2965.9, 2853.6, 1638.7 and 1546.7; 
δH 1.29 (3 H, td, 3JHH 7.4, 6JHF 0.5, CH3), 3.09 (2 H, qd, 3JHH 7.4, 5JHF 1.6, SCH2), 3.41 (4 
H, td, 3JHH 4.7, 5JHF 2.3, NCH2), 3.84 (4 H, t, 3JHH 4.7, OCH2); δC 14.91 (d, 5JCF 0.9, CH3), 
28.52 (d, 4JCF 8.9, SCH2), 51.02 (d, 4JCF 4.6, NCH2), 67.19 (d, 5JCF 1.5, OCH2), 121.38 (dd, 
2JCF 32.6, 3JCF 6.8, C-4), 140.97 (dd, 2JCF 23.4, 3JCF 7.1, C-5), 159.58 (dd, 1JCF 243.2, 4JCF 
1.5, C-6), 164.72 (d, 1JCF 237.9, C-3); δF -88.37 (1 F, d, 5JFF 31.2, F-3), -78.54 (1 F, d, 5JFF 
31.2, F-6); m/z (ES+) 260.9 ([M]+, 100%). 
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3,6-Difluoro-4-phenyl-5-(phenylthio)pyridazine 20 
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DIPEA (0.19 mL, 1.1 mmol) and thiophenol (0.07 mL, 0.68 mmol) were added to a stirred 
solution of 3,4,6-trifluoro-5-phenylpyridazine 11 (150 mg, 0.714 mmol) in THF (10 mL) at 
0 °C under nitrogen, and the solution was stirred for 1 hour. Aqueous NaOH was then 
added to the mixture, which was partitioned with EtOAc. The aqueous phase was extracted 
with two further portions of EtOAc and the combined organic phases were combined, dried 
and concentrated to give approx. 0.3 g of crude product. Purification by Biotage SP4, 
40+M SiO2 column (initial solvent - 1% THF in cyclohexane (2 column volumes), then a 
gradient elution over 10 CV's (1% THF in cyclohexane to 7% THF in cyclohexane), then 
7% THF in cyclohexane for 5 CV's) gave 3,6-difluoro-4-phenyl-5-(phenylthio)pyridazine 
20 (188 mg, 88%) as off-white crystals, mp 78.9-80.0 °C (Found: C, 63.97%, H, 3.42%, N, 
9.35%. C16H10F2N2S2 requires C, 63.99%, H, 3.36%, N, 9.33%); νmax/cm-1 1523.7, 1443.0 
and 1386.5; δH 7.20 - 7.31 (5 H, m), 7.33 - 7.40 (2 H, m), 7.44 - 7.55 (3 H, m); δC 128.65 
(s, C-2’, C-6’), 128.84 (d, 3JCF 2.4, C-1’), 128.92 (s, C-4’’), 129.34 (s, C-3’’, C-5’’), 129.42 
(s, C-3’, C-5’), 130.13 (s, C-4’), 130.35 (d, 4JCF 2.4, C-1’’), 132.09 (s, C-2’’, C-6’’), 132.48 
(dd, 2JCF 29.6, 3JCF 4.0, C-4), 134.52 (dd, 2JCF 31.2, 3JCF 3.2, C-5), 162.18 (d, 1JCF 245.3, C-
6), 163.36 (d, 1JCF 244.5, C-3); δF -83.29 (1 F, d, 5JFF 31.0, F-3), -75.29 (1 F, d, 5JFF 31.0, F-
6); m/z (ES+) 301.2 ([MH]+, 100%). 
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3,6-Difluoro-4-[(1-methylethyl)oxy]-5-(phenylthio)pyridazine 21 
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DIPEA (0.22 mL, 1.3 mmol) and thiophenol (0.077 mL, 0.75 mmol) were added to a stirred 
solution of 3,4,6-trifluoro-5-[(1-methylethyl)oxy]pyridazine 10 (160 mg, 0.833 mmol) in 
THF (10 mL) at 0 °C under nitrogen, and the solution was stirred for 1 hour. Aqueous 
NaOH was then added to the mixture, which was partitioned with EtOAc. The aqueous 
phase was extracted with two further portions of EtOAc and the combined organic phases 
were combined, dried and concentrated to give approx. 0.3 g of crude product. Purification 
by Biotage SP4, 40+M SiO2 column (initial solvent - 1% THF in cyclohexane (2 column 
volumes), then a gradient elution over 10 CV's (1% THF in cyclohexane to 7% THF in 
cyclohexane), then 7% THF in cyclohexane for 5 CV's) gave incomplete separation, so the 
mixture was recolumned on a 40+M column in toluene over 20 CV to give 205 mg of 
product containing ~2% disubstituted product (LCMS). 87 mg were further purified by RP-
HPLC, giving 3,6-difluoro-4-[(1-methylethyl)oxy]-5-(phenylthio)pyridazine 21 (77 mg, 
33%) as pale yellow crystals, mp 45.1-46.9 °C (Found: [MH]+, 283.07113. C13H12F2N2OS 
requires: [MH]+, 283.07112); νmax/cm-1 2985.5, 1581.1 and 1544.4; δH 1.26 (6 H, dd, 3JHH 
6.1, 6JHF 0.9, CH3), 4.97 - 5.08 (1 H, m, 3JHH 6.1, 5JHF 1.9, CH), 7.29 - 7.43 (5 H, m, CH); 
δC 22.40 (s, CH3), 78.48 (d, 5JCF 8.0, CH), 121.17 (dd, 2JCF 32.0, 3JCF 7.2, C-5), 128.60 (s, 
C-4’), 129.31 (s, C-3’, C-5’), 130.68 (s, C-1’), 131.86 (s, C-2’, C-6’), 147.08 (dd, 2JCF 24.0, 
3JCF 6.4, C-4), 157.86 (d, 1JCF 241.3, C-6), 163.88 (d, 1JCF 240.5, C-3); δF -92.13 (1 F, d, 
5JFF 31.6, F-3), -76.49 (1 F, d, 5JFF 31.6, F-6); m/z (ES+) 283.2 ([MH]+, 76%). 
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4-[3,6-Difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 22 
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DIPEA (0.15 mL, 0.88 mmol) and thiophenol (0.06 mL, 0.58 mmol) were added to a stirred 
solution of 4-(3,5,6-trifluoro-4-pyridazinyl)morpholine 1 (129 mg, 0.589 mmol) in THF 
(10 mL) at 0 °C under nitrogen, and the solution was stirred for 1 hour. Aqueous NaOH 
was then added to the mixture, which was partitioned with EtOAc. The aqueous phase was 
extracted with two further portions of EtOAc and the combined organic phases were 
combined, dried and concentrated to give approx. 0.2 g of crude product. TLC (of the crude 
reaction NMR sample) showed Rf = 1.8 in 4:1 cyclohexane:EtOAc. Purification by Biotage 
SP4, 40+S SiO2 column (initial solvent - 5% EtOAc in cyclohexane (2 column volumes), 
then a gradient elution over 10 CV's (5% EtOAc in cyclohexane to 25% EtOAc in 
cyclohexane), then 25% EtOAc in cyclohexane for 5 CV's) gave 169 mg of product in 
>99% purity (LCMS and NMR spectroscopy). Further purification by RP-HPLC gave 4-
[3,6-difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 22 (146 mg, 80%) as pale yellow 
crystals, mp 109.7-111.2 °C (Found: C, 54.13%, H, 4.19%, N, 13.60%. C14H13F2N3OS 
requires C, 54.36%, H, 4.23%, N, 13.58%); νmax/cm-1 2982.7, 1581.2 and 1542.1; δH 3.40 
(4 H, td, 3JHH 4.7, 5JHF 2.1, NCH2), 3.70 (4 H, dd, 3JHH 4.7, 4.5, OCH2), 7.21 - 7.25 (2 H, m, 
CH), 7.30 - 7.37 (3 H, m, CH); δC 50.42 (d, 4JCF 4.8, NCH2), 66.83 (s, OCH2), 116.35 (dd, 
2JCF 32.0, 3JCF 5.6, C-4), 128.08 (1 C, s), 129.04 (2 C, s), 129.57 (2 C, s), 131.90 (1 C, s), 
141.42 (dd, 2JCF 23.2, 3JCF 4.8, C-5), 159.07 (d, 1JCF 243.7, C-6), 164.90 (d, 1JCF 239.7, C-
3); δF -86.16 (1 F, d, 5JFF 31.0, F-3), -75.95 (1 F, d, 5JFF 31.0, F-6); m/z (ES+) 310.2 ([MH]+, 
100%). 
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4-(Ethylthio)-3,6-difluoro-5-isopropoxypyridazine 23 
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Lithium isopropoxide (2 M in THF, 0.58 mL, 1.16 mmol) was added to a stirred solution of 
4-(ethylthio)-3,5,6-trifluoropyridazine 16 (227 mg, 1.17 mmol) in THF (10 mL) under 
argon at -78 °C, and the solution was allowed to come to RT overnight. The reaction was 
quenched by the addition of wet THF, then concentrated in vacuo, partitioned between 
EtOAc and water, the phases were separated and the aqueous phase was extracted with 
EtOAc. The combined organic phases were concentrated in vacuo to give approx. 267 mg 
of crude product. Purification by column chromatography (silica, 9:1 hexane:EtOAc) gave 
4-(ethylthio)-3,6-difluoro-5-isopropoxypyridazine 23 (213 mg, 78%) as a colourless oil 
(Found: C, 46.39%, H, 5.27%, N, 11.78%. C9H12F2N2OS requires C, 46.14%, H, 5.16%, N, 
11.96% ); δH 1.31 (3 H, t, 3JHH 7.4, CH2CH3), 1.42 (6 H, d, 3JHH 5.9, CHCH3), 3.16 (2 H, 
qd, 3JHH 7.4, 5JHF 1.3, CH2), 4.99 (1 H, heptd, 3JHH 5.9, 5JHF 1.3, CH); δC 15.14 (s, 
CH2CH3), 22.82 (s, CHCH3), 27.39 (d, 4JCF 7.1, CH2), 78.76 (d, 4JCF 7.2, CH), 123.31 (dd, 
2JCF 32.8, 3JCF 6.6, C-4), 146.82 (dd, 2JCF 24.4, 3JCF 7.8, C-5), 158.23 (dd, 1JCF 242.4, 4JCF 
2.1, C-3), 164.04 (d, 1JCF 238.4, C-6); δF -93.80 (1 F, d, 5JFF 31.1, F-6), -78.72 (1 F, d, 5JFF 
31.1, F-3); m/z (ES+) 235.1 ([MH]+, 100%). 
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3,6-Difluoro-4-isopropoxy-5-phenylpyridazine 24 
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Lithium isopropoxide (2 M in THF, 0.40 mL, 0.80 mmol) was added to a stirred solution of 
3,4,6-trifluoro-5-phenylpyridazine 11 (169 mg, 0.804 mmol) in THF (10 mL) under 
nitrogen at -78 °C. The mixture was allowed to come to RT overnight. The reaction was 
quenched by the addition of wet THF, and then concentrated, partitioned between EtOAc 
and water, and extracted with two further portions of EtOAc. The combined organic phases 
were dried and concentrated in vacuo to give 199 mg of crude product, Rf = 0.24 in 9:1 
cyclohexane:EtOAc. Purification by Biotage SP4, 40+M SiO2 column (initial solvent - 2% 
EtOAc in cyclohexane (2 column volumes), then a gradient elution over 10 CV's (2% 
EtOAc in cyclohexane to 13% EtOAc in cyclohexane), then 13% EtOAc in cyclohexane for 
5 CV's) gave 3,6-difluoro-4-isopropoxy-5-phenylpyridazine 24 (138 mg, containing <10% 
of an inseparable isomer) as a colourless oil; δH 1.22 (6 H, dd, 3JHH 6.1, 6JHF 0.6, CH3), 4.65 
- 4.77 (1 H, m, CH), 7.49 - 7.52 (5 H, m, ArH); δF -92.32 (1 F, d, 5JFF 32.1, F-3), -83.02 (1 
F, d, 5JFF 32.1, F-6); m/z (ES+) 251.2 ([MH]+, 92%). 
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4-(3,5-Difluoro-6-phenylpyridazin-4-yl)morpholine 25 and 4-(5,6-difluoro-3-
phenylpyridazin-4-yl)morpholine 26 
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Phenylmagnesium bromide (1 M in THF, 0.85 mL, 0.85 mmol) was added to a stirred 
solution of 4-(3,5,6-trifluoro-4-pyridazinyl)morpholine 1 (187 mg, 0.853 mmol) in THF 
(10 mL) under nitrogen at -78 °C. The mixture was allowed to come to RT overnight. The 
reaction was quenched by the addition of wet THF, and then concentrated, partitioned 
between EtOAc and water, and extracted with two further portions of EtOAc. The 
combined organic phases were dried and concentrated in vacuo to give 224 mg of crude 
product, Rf = 0.3 in 1.5:8.5 toluene:DCM (SM Rf = 0.4). The crude product was purified 
by Biotage SP4, 40+S SiO2 column. Isocratic elution over 35 CV's, 5% toluene in DCM, to 
give 29 mg of an approximately 4:1 mixture of isomers (Minor product identified as 4-(5,6-
difluoro-3-phenylpyridazin-4-yl)morpholine 26; δF -150.65 (1F, d, 3JFF 26.6, F-5), -102.33 
(1F, d, 3JFF 26.6, F-6)). Further purification by MDAP gave 4-(3,5-difluoro-6-
phenylpyridazin-4-yl)morpholine 25 (15 mg, 6%) as a colourless oil (Found: [MH]+, 
278.10980. C14H14F2N3O requires: [MH]+, 278.10994); δH 3.49 - 3.52 (4 H, m, NCH2), 3.83 
- 3.87 (4 H, m, OCH2), 7.50 - 7.53 (3 H, m, ArH), 7.83 - 7.87 (2 H, m, ArH); δC 50.5 (t, 
5JCF 4.1, NCH2), 67.0 (s, OCH2), 126.5 (dd, 2JCF 22.8, 2JCF 7.9, C-4), 128.6 (s, C-3’, C-5’), 
128.9 (d, 4JCF 4.3, C-2’, C-6’), 130.1 (s, C-4’), 132.1 (d, 3JCF 4.2, C-1’), 151.7 (dd, 1JCF 
269.7, 3JCF 8.1, C-5), 152.0 (dd, 2JCF 8.8, 4JCF 2.9, C-6), 159.4 (dd, 1JCF 242.3, 3JCF 3.8, C-
3); δF -128.2 (1 F, d, 4JFF 29.5, F-5), -85.0 (1 F, d, 4JFF 29.5, F-3), m/z (ES+) 278.1 ([MH]+, 
100%). 
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3,5-Difluoro-4-isopropoxy-6-phenylpyridazine 27 and 3,4-difluoro-5-isopropoxy-6-
phenylpyridazine 28 
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Phenylmagnesium bromide (0.87 mL, 0.87 mmol) was added to a stirred solution of 3,4,6-
trifluoro-5-[(1-methylethyl)oxy]pyridazine 10 (168 mg, 0.874 mmol) in THF (10 mL) 
under nitrogen at -78 °C. The mixture was allowed to come to RT overnight. The reaction 
was quenched by the addition of wet THF, and then concentrated, partitioned between 
EtOAc and water, and extracted with two further portions of EtOAc. The combined organic 
phases were dried and concentrated in vacuo to give 200 mg of crude product. Purification 
by Biotage SP4, 40+M SiO2 column, initial solvent - 1% EtOAc in toluene (2 column 
volumes), then a gradient elution over 10 CV's (1% EtOAc in toluene to 7% EtOAc in 
cyclohexane), then 7% EtOAc in toluene for 5 CV's gave 81 mg of impure, inseparable, 
product in a 3:1 ratio. 3,5-Difluoro-4-isopropoxy-6-phenylpyridazine 27; δF -133.2 (1F, m, 
F-5), -91.6 (1F, m, F-3); m/z (ES+) 251.2 ([MH]+, 100%). 3,4-Difluoro-5-isopropoxy-6-
phenylpyridazine 28; δF -155.2 (1F, m, F-5), -100.3 (1F, m, F-3); m/z (ES+) 251.2 ([MH]+, 
100%). 
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4-(Ethylthio)-3,5-difluoro-6-phenylpyridazine 29 and 4-(ethylthio)-3,6-difluoro-5-
phenylpyridazine 30 
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Phenylmagnesium bromide (1 M in THF, 1.0 mL, 1.0 mmol) was added to a stirred 
solution of 4-(ethylthio)-3,5,6-trifluoropyridazine 16 (217 mg, 1.12 mmol) in THF (10 mL) 
under nitrogen at -78 °C. The mixture was allowed to come to RT overnight. The reaction 
was quenched by the addition of wet THF, and then concentrated, partitioned between 
EtOAc and water, and extracted with two further portions of EtOAc. The combined organic 
phases were dried and concentrated in vacuo to give 342 mg of crude product. Purification 
by column chromatography (silica, hexane:ethyl acetate, gradient elution) gave 199 mg of 
product as an inseparable mixture (1.8:1) of isomers. 4-(Ethylthio)-3,5-difluoro-6-
phenylpyridazine 29; δF -109.6 (1F, d, 4JFF 22.4, F-5), -77.3 (1F, d, 4JFF 22.4, F-3). 4-
(Ethylthio)-3,6-difluoro-5-phenylpyridazine 30; δF -85.2 (1F, d, 5JFF 31.2, F-3), -79.1 (1F, 
d, 5JFF 31.2, F-6). 
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4-(3-Fluoro-6-isopropoxy-5-(phenylthio)pyridazin-4-yl)morpholine 31 and 4-(6-fluoro-3-
isopropoxy-5-(phenylthio)pyridazin-4-yl)morpholine 32 
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Lithium isopropoxide (2 M in THF, 0.11 mL, 0.22 mmol) was added to a stirred solution of 
4-[3,6-difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 22 (68 mg, 0.22 mmol) in THF 
(10 ml) under nitrogen at -78 °C. The mixture was allowed to come to RT overnight. The 
reaction was quenched by the addition of wet THF, and then concentrated, partitioned 
between EtOAc and water, and extracted with two further portions of EtOAc. The 
combined organic phases were dried and concentrated in vacuo to give 89 mg of crude 
product. Purification by column chromatography (silica, 4:1 hexane:ethyl acetate) gave 73 
mg of product as an inseparable mixture (4.5:1) of isomers. 
Major isomer; δF -82.0 (1F, s); m/z (ES+) 349.2 ([MH]+, 68%). 
Minor isomer; δF -92.1 (1F, s); m/z (ES+) 349.1 ([MH]+, 35%). 
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4,4'-(6-Fluoro-4-(phenylthio)pyridazine-3,5-diyl)dimorpholine 33 
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Morpholine (56 mg, 0.626 mmol) and DIPEA (84 mg, 1.20 mmol) were added to a stirred 
solution of 4-[3,6-difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 22 (204 mg, 0.626 
mmol) in THF (4 mL). After heating to 150 °C (mw) for 80 min, the mixture was 
concentrated, partitioned between EtOAc and water, and extracted with two further 
portions of EtOAc. The combined organic phases were dried and concentrated in vacuo to 
give 574 mg of crude product. Purification by column chromatography (silica, hexane:ethyl 
acetate, gradient elution) gave 4,4'-(6-fluoro-4-(phenylthio)pyridazine-3,5-
diyl)dimorpholine 33 (168 mg, 71%) as white crystals, mp 159.3-160.0 °C (Found: [MH]+, 
377.1436. C18H21F2N4O2S requires: [MH]+, 377.1448); δH 3.15-3.19 (4H, m, CH2NC-5), 
3.31 (4H, t, 3JHH 4.7, CH2NC-3), 3.61 (4H, t, 4.7, 3JHH CH2CH2NC-5), 3.64 (4H, t, 3JHH 4.7, 
CH2CH2NC-3), 7.06-7.09 (2H, m, ArH), 7.22-7.29 (3H, m, ArH); δC 50.51 (s, CH2NC-3), 
50.57 (d, 4JCF 4.2, CH2NC-5), 66.66 (s, CH2CH2NC-3), 66.95 (s, CH2CH2NC-5), 121.48 (d, 
3JCF 6.9, C-4), 127.65 (s, C-4’), 128.45 (s, C-3’,C-5’), 129.24 (s, C-2’, C-6’), 133.83 (s, C-
1’), 140.26 (d, 2JCF 23.4, C-5), 158.71 (d, 1JCF 241.2, C-6), 163.91 (s, C-3); δF -92.57 (1F, 
s); m/z (ES+) 377.1 ([MH]+, 100%). 
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6.3 Experimental to Chapter 3 
 
3-Fluoro-5,8-dimethyl-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 34 
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DIPEA (0.25 mL, 1.5 mmol) and N,N'-dimethyl-ethane-1,2-diamine (0.05 mL, 0.5 mmol) 
were added to a stirred solution of 4-(3,5,6-trifluoro-pyridazin-4-yl)-morpholine 1 (100 mg, 
0.46 mmol) in THF (4 mL), and the mixture was stirred at room temperature for 5 days. 
The mixture was then concentrated, partitioned between DCM and water, the phases were 
separated and the aqueous phase further extracted with DCM. The organic phases were 
combined, dried and concentrated to give approximately 1.2 g of crude product. 
Purification by column chromatography (silica, 1:2 toluene:THF) gave 3-fluoro-5,8-
dimethyl-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 34 (103 mg, 84%) 
as white crystals; mp 144.2 – 147.3 °C (Found: [MH]+ , 268.1574. C12H18FN5O requires 
[MH]+ , 268.1574); δH 3.08 (4H, td, 3JHH 4.7, 5JHF 1.8, CH2NC-4), 3.14 (3H, s, CH3N-5), 
3.30 – 3.33 (2H, m, CH2N), 3.31 (3H, s, CH3N-8), 3.38 – 3.40 (2H, m, CH2N), 3.76 (4H, t, 
3JHH 4.7, CH2O); δC 38.32 (s, CN-8), 41.48 (s, CN-5), 46.59 (s, C-7), 50.40 (d, 4JCF 4.3, 
CNC-4), 51.01 (s, C-6), 67.01 (d, 5JCF 0.5, CO), 119.53 (d, 2JCF 29.1, C-4), 134.93 (d, 3JCF 
8.9, C-4a), 151.81 (s, C-8a), 161.23 (d, 1JCF 236.6, C-3); δF -94.54 (1F, s); m/z (AP+) 267 
([M]+, 100%). 
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3-Fluoro-4-morpholin-4-yl-9-oxa-10-thia-1,2-diaza-anthracene 35 
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DIPEA (1.2 mL, 6.9 mmol) and 2-mercaptophenol (0.23 mL, 2.3 mmol) were added to a 
stirred solution of 4-(3,5,6-trifluoro-pyridazin-4-yl)-morpholine 1 (504 mg, 2.3 mmol) in 
THF (4 mL), and the mixture was stirred at room temperature overnight. The mixture was 
then concentrated, partitioned between DCM and water, the phases were separated and the 
aqueous phase further extracted with DCM. The organic phases were combined, dried and 
concentrated to give approximately 1.7 g of crude product. Purification by column 
chromatography (silica, hexane:ethyl acetate, gradient elution), followed by 
recrystallisation from ethanol gave 3-fluoro-4-morpholin-4-yl-9-oxa-10-thia-1,2-diaza-
anthracene 35 (476 mg, 68%) as pale yellow crystals; mp 167.7 – 169.1 °C (Found: [MH]+ 
, 306.0707. C14H12FN3O2S requires [MH]+ , 306.0713); δH 3.24 (4H, td, 3JHH 4.7, 5JHF 2.1, 
CH2N), 3.85 (4H, t, 3JHH 4.7, CH2O), 7.07 – 7.10 (2H, m, H-6, H-8), 7.13 – 7.15 (1H, m, H-
7), 7.20 – 7.22 (1H, m, H-5); δC 49.99 (d, 4JCF 3.9, CH2N), 67.28 (d, 5JCF 1.3, CH2O), 
114.56 (s, C-10a), 118.94 (s, C-8), 123.54 (d, 3JCF 8.0, C-4a), 125.74 (s, C-6), 126.36 (s, C-
7), 129.31 (s, C-5), 134.18 (d, 2JCF 26.3, C-4), 149.96 (d, 4JCF 1.0, C-9a), 159.32 (s, C-8a), 
160.30 (d, 1JCF 243.0, C-3); δF -90.01 (1F, s); m/z (AP+) 305 ([M]+, 100%). 
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4-Amino-3,5,6-trifluoropyridazine 36 
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DIPEA (0.4 mL, 2.3 mmol) and ammonia (1 M solution in dioxane, 2.1 mL, 2.1 mmol) 
were added to a stirred solution of tetrafluoropyridazine (312 mg, 2.1 mmol) in THF (10 
mL), and the mixture was stirred at room temperature overnight. The mixture was then 
concentrated, partitioned between DCM and water, the phases were separated and the 
aqueous phase further extracted with DCM. The organic phases were combined, dried and 
concentrated to give approximately 500 mg of crude product. Purification by column 
chromatography (silica, hexane:ethyl acetate) gave 4-amino-3,5,6-trifluoropyridazine1 
 36 (264 mg, 86%) as a white solid; δH 4.70 (2H, br. s, NH2); δF -153.66 (1 F, dd, 4JFF 30.1, 
3JFF 25.9, F-5), -100.02 (1 F, dd, 5JFF 28.8, 3JFF 25.9, F-6), -93.30 (1 F, dd, 4JFF 30.1, 5JFF 
28.8, F-3). 
 
3-Fluoro-9-oxa-10-thia-1,2-diaza-anthracen-4-ylamine 37 
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DIPEA (0.53 mL, 3.0 mmol) and 2-mercaptophenol (0.1 mL, 1.0 mmol) were added to a 
stirred solution of 3,5,6-trifluoro-pyridazin-4-ylamine 36 (150 mg, 1.0 mmol) in THF (4 
mL), and the mixture was heated by microwave irradiation to a temperature of 150 °C for a 
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period of 10 minutes. The mixture was then concentrated, partitioned between DCM and 
water, the phases were separated and the aqueous phase further extracted with DCM. The 
organic phases were combined, dried and concentrated to give approximately 200 mg of 
crude product. Purification by column chromatography (silica, 1:1 hexane:ethyl acetate) 
followed by sublimation gave 3-fluoro-9-oxa-10-thia-1,2-diaza-anthracen-4-ylamine 37 
(29 mg, 12%) as an off-white solid; δH 3.34 (2H, br. s, NH2), 7.15 – 7.22 (2H, m, H-6, H-
8), 7.27 – 7.35 (2H, m, H-5, H-7), δC 102.97 (d, 3JCF 7.3, C-4a), 115.88 (s, C-8), 118.39 (s, 
C-10a), 125.74 (s, C-6), 126.95 (s, C-7), 129.06 (s, C-5), 133.42 (d, 2JCF 30.2, C-4), 150.26 
(s, C-8a), 154.24 (d, 1JCF 233.5, C-3), 158.84 (s, C-9a); δF -98.415 (1F, s); m/z (EI+) 235 
([M]+, 100%). 
 
4-Ethylsulfanyl-3-fluoro-5,8-dimethyl-5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 38 
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DIPEA (0.7 mL, 4 mmol) and N,N'-dimethyl-ethane-1,2-diamine (0.16 mL, 1.6 mmol) 
were added to a stirred solution of 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 16 (200 mg, 
1.0 mmol) in THF (4 mL), and the mixture was stirred at room temperature overnight. The 
mixture was then concentrated, partitioned between DCM and water, the phases were 
separated and the aqueous phase further extracted with DCM. The organic phases were 
combined, dried and concentrated to give approximately 250 mg of crude product. 
Purification by column chromatography (silica, 1:9 hexane:ethyl acetate) gave 4-
ethylsulfanyl-3-fluoro-5,8-dimethyl-5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 38 (191 
mg, 77%) as a white solid; mp 78.1 – 80.0 °C (Found: C, 49.4%; H, 6.2%; N, 23.0%. 
C10H15FN4S requires: C, 49.6%; H, 6.2%; N, 23.1%); δH 1.19 (3H, t, 3JHH 7.4, CH3CH2S), 
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2.78 (2H, q, 3JHH 7.4, CH2S), 3.11 (3H, s, CH3N-5), 3.31 (3H, s, CH3N-8), 3.30 – 3.32 (2H, 
m, CH2N), 3.46 – 3.49 (2H, m, CH2N); δC 14.41 (s, CH3CH2S), 29.18 (d, 4JCF 4.4, CH2S), 
37.85 (s, CH3N), 43.15 (s, CH3N), 46.77 (s, CH2N), 51.85 (s, CH2N), 101.99 (d, 2JCF 36.1, 
C-4), 141.61 (d, 3JCF 5.2, C-4a), 150.82 (s, C-8a), 162.34 (d, 1JCF 227.0, C-3); δF -87.00 
(1F, s); m/z (EI+) 242 ([M]+, 100%). 
 
4-Ethylsulfanyl-3-fluoro-9-oxa-10-thia-1,2-diaza-anthracene 39 
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DIPEA (0.40 mL, 2.3 mmol) and 2-mercaptophenol (0.08 mL, 0.8 mmol) were added to a 
stirred solution of 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 16 (150 mg, 0.77 mmol) in 
THF (4 mL), and the mixture was stirred at room temperature overnight. The mixture was 
then concentrated, partitioned between DCM and water, the phases were separated and the 
aqueous phase further extracted with DCM. The organic phases were combined, dried and 
concentrated to give approximately 0.3 g of crude product. Purification by column 
chromatography (silica, 19:1 toluene:ethyl acetate) gave 4-ethylsulfanyl-3-fluoro-9-oxa-10-
thia-1,2-diaza-anthracene 39 (161 mg, 74%) as yellow crystals; mp 121.4 – 123.0 °C 
(Found: [MH]+ , 281.0220. C12H9FN2OS2 requires [MH]+ , 281.0219); δH 1.34 (3H, t, 3JHH 
7.4, CH3), 3.14 (2H, qd, 3JHH 7.4, 5JHF 1.0, CH2), 7.07 – 7.09 (2H, m, H-6, H-8), 7.12 – 7.14 
(1H, m, H-7), 7.19 – 7.23 (1H, m, H-5); δC 15.31 (s, CH3), 28.82 (d, 4JCF 6.9, CH2), 114.49 
(s, C-10a), 118.83 (s, C-8), 124.04 (d, 2JCF 36.3, C-4), 125.86 (s, C-6), 126.43 (s, C-7), 
129.46 (s, C-5), 133.25 (d, 3JCF 4.9, C-4a), 149.44 (s, C-8a), 157.69 (d, 4JCF 1.9, C-9a), 
162.92 (d, 1JCF 238.2, C-3); δF -82.19 (1F, s); m/z (AP+) 280 ([M]+, 100%). 
 
165 
Chapter 6: Experimental 
4-Ethylsulfanyl-3-fluoro-10H-9-oxa-1,2,10-triaza-anthracene 40 
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16 40  
 
DIPEA (0.40 mL, 2.3 mmol) and 2-aminophenol (84 mg, 0.77 mmol) were added to a 
stirred solution of 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 16 (150 mg, 0.77 mmol) in 
THF (4 mL), and the mixture was heated by microwave irradiation to a temperature of 100 
°C for a period of 5 minutes. The mixture was then concentrated, partitioned between DCM 
and water, the phases were separated and the aqueous phase further extracted with DCM. 
The organic phases were combined, dried and concentrated to give approximately 200 mg 
of crude product. Purification by column chromatography (silica, 5:2:3 hexane:ethyl 
acetate:DCM) gave 4-ethylsulfanyl-3-fluoro-10H-9-oxa-1,2,10-triaza-anthracene 40 (153 
mg, 75%) as a yellow solid; mp (with decomposition) 260 °C (Found: [MH]+ , 264.0597. 
C12H10FN3OS requires [MH]+ , 264.0607); δH 1.31 (3H, t, 3JHH 7.4, CH3), 1.62 (1H, br. s, 
NH), 2.90 (2H, q, 3JHH 7.4, CH2), 6.63 – 6.65 (1H, m, H-5), 6.87 – 6.94 (3H, m, H-6, H-7, 
H-8); δC 15.29 (s, CH3), 28.91 (d, 4JCF 3.1, CH2), 102.27 (d, 2JCF 40.1, C-4), 114.63 (s, C-
5), 117.15 (s, C-8), 124.72 (s, C-7), 125.07 (s, C-6), 125.82 (s, C-10a), 137.67 (d, 3JCF 7.1, 
C-4a), 142.82 (s, C-8a), 153.49 (d, 4JCF 0.9, C-9a), 164.44 (d, 1JCF 235.1, C-3); δF -80.98 
(1F, s); m/z (AP+) 263 ([M]+, 100%). 
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4-Ethylsulfanyl-3-fluoro-10H-9-thia-1,2,10-triaza-anthracene 41 
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16 41  
 
DIPEA (1.4 mL, 7.9 mmol) and 2-aminophenol (0.28 mL, 1.9 mmol) were added to a 
stirred solution of 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 16 (397 mg, 2.0 mmol) in THF 
(4 mL), and the mixture was heated by microwave irradiation to a temperature of 100 °C 
for a period of 30 minutes. The mixture was then concentrated, partitioned between DCM 
and water, the phases were separated and the aqueous phase further extracted with DCM. 
The organic phases were combined, dried and concentrated to give approximately 600 mg 
of crude product. Recrystallisation from chloroform gave 4-ethylsulfanyl-3-fluoro-10H-9-
thia-1,2,10-triaza-anthracene 41 (333 mg, 63%) as yellow crystals; mp 249.2 – 251.8 °C 
(Found: [MH]+ , 280.0378. C12H10FN3S2 requires [MH]+ , 280.0378); δH 1.35 (3H, t, 3JHH 
7.4, CH3), 2.48 (1H, br. s, NH), 3.11 (2H, qd, 3JHH 7.4, 5JHF 0.8, CH2), 6.83 – 6.88 (3H, m, 
H-5, H-6, H-7), 7.05 – 7.07 (1H, m, H-8); δC 15.32 (s, CH3), 28.87 (d, 4JCF 6.9, CH2), 
113.83 (s, C-8a), 117.01 (s, C-5), 122.75 (d, 2JCF 38.4, C-4), 124.31 (s, C-7), 126.18 (s, C-
8), 129.29 (s, C-6), 135.44 (d, 3JCF 4.6, C-4a), 135.80 (s, C-10a), 151.74 (s, C-9a), 160.86 
(d, 1JCF 237.5, C-3); δF -85.61 (1F, s); m/z (AP+) 279 ([M]+, 100%). 
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4-Ethylsulfanyl-3-fluoro-1,2,4b,9-tetraaza-fluorene 42 
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16 42  
 
DIPEA (0.70 mL, 4.0 mmol) and pyridin-2-ylamine (143 mg, 1.5 mmol) were added to a 
stirred solution of 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 16 (199 mg, 1.03 mmol) in 
THF (4 mL), and the mixture was heated by microwave irradiation to a temperature of 150 
°C for a period of 30 minutes. The mixture was then concentrated, partitioned between 
DCM and water, the phases were separated and the aqueous phase further extracted with 
DCM. The organic phases were combined, dried and concentrated to give approximately 
300 mg of crude product. Purification by column chromatography (silica, 1:9 hexane:ethyl 
acetate) followed by recrystallisation from ethanol gave 4-ethylsulfanyl-3-fluoro-1,2,4b,9-
tetraaza-fluorene 42 (35 mg, 14%) as orange crystals; mp 197.8 – 199.5 °C (Found: [MH]+ 
, 249.0601. C11H9FN4S requires [MH]+ , 249.0610); δH 1.38 (3H, t, 3JHH 7.4, CH3), 3.32 
(2H, qd, 3JHH 7.4, 5JHF 0.7, CH2), 6.97 (1H, td, 3JHH 7.2, 3JHH 6.8, 4JHH 1.1, H-6), 7.64 (1H, 
ddd, 3JHH 9.4, 3JHH 6.8, 4JHH 1.3, H-7), 7.79 (1H, dt, 3JHH 9.4, 5JHH 1.2, 4JHH 1.1, H-8), 9.44 
(1H, dt, 3JHH 7.2, 4JHH 1.3, 5JHH 1.2, H-5); δC 15.40 (s, CH3), 26.92 (d, 4JCF 7.5, CH2), 
111.12 (d, 2JCF 38.5, C-4), 112.07 (s, C-8), 119.14 (s, C-6), 126.41 (d, 3JCF 8.0, C-4a), 
129.55 (s, C-7), 133.76 (s, C-5), 153.39 (d, 4JCF 0.9, C-9a), 158.82 (s, C-8a), 160.76 (d, 1JCF 
229.2, C-3); δF -89.37 (1F, s); m/z (ES+) 249 ([MH]+, 100%). 
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4-Ethylsulfanyl-3-fluoro-8-methyl-1,2,4b,9-tetraaza-fluorene 43 
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DIPEA (0.70 mL, 4.0 mmol) and pyridin-2-ylamine (0.15 mL, 1.29 mmol) were added to a 
stirred solution of 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 16 (200 mg, 1.03 mmol) in 
THF (4 mL), and the mixture was stirred at room temperature for seven days. The mixture 
was then concentrated, partitioned between DCM and water, the phases were separated and 
the aqueous phase further extracted with DCM. The organic phases were combined, dried 
and concentrated to give approximately 350 mg of crude product. Purification by column 
chromatography (silica, 1:9 hexane:ethyl acetate) gave 4-ethylsulfanyl-3-fluoro-8-methyl-
1,2,4b,9-tetraaza-fluorene 43 (134 mg, 50%) as orange crystals; mp 160.2 – 161.1 °C 
(Found: [MH]+ , 263.0760. C12H11FN4S requires [MH]+ , 263.0767); δH 1.37 (3H, t, 3JHH 
7.3, CH3CH2S), 2.72 (3H, s, CH3C-8), 3.30 (2H, qd, 3JHH 7.3, 5JHF 0.9, CH2), 6.89 (1H, dd, 
3JHH 7.0, 6.9, H-6), 7.42 (1H, d, 3JHH 6.9, H-7), 9.31 (1H, d, 3JHH 7.0, H-5); δC 15.39 (s, 
CH3CH2S), 17.69 (s, CH3C-8), 29.57 (d, 4JCF 7.2, CH2), 110.87 (d, 2JCF 39.4, C-4), 112.14 
(s, C-7), 126.93 (s, C-5), 126.98 (d, 3JCF 7.9, C-4a), 129.30 (s, C-8), 131.59 (s, C-6), 154.16 
(d, 4JCF 1.0, C-9a), 158.77 (s, C-8a), 160.78 (d, 1JCF 228.9, C-3), δF -89.55 (1F, s); m/z (EI+) 
262 ([M]+, 100%). 
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4-Ethylsulfanyl-3-fluoro-6-methyl-furo[2,3-c]pyridazine-5-carboxylic acid ethyl ester 44 
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DIPEA (0.82 mL, 4.7 mmol) and 3-oxo-butyric acid ethyl ester (0.17 mL, 1.3 mmol) were 
added to a stirred solution of 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 16 (234 mg, 1.21 
mmol) in THF (4 mL), and the mixture was heated by microwave irradiation to a 
temperature of 180 °C for a period of 90 minutes. The mixture was then concentrated, 
partitioned between DCM and water, the phases were separated and the aqueous phase 
further extracted with DCM. The organic phases were combined, dried and concentrated to 
give approximately 500 mg of crude product. Purification by column chromatography 
(silica, 2:1 hexane:ethyl acetate) gave 4-ethylsulfanyl-3-fluoro-6-methyl-furo[2,3-
c]pyridazine-5-carboxylic acid ethyl ester 44 (95 mg, 28%) as a colourless oil; (Found: 
[MH]+ , 285.0711. C12H13FN2O3S requires [MH]+ , 285.0709); δH 1.29 (3H, t, 3JHH 7.4, 
SCH2CH3), 1.43 (3H, t, 3JHH 7.2, OCH2CH3), 2.77 (3H, s, CH3C-6), 3.18 (2H, qd, 3JHH 7.4, 
5JHF 2.3, SCH2), 4.43 (2H, q, 3JHH 7.2, OCH2); δC 14.37 (s, CH3C-6), 14.98 (d, 5JCF 1.9, 
SCH2CH3), 15.04 (s, OCH2CH3), 28.68 (d, 4JCF 11.5, SCH2), 61.80 (s, OCH2), 111.04 (d, 
3JCF 4.7, C-4a), 122.82 (d, 2JCF 34.8, C-4), 126.64 (d, 4JCF 6.6, C-7a), 161.73 (s, C-5), 
162.13 (s, C-6), 162.95 (d, 1JCF 232.4, C-3), 168.34 (s, C=O); δF -84.97 (1F, s); m/z (ES+) 
285 ([MH]+, 100%). 
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6.4 Experimental to Chapter 4 
 
2-Fluorothiophene 45 
 
S Br S F
i) BuLi
Solvent
ii) NFSI
THF
45  
 
Method A: 
2-Bromothiophene (0.82 g, 5 mmol) was dissolved in THF (30 mL) at -78 oC under argon. 
n-Butyllithium (3.8 mL, 1.6 M in hexanes) was added and the mixture left with stirring for 
1h. NFSI (1.89 g, 6 mmol) in THF (15 mL) was then added and the mixture was left with 
stirring for a further 1h. Ammonium chloride (1 g, 19 mmol) in water (10 mL) was added 
and the mixture was allowed to come to room temperature. Analysis of the reaction mixture 
by 19F NMR spectroscopy showed 2-fluorothiophene2 45 (0.41 g, 80% (by comparison with 
a known mass of fluorobenzene)); δF -134.85 (br. s). No further purification was attempted 
due to the volatility of the product. 
 
Method B: 
As previously, but with the first step performed in diethyl ether (30 mL). 2-fluorothiophene 
45 was observed in 85% yield. 
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3-Fluorothiophene 46 
 
S S
i) BuLi
Solvent
ii) NFSI
THF
Br F
46  
 
Method A: 
3-Bromothiophene (0.82 g, 5 mmol) was dissolved in THF (30 mL) at -78 oC under argon. 
n-Butyllithium (3.8 mL, 1.6 M in hexanes) was added and the mixture left with stirring for 
1h. NFSI (1.89 g, 6 mmol) in THF (15 mL) was then added and the mixture was left with 
stirring for a further 1h. Ammonium chloride (1 g, 19 mmol) in water (10 mL) was added 
and the mixture was allowed to come to room temperature. Analysis of the reaction mixture 
by 19F NMR spectroscopy showed 3-fluorothiophene2 46 (0.18 g, 36% (by comparison with 
a known mass of fluorobenzene)); δF -131.13 (d, 3JHF 3.0). No further purification was 
attempted due to the volatility of the product. 
 
Method B: 
As previously, but with the first step performed in diethyl ether (30 mL). 3-fluorothiophene 
46 was observed in 50% yield. 
 
2-Fluoro-5-methylthiophene 47 
 
S Br S
1) BuLi
2) NFSI
THF/ether F
47  
 
2-Bromo-5-methylthiophene (0.89 g, 5 mmol) was dissolved in ether (30 mL) at -78 oC 
under argon. n-Butyllithium (3.2 mL, 1.6 M in hexanes) was added and the mixture was left 
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with stirring for 1h. NFSI (1.58 g, 5 mmol) in THF (10 mL) was then added and the 
mixture was left with stirring for a further 1h. Ammonium chloride (1 g, 19 mmol) in water 
(10 mL) was added and the mixture was allowed to come to room temperature. Analysis of 
the reaction mixture by 19F NMR spectroscopy showed 2-fluoro-5-methylthiophene 47 
(0.51g, 88% (by comparison with a known mass of fluorobenzene)); δF -133.80 (dd, 3JHF 
4.7, 4JHF 2.8). No further purification was attempted due to the volatility of the product. 
 
2-Fluoro-3-methylthiophene 48 
 
S Br S
1) BuLi
2) NFSI
THF/ether F
48  
 
2-Bromo-3-methylthiophene (0.89 g, 5 mmol) was dissolved in ether (30 mL) at -78 oC 
under argon. n-Butyllithium (3.2 mL, 1.6 M in hexanes) was added and the mixture was left 
with stirring for 1h. NFSI (1.58 g, 5 mmol) in THF (10 mL) was then added and the 
mixture was left with stirring for a further 1h. Ammonium chloride (1 g, 19 mmol) in water 
(10 mL) was added and the mixture was allowed to come to room temperature. Analysis of 
the reaction mixture by 19F NMR spectroscopy showed 2-fluoro-3-methylthiophene 48 
(0.45 g, 78% (by comparison with a known mass of fluorobenzene)); δF -142.14 (d, 4JHF 
1.5). No further purification was attempted due to the volatility of the product. 
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2-Chloro-5-fluorothiophene 49 
 
S Br S
1) BuLi
2) NFSI
THF/ether FCl Cl
49  
 
2-Bromo-5-chlorothiophene (0.99 g, 5 mmol) was dissolved in ether (30 mL) at -78 oC 
under argon. n-Butyllithium (3.2 mL, 1.6 M in hexanes) was added and the mixture was left 
with stirring for 1h. NFSI (1.58 g, 5 mmol) in THF (15 mL) was then added and the 
mixture was left with stirring for a further 1h. Ammonium chloride (1 g, 19 mmol) in water 
(10 mL) was added and the mixture was allowed to come to room temperature. Analysis of 
the reaction mixture by 19F NMR spectroscopy showed 2-chloro-5-fluorothiophene 49 
(0.29 g, 43% (by comparison with a known mass of fluorobenzene)); δF -128.13 (dd, 3JHF 
3.0, 4JHF 3.0). No further purification was attempted due to the volatility of the product. 
 
3-Bromo-2-fluorothiophene 50 
 
S
Br
Br S
Br
1) BuLi
2) NFSI
THF/ether F
50  
 
2,3-Dibromothiophene (1.21 g, 5 mmol) was dissolved in ether (30 mL) at -78 oC under 
argon. n-Butyllithium (3.8 mL, 1.6 M in hexanes) was added and the mixture was left with 
stirring for 1h. NFSI (1.89 g, 6 mmol) in THF (15 mL) was then added and the mixture was 
left with stirring for a further 1h. Ammonium chloride (1 g, 19 mmol) in water (10 mL) was 
added and the mixture was allowed to come to room temperature. Analysis of the reaction 
mixture by 19F NMR spectroscopy showed 3-bromo-2-fluorothiophene 50 (0.59 g, 65% (by 
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comparison with a known mass of fluorobenzene)); δF -133.53 (d, 4JHF 3.0). No further 
purification was attempted due to the volatility of the product. 
 
Tetrabromothiophene 51 
 
S SBr
Br Br
1) Br2
2) KOH
BrEtOH
51  
 
Thiophene (5.05 g, 0.06 mol) and chloroform (2.4 mL) were placed in a round bottomed 
flask and bromine (13.8 mL, 0.27 mol) was added dropwise to the stirred solution. The 
mixture was stirred at room temperature for 17h, then heated at reflux for 2h. The solution 
was cooled to room temperature, then potassium hydroxide (6.6 g, 0.12 mol) in ethanol (36 
mL) was added and the mixture was heated at reflux for a further 4h, then poured into 
ice/water (80 mL). The product was extracted into chloroform and recrystallised from 
chloroform and ethanol to give tetrabromothiophene3 51 (15.09 g, 63%) as white crystals, 
mp 115.9 - 116.4 oC (lit. mp 117 - 118 °C) (Found: C, 12.03%. C4Br4S requires C, 
12.02%); δC 110.3 (s, C-2, C-5), 117.0 (s, C-3, C-4); m/z (EI) 399.5 ([M]+, 64%), 320.5 
(55), 239.6 (59), 160.7 (67), 79.5 (100). 
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2,3,4-Tribromothiophene 52 
 
SBr
Br Br
Br SBr
Br Br
1) BuLi
2) H+, H2O
THF
51 52  
 
Tetrabromothiophene 51 (2.00 g, 5 mmol) in THF (20 mL) was added to n-butyllithium 
(3.13 mL, 1.6 M in hexanes) in THF (30 mL) under argon at -78 oC. The mixture was left 
with stirring for 30 min. aq. HCl (0.5 M, 10 mL) was then added, and the mixture allowed 
to come to room temperature. Water was added, and the product was extracted into DCM. 
The extracts were combined, dried and concentrated, and the crude product, after 
purification by column chromatography (silica, hexane) gave 2,3,4-tribromothiophene3 52 
(1.32 g, 82%) as white crystals, mp 42.8 - 44.6 oC (lit. mp 43 – 46 °C); δH 7.35 (1 H, s); δC 
111.64 (s, C-2), 113.20 (s, C-4), 117.75 (s, C-3), 124.11(s, C-1). 
 
2,3,4-Tribromo-5-methylthiophene 53 
 
SBr
Br Br
Br SBr
Br Br
1) BuLi
2) MeI
THF
51 53  
 
Tetrabromothiophene 51 (2.00 g, 5 mmol) in THF (20 mL) was added to n-butyllithium 
(3.13 mL, 1.6 M in hexanes) in THF (30 mL) under argon at -78 oC. The mixture was left 
with stirring for 1h. Iodomethane (0.71 g, 5 mmol) was added and the mixture was left with 
stirring for a further 1h. Water was added, and the product was extracted into DCM. The 
extracts were combined, dried and concentrated to give 1.8 g of crude product. 
Recrystallisation from hexane gave 2,3,4-tribromo-5-methylthiophene 53 (0.882 g, 53%) as 
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white crystals, mp 86.3 - 87.0 oC (Found: C, 18.09%, H, 0.90%. C5H3Br3S requires C, 
17.94%, H, 0.90%); δH 2.39 (3 H, s, CH3); δC 16.7 (s, CH3), 107.3 (s, C-2), 112.2 (s, C-4), 
117.0 (s, C-3), 136.2 (s, C-5); m/z (EI) 333.5 ([M]+, 88%), 254.7 (85), 173.6 (92), 94.5 
(100). 
 
2,3,4-Tribromo-5-phenylthiophene 54 
  
SBr
Br Br
Br SBr
Br Br
Pd(PPh3)4
PhB(OH)2
base
solvent
51 54  
 
Tetrabromothiophene 51 (0.50 g, 1.25 mmol), phenylboronic acid (152 mg, 1.25 mmol), 
base (2.5 mmol), and palladium tetrakis triphenylphosphine (72 mg, 0.063 mmol) were 
dissolved in degassed solvent (3 mL). The mixture was stirred at reflux under an argon 
atmosphere for 18 h. At the end of this period the mixture was allowed to cool, and was 
partitioned between DCM and water. The combined organic phases were combined and 
concentrated, at which point analysis by GC-MS showed 2,3,4-tribromo-5-phenylthiophene 
54 (0 – 40 mg, 0 – 81% (varying with solvent and base employed)); m/z (EI) 397.5 ([M]+, 
78%), 316.6 (20), 237.7 (77), 156.6 (100). 
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Appendix 
 
Crystal Structure Data Tables 
 
A.1) 4,4'-(6-Fluoro-4-(phenylthio)pyridazine-3,5-diyl)dimorpholine 33  
 
Table 1: Crystal data and structure refinement for 10srv173  
Identification code  10srv173 
Empirical formula  C18H21N4O2FS 
Formula weight  376.45 
Temperature / K  120 
Crystal system  monoclinic 
Space group  P21
a / Å, b / Å, c / Å  6.5813(2), 13.5706(4), 10.4143(4) 
α/°, β/°, γ/°  90.00, 107.70(2), 90.00 
Volume / Å3  886.07(5) 
Z  2 
ρcalc / mg mm-3  1.411 
μ / mm‑1  0.214 
F(000)  396 
Crystal size / mm3  0.32 × 0.2 × 0.11 
Theta range for data collection  2.05 to 59.98° 
Index ranges  -9 ≤ h ≤ 9, -18 ≤ k ≤ 19, -14 ≤ l ≤ 14 
Reflections collected  16499 
Independent reflections  5013[R(int) = 0.0534] 
Data/restraints/parameters  5013/1/319 
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Goodness-of-fit on F2  1.053 
Final R indexes [I>2σ (I)]  R1 = 0.0364, wR2 = 0.0863 
Final R indexes [all data]  R1 = 0.0385, wR2 = 0.0885 
Largest diff. peak/hole / e Å-3  0.306/-0.250 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for 10srv173. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
Atom x y z U(eq) 
S1 608.2(5) 4042.3(3) 3503.9(3) 19.35(9) 
F1 6231.0(16) 6141.8(7) 2210.2(10) 26.1(2) 
O1 2875(2) 7497.6(9) 5456.0(14) 30.1(3) 
O2 -1320(2) 1338.9(11) -157.0(14) 33.9(3) 
N1 4185(2) 3844.1(10) 1010.9(13) 20.9(3) 
N2 5443(2) 4657.4(11) 1313.5(13) 21.0(3) 
N3 3348(2) 5967.3(10) 3728.8(13) 19.4(3) 
N4 1395(2) 2877.6(10) 1244.4(13) 18.5(2) 
C1 5056(2) 5312.3(12) 2107.7(15) 19.1(3) 
C2 3541(2) 5257.6(11) 2822.1(14) 16.2(3) 
C3 2345(2) 4387.1(12) 2578.7(14) 16.1(3) 
C4 2645(2) 3727.7(11) 1587.2(14) 17.1(3) 
C5 5181(3) 6558.9(13) 4475.9(18) 23.2(3) 
C6 4797(3) 6930.1(15) 5759.9(19) 28.6(4) 
C7 1092(3) 6893.5(14) 4774(2) 29.3(4) 
C8 1317(3) 6497.0(13) 3465.4(18) 23.8(3) 
C9 -889(2) 3054.3(14) 548.3(17) 23.2(3) 
C10 -2118(3) 2107.9(15) 503(2) 29.7(4) 
C11 895(3) 1176.9(14) 509(2) 29.8(4) 
C12 2203(3) 2101.8(12) 548.3(17) 21.6(3) 
C13 2206(2) 4221.6(10) 5204.6(14) 17.8(3) 
C14 1107(3) 4362.7(13) 6147.5(16) 24.3(3) 
C15 2239(3) 4438.1(16) 7513.3(17) 30.9(4) 
C16 4453(3) 4390.7(16) 7946.0(17) 30.3(4) 
C17 5535(3) 4245.1(13) 6999.6(16) 25.0(4) 
C18 4424(2) 4159.3(12) 5640.1(15) 20.5(3) 
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Table 3 Anisotropic Displacement Parameters (Å2×103) for 10srv173. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12
S1 18.36(16) 25.39(18) 16.21(15) -2.07(14) 8.14(12) -4.51(16) 
F1 25.4(5) 26.4(5) 29.4(5) 0.6(4) 12.8(4) -7.0(4) 
O1 34.6(7) 22.5(6) 38.1(7) -9.9(5) 18.6(6) -5.7(5) 
O2 26.2(6) 37.1(7) 40.2(7) -20.4(6) 12.7(6) -9.5(6) 
N1 20.1(6) 26.7(7) 17.4(6) -0.7(5) 7.7(5) -0.9(5) 
N2 19.6(6) 26.1(7) 19.0(6) 1.4(5) 8.4(5) -1.5(6) 
N3 17.9(6) 19.9(6) 20.4(6) -4.1(5) 6.1(5) -0.9(5) 
N4 16.6(6) 21.4(6) 17.8(6) -4.4(5) 5.7(5) -1.1(5) 
C1 16.0(6) 21.8(7) 19.8(6) 2.9(6) 6.1(5) -1.2(6) 
C2 15.1(6) 18.8(7) 15.1(6) 2.0(5) 5.0(5) 1.3(6) 
C3 14.8(6) 19.6(6) 14.1(6) 1.0(5) 4.8(5) 0.0(5) 
C4 15.7(6) 20.4(7) 14.5(6) 0.7(5) 3.6(5) 1.1(5) 
C5 19.9(7) 21.8(8) 26.9(8) -6.7(6) 5.6(6) -4.6(6) 
C6 35.1(9) 26.0(9) 24.6(8) -6.9(7) 9.1(7) -5.9(8) 
C7 30.9(9) 22.0(8) 41.7(10) -7.5(7) 20.8(8) -4.2(7) 
C8 20.2(7) 23.2(8) 28.3(8) -2.4(7) 7.5(6) 2.7(7) 
C9 15.3(7) 32.1(9) 20.8(7) -4.9(6) 3.6(6) 1.4(6) 
C10 23.1(8) 37.4(10) 30.4(9) -14.1(8) 10.8(7) -6.8(8) 
C11 29.8(9) 24.5(8) 37.6(10) -9.1(7) 13.8(7) -4.7(7) 
C12 20.9(7) 23.5(8) 21.8(7) -5.9(6) 8.7(6) 0.3(6) 
C13 22.9(7) 16.6(8) 15.8(6) 0.2(5) 8.9(5) 0.3(5) 
C14 23.6(7) 32.4(9) 20.7(7) -1.1(6) 12.3(6) 0.2(7) 
C15 33.9(9) 42.5(10) 20.6(8) -1.9(7) 15.0(7) -1.3(8) 
C16 34.5(9) 41.2(10) 15.7(7) 0.5(7) 8.5(7) 0.1(8) 
C17 26.1(7) 30.3(10) 18.8(7) 3.0(6) 7.1(6) 1.2(7) 
C18 22.2(7) 21.5(8) 19.6(6) 1.6(6) 8.8(5) 2.3(6) 
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Table 4 Bond Lengths for 10srv173. 
Atom Atom Length/Å Atom Atom Length/Å 
S1 C3 1.7674(14) N4 C12 1.467(2) 
S1 C13 1.7802(16) C1 C2 1.416(2) 
F1 C1 1.3515(19) C2 C3 1.399(2) 
O1 C6 1.431(2) C3 C4 1.425(2) 
O1 C7 1.431(2) C5 C6 1.520(2) 
O2 C10 1.434(2) C7 C8 1.514(2) 
O2 C11 1.429(2) C9 C10 1.511(3) 
N1 N2 1.3581(19) C11 C12 1.515(3) 
N1 C4 1.3351(18) C13 C14 1.3987(19) 
N2 C1 1.291(2) C13 C18 1.393(2) 
N3 C2 1.3813(19) C14 C15 1.394(2) 
N3 C5 1.461(2) C15 C16 1.390(3) 
N3 C8 1.468(2) C16 C17 1.394(2) 
N4 C4 1.399(2) C17 C18 1.387(2) 
N4 C9 1.476(2)    
 
Table 5 Bond Angles for 10srv173. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
F1 C1 C2 118.67(14) C2 C3 C4 117.86(13) 
O1 C6 C5 110.84(16) C3 S1 C13 102.82(7) 
O1 C7 C8 111.10(14) C3 C2 C1 113.34(13) 
O2 C10 C9 111.30(14) C4 N1 N2 118.98(13) 
O2 C11 C12 111.89(16) C4 N4 C9 115.05(13) 
N1 C4 N4 116.80(13) C4 N4 C12 116.40(12) 
N1 C4 C3 122.89(14) C4 C3 S1 118.95(11) 
N2 C1 F1 113.83(13) C5 N3 C8 112.81(13) 
N2 C1 C2 127.48(15) C7 O1 C6 109.74(14) 
N3 C2 C1 123.26(14) C11 O2 C10 110.33(14) 
N3 C2 C3 123.30(13) C12 N4 C9 109.99(13) 
N3 C5 C6 108.63(13) C14 C13 S1 116.24(12) 
N3 C8 C7 109.80(15) C15 C14 C13 119.77(15) 
N4 C4 C3 120.17(13) C15 C16 C17 119.19(16) 
N4 C9 C10 109.44(15) C16 C15 C14 120.63(15) 
N4 C12 C11 108.62(13) C17 C18 C13 120.14(13) 
C1 N2 N1 118.86(12) C18 C13 S1 123.99(11) 
C2 N3 C5 120.98(13) C18 C13 C14 119.61(14) 
C2 N3 C8 118.77(13) C18 C17 C16 120.65(15) 
C2 C3 S1 123.10(11)     
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Table 6 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for 10srv173.  
Atom x y z U(eq) 
H5B 5390.0(3) 7104(17) 3950.0(2) 27(5) 
H5A 6470.0(4) 6140(18) 4670.0(2) 33(6) 
H6A 4730.0(3) 6401(16) 6360.0(2) 22(5) 
H6B 6050.0(4) 7363(17) 6260.0(2) 27(5) 
H7A 1000.0(3) 6319(16) 5360.0(2) 29(6) 
H7B -210.0(4) 7311(19) 4610.0(2) 35(6) 
H8A 120.0(3) 6065(17) 3030.0(2) 23(5) 
H8B 1290.0(4) 7048(19) 2860.0(2) 32(6) 
H9A -1120.0(3) 3293(16) -420.0(2) 28(5) 
H9B -1460.0(4) 3639(19) 980.0(3) 40(7) 
H10B -3750.0(4) 2151(19) -70.0(3) 37(6) 
H10A -1990.0(4) 1860(18) 1440.0(2) 37(6) 
H11B 1170.0(3) 938(17) 1410.0(2) 26(5) 
H11A 1330.0(4) 690.0(2) -70.0(3) 46(7) 
H12A 2120.0(4) 2305(19) -380.0(2) 36(6) 
H12B 3660.0(3) 1971(17) 1060.0(2) 25(5) 
H14 -430.0(3) 4438(16) 5830.0(2) 22(5) 
H15 1440.0(3) 4545(17) 8150.0(2) 30(6) 
H16 5180.0(4) 4471(19) 8880.0(3) 40(6) 
H17 7150.0(4) 4175(19) 7270.0(2) 36(6) 
H18 5300.0(3) 3983(17) 4990.0(2) 25(5) 
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A.2) 4-Ethylsulfanyl-3-fluoro-9-oxa-10-thia-1,2-diaza-anthracene 39 
 
Table 1 Crystal data and structure refinement for 09srv149  
Identification code  s149 
Empirical formula  C12H9N2OFS2
Formula weight  280.33 
Temperature  120(2) 
Crystal system  Monoclinic 
Space group  P21/n 
a/Å, b/Å, c/Å  10.6924(5), 9.8670(4), 11.0623(5) 
α/°, β/°, γ/°,  90.00, 92.444(10), 90.00 
Volume/Å3  1166.03(9) 
Z  4 
ρcalcmg/mm3  1.597 
m/mm‑1  0.457 
F(000)  576 
Crystal size  0.42 × 0.21 × 0.04 
Theta range for data collection  2.59 to 29.50° 
Index ranges  -14 ≤ h ≤ 14, -13 ≤ k ≤ 13, -15 ≤ l ≤ 15 
Reflections collected  10747 
Independent reflections  3249[R(int) = 0.0657] 
Data/restraints/parameters  3249/0/199 
Goodness-of-fit on F2  1.008 
Final R indexes [I>2σ (I)]  R1 = 0.0429, wR2 = 0.1035 
Final R indexes [all data]  R1 = 0.0637, wR2 = 0.1129 
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Largest diff. peak/hole  0.609/-0.354 
 
Table 2 Atomic Coordinates (Å×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for 09srv149. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
S1 8239.2(5) 6351.8(5) 4028.4(4) 21.63(14) 
S2 8039.8(5) 4398.8(5) 6125.4(4) 23.13(14) 
F1 8568.5(13) 1401.9(12) 5237.8(11) 32(3) 
O1 9090.9(14) 4916.1(14) 1677.3(11) 25.5(3) 
N1 9236.7(16) 2863.1(17) 2481.6(14) 22.4(4) 
N2 9068(16) 1953.6(17) 3382.6(15) 23.8(4) 
C1 9064(18) 8474.4(19) 2731.7(17) 19.4(4) 
C2 9546.3(19) 9104(2) 1734.6(18) 21.6(4) 
C3 9869.4(19) 8325(2) 743.9(17) 22.2(4) 
C4 9714.2(19) 6931(2) 753.8(16) 21.4(4) 
C5 9230.1(18) 6316.2(19) 1755.6(16) 19(4) 
C6 8893.7(17) 7077.4(19) 2748.3(16) 17.9(4) 
C7 8988.8(18) 4135(2) 2692.2(17) 19.1(4) 
C8 8604.5(17) 4658.2(18) 3804.2(16) 18.2(4) 
C9 8464.6(17) 3737.1(19) 4735.9(16) 18(4) 
C10 8709.2(19) 2389(2) 4415.9(18) 22.8(4) 
C11 7560(2) 3013(2) 7083.8(18) 24.9(4) 
C12 7171(2) 3679(3) 8252(19) 29.9(5) 
 
Table 3 Anisotropic Displacement Parameters (Å2×103) for 09srv149. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12
S1 30.3(3) 17.1(2) 18.1(2) -0.41(17) 7.76(19) 2.31(19) 
S2 31.4(3) 21(3) 17.3(2) 1.07(17) 4.92(19) -0.7(2) 
F1 49.3(8) 18.7(6) 28.1(6) 6(5) 4.1(6) 2.8(6) 
O1 41.3(9) 17.7(7) 18(6) -2.4(5) 8.7(6) -3.7(6) 
N1 24.6(9) 18.3(8) 24.5(8) -1.4(6) 3.7(7) -1(7) 
N2 26.2(9) 18.6(8) 26.8(8) -0.2(7) 1.5(7) 0.8(7) 
C1 20.7(9) 20.1(10) 17.5(8) -1.4(7) 0.5(7) 2.4(7) 
C2 23.3(10) 19.7(10) 21.8(9) 1.6(7) -0.4(8) 0.2(8) 
C3 22.2(10) 25.6(10) 19.1(9) 5.5(7) 2.8(8) 0.7(8) 
C4 23.9(10) 23.7(10) 16.8(8) -0.5(7) 3.6(8) 2.1(8) 
C5 21.5(9) 17.5(9) 18.1(8) -0.9(7) 1.7(7) -0.8(7) 
C6 19(9) 18.4(9) 16.5(8) 1.1(7) 3.2(7) -1.1(7) 
C7 17.5(9) 19.5(9) 20.3(9) -0.7(7) 2.7(7) -2.1(7) 
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C8 19.1(9) 15.6(9) 19.8(8) -0.1(7) 0.6(7) -0.5(7) 
C9 15(9) 19.8(9) 19.2(8) -0.7(7) 0.4(7) -1.2(7) 
C10 24.3(10) 19.5(10) 24.6(9) 2.1(7) 0.5(8) -0.4(8) 
C11 26.7(11) 25.7(11) 22.6(9) 6.6(8) 4(8) -1.3(9) 
C12 27.2(11) 40(13) 23(10) 9.7(9) 6.3(9) 4.1(10) 
 
Table 4 Bond Lengths for 09srv149. 
Atom Atom Length/Å Atom Atom Length/Å 
S1 C8 1.7363(19) C1 C2 1.385(3) 
S1 C6 1.7584(18) C1 C6 1.391(3) 
S2 C9 1.7478(19) C2 C3 1.394(3) 
S2 C11 1.818(2) C3 C4 1.386(3) 
F1 C10 1.345(2) C4 C5 1.383(3) 
O1 C7 1.370(2) C5 C6 1.390(3) 
O1 C5 1.392(2) C7 C8 1.411(3) 
N1 C7 1.305(3) C8 C9 1.387(3) 
N1 N2 1.359(2) C9 C10 1.404(3) 
N2 C10 1.295(3) C11 C12 1.523(3) 
 
Table 5 Bond Angles for 09srv149. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C8 S1 C6 100.21(9) C1 C6 S1 118.11(14) 
C9 S2 C11 108.81(9) N1 C7 O1 111.76(16) 
C7 O1 C5 121.31(14) N1 C7 C8 125.19(18) 
C7 N1 N2 118.00(16) O1 C7 C8 122.99(17) 
C10 N2 N1 118.81(17) C9 C8 C7 116.91(17) 
C2 C1 C6 120.59(18) C9 C8 S1 119.50(14) 
C1 C2 C3 119.48(18) C7 C8 S1 123.53(14) 
C4 C3 C2 120.48(17) C8 C9 C10 113.97(17) 
C5 C4 C3 119.39(17) C8 C9 S2 116.68(14) 
C4 C5 C6 120.94(17) C10 C9 S2 129.34(15) 
C4 C5 O1 115.35(16) N2 C10 F1 113.70(17) 
C6 C5 O1 123.70(16) N2 C10 C9 127.07(19) 
C5 C6 C1 119.11(17) F1 C10 C9 119.23(17) 
C5 C6 S1 122.77(14) C12 C11 S2 105.34(15) 
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Table 6 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for 09srv149.  
Atom x y z U(eq) 
H1 8900(2) 9000(2) 3374(19) 22(6) 
H2 9651(19) 10030(2) 1684(18) 21(5) 
H3 10210(2) 8730(2) 70(2) 26(6) 
H4 9940(2) 6410(2) 130(2) 33(6) 
H111 6850(2) 2530(3) 6700(2) 38(7) 
H112 8260(2) 2410(2) 7230(19) 29(6) 
H121 6450(2) 4300(2) 8120(2) 32(6) 
H122 6960(2) 3030(3) 8780(2) 33(7) 
H123 7870(2) 4250(2) 8660(2) 34(7) 
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A.3) 4-Ethylsulfanyl-3-fluoro-10H-9-oxa-1,2,10-triaza-anthracene 40 
 
Table 1 Crystal data and structure refinement for 09srv155  
Identification code  s155ncs 
Empirical formula  C12H10N3SFO 
Formula weight  263.29 
Temperature  120(2) 
Crystal system  Orthorhombic 
Space group  Pca21
a/Å, b/Å, c/Å  12.566(9), 5.2062(4), 35.081(3) 
α/°, β/°, γ/°,  90.00, 90.00, 90.00 
Volume/Å3  2295.0(17) 
Z  8 
ρcalcmg/mm3  1.524 
m/mm‑1  0.286 
F(000)  1088 
Crystal size  0.48 × 0.1 × 0.04 
Theta range for data collection  3.24 to 27.30° 
Index ranges  -15 ≤ h ≤ 15, -6 ≤ k ≤ 6, -35 ≤ l ≤ 44 
Reflections collected  13348 
Independent reflections  4103[R(int) = 0.0642] 
Data/restraints/parameters  4103/1/336 
Goodness-of-fit on F2  1.014 
Final R indexes [I>2σ (I)]  R1 = 0.0490, wR2 = 0.0989 
Final R indexes [all data]  R1 = 0.0833, wR2 = 0.1088 
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Largest diff. peak/hole  0.241/-0.294 
 
Table 2 Atomic Coordinates (Å×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for 09srv155. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
S1 6624.7(7) 12446(2) 4062.6(4) 29.1(3) 
F1 4546(4) 15220(6) 4167.7(16) 42.5(13) 
O1 4069(2) 7973(6) 3115.3(10) 31.6(8) 
N2 3439(3) 11148(8) 3480.7(12) 32.4(9) 
N1 6076(3) 8337(7) 3455(11) 23.3(9) 
N3 3554(3) 13040(7) 3747.5(12) 33.9(10) 
C1 4481(3) 13300(9) 3907.6(14) 27.4(11) 
C2 5392(3) 11845(9) 3835.9(13) 25(10) 
C3 5297(5) 9951(7) 3569(2) 19(2) 
C4 4266(5) 9741(9) 3407(2) 21.8(16) 
C5 6695(5) 4723(10) 3058(2) 24.3(18) 
C6 6450(3) 2873(9) 2797.8(14) 29.7(11) 
C7 5451(4) 2754(10) 2629.8(13) 32.9(11) 
C8 4670(5) 4470(12) 2740(2) 29.8(14) 
C9 4882(3) 6282(9) 3010.9(14) 23.4(10) 
C10 5887(3) 6484(9) 3177.1(13) 22.2(10) 
C11 6647(7) 9734(11) 4398(3) 44(2) 
C12 5773(8) 9864(13) 4700(3) 66(3) 
S2 4103.8(7) 2537(2) 5640.1(4) 29(2) 
F2 2012(4) -230(6) 5549.7(15) 37.6(12) 
O2 1546(2) 7024(5) 6588.7(9) 29.8(7) 
N21 3551(3) 6681(7) 6250.1(11) 23.5(9) 
N22 923(2) 3867(8) 6215.9(12) 30.4(9) 
N23 1022(3) 1978(8) 5952.1(12) 34.6(10) 
C21 1961(3) 1679(9) 5800.8(14) 27.9(11) 
C22 2878(3) 3162(8) 5865.2(13) 22.1(10) 
C23 2756(5) 5071(8) 6141(3) 23(2) 
C24 1734(4) 5313(10) 6320(2) 23.3(16) 
C25 4119(5) 10276(10) 6623(2) 21.2(16) 
C26 3929(3) 12153(9) 6904(13) 27.7(10) 
C27 2929(4) 12272(10) 7071.8(14) 31.3(11) 
C28 2145(5) 10520(12) 6966(2) 30.9(15) 
C29 2368(3) 8706(8) 6696.6(13) 22.5(10) 
C30 3377(3) 8532(8) 6524.4(13) 19.1(9) 
C31 4159(6) 5206(9) 5319(3) 30.2(19) 
C32 3331(6) 5164(10) 5016(3) 39(2) 
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Table 3 Anisotropic Displacement Parameters (Å2×103) for 09srv155. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12
S1 24(4) 25.9(6) 37.3(7) -3.8(6) 1.5(4) -4.7(5) 
F1 32(2) 39(3) 56(3) -11.4(16) 11(2) 9.8(12) 
O1 14(12) 30(2) 50(2) 3.1(16) -6.8(14) 2.5(12) 
N2 19.7(18) 30(3) 47(3) 11(2) 3.5(18) 2.1(18) 
N1 12.7(15) 25(2) 32(2) -6(18) -3.6(16) 1.8(14) 
N3 24.5(19) 32(3) 45(3) 7(2) 10.2(18) 8.2(16) 
C1 28(2) 25(3) 29(3) 1(2) 10.8(19) 5(18) 
C2 25(2) 26(3) 24(3) 4(2) 7.1(18) -2.3(17) 
C3 16(3) 23(6) 17(4) 8.2(18) 2(3) -0.2(14) 
C4 26(3) 16(3) 24(4) 10(2) 2(3) 1.4(18) 
C5 17(3) 22(3) 34(4) -4(2) 7(2) 8.4(17) 
C6 28(2) 32(3) 29(3) -8(2) 8(2) -0.8(19) 
C7 40(3) 39(3) 20(2) -4(2) 2(2) -12(2) 
C8 21(3) 35(3) 34(4) 10(3) -6(2) -3(3) 
C9 17.7(19) 26(3) 27(3) 7(2) 0(19) 1(17) 
C10 16.6(19) 24(3) 26(3) 2(2) 0.7(17) -1.7(16) 
C11 47(4) 39(5) 46(6) 5(3) -20(4) -7(3) 
C12 82(6) 86(8) 30(6) 13(3) 11(5) -21(3) 
S2 24.1(5) 25.1(6) 37.7(6) -5(6) -1.1(4) 3.7(5) 
F2 45(2) 31(2) 36(3) -4.9(14) -10(2) -8.3(12) 
O2 15.3(13) 28.7(18) 45(2) -0.8(16) 8.1(13) 2.9(12) 
N21 12.7(16) 23(2) 35(3) -1.1(19) 3.8(16) -2.8(13) 
N22 12.6(16) 34(3) 44(3) 8(2) -3.3(17) -5.1(17) 
N23 23.5(19) 39(3) 41(3) 2(2) -7.1(18) -8.2(17) 
C21 29(2) 19(3) 36(3) 5(2) -10(2) -1.9(18) 
C22 13.4(17) 22(3) 31(3) 7(2) -3.7(17) -1.6(16) 
C23 10(3) 16(5) 43(6) 4.9(19) 1(3) 0(14) 
C24 6(2) 27(3) 37(4) -1(3) -1(3) 2(17) 
C25 18(3) 30(3) 16(3) 5(2) 0(2) 6.9(18) 
C26 31(2) 25(3) 27(3) 3(2) -2.7(19) 1(19) 
C27 37(2) 26(3) 31(3) -5(2) 1(2) 10(2) 
C28 26(3) 36(3) 31(4) -2(3) 9(3) 15(3) 
C29 16.2(19) 19(3) 32(3) 4(2) 0.4(19) 0.4(17) 
C30 19(2) 17(2) 21(3) 2(2) 2.4(17) 7.6(15) 
C31 28(3) 23(4) 39(5) -5(2) 8(3) -1.3(17) 
C32 42(4) 41(5) 36(5) 7(2) 11(4) 0(2) 
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Table 4 Bond Lengths for 09srv155. 
Atom Atom Length/Å Atom Atom Length/Å 
S1 C2 1.769(4) S2 C22 1.761(4) 
S1 C11 1.837(9) S2 C31 1.791(8) 
F1 C1 1.356(6) F2 C21 1.330(6) 
O1 C9 1.397(5) O2 C24 1.319(7) 
O1 C4 1.398(7) O2 C29 1.406(5) 
N2 C4 1.298(7) N21 C23 1.360(7) 
N2 N3 1.367(6) N21 C30 1.379(6) 
N1 C3 1.351(7) N22 C24 1.318(7) 
N1 C10 1.392(6) N22 N23 1.356(6) 
N3 C1 1.300(6) N23 C21 1.303(6) 
C1 C2 1.396(6) C21 C22 1.406(6) 
C2 C3 1.365(8) C22 C23 1.395(8) 
C3 C4 1.420(9) C23 C24 1.434(9) 
C5 C6 1.363(8) C25 C30 1.347(7) 
C5 C10 1.430(7) C25 C26 1.407(8) 
C6 C7 1.388(6) C26 C27 1.389(6) 
C7 C8 1.383(8) C27 C28 1.392(8) 
C8 C9 1.366(8) C28 C29 1.365(8) 
C9 C10 1.395(6) C29 C30 1.407(6) 
C11 C12 1.529(14) C31 C32 1.487(13) 
 
Table 5 Bond Angles for 09srv155. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 S1 C11 99.5(3) C22 S2 C31 100.0(3) 
C9 O1 C4 118.5(4) C24 O2 C29 118.8(4) 
C4 N2 N3 117.3(4) C23 N21 C30 120.7(4) 
C3 N1 C10 121.0(4) C24 N22 N23 122.1(4) 
C1 N3 N2 117.8(4) C21 N23 N22 116.6(4) 
N3 C1 F1 114.9(4) N23 C21 F2 113.8(4) 
N3 C1 C2 126.9(5) N23 C21 C22 127.7(5) 
F1 C1 C2 118.2(4) F2 C21 C22 118.5(5) 
C3 C2 C1 116.3(5) C23 C22 C21 114.3(4) 
C3 C2 S1 120.9(4) C23 C22 S2 122.6(4) 
C1 C2 S1 122.8(4) C21 C22 S2 122.9(4) 
N1 C3 C2 126.1(6) N21 C23 C22 123.6(6) 
N1 C3 C4 119.6(6) N21 C23 C24 118.7(6) 
C2 C3 C4 114.3(5) C22 C23 C24 117.7(5) 
N2 C4 O1 112.1(5) N22 C24 O2 116.5(5) 
N2 C4 C3 127.4(6) N22 C24 C23 121.4(6) 
O1 C4 C3 120.4(5) O2 C24 C23 122.2(5) 
C6 C5 C10 119.2(5) C30 C25 C26 122.0(5) 
C5 C6 C7 121.3(5) C27 C26 C25 118.7(5) 
C8 C7 C6 119.7(5) C26 C27 C28 119.8(5) 
C9 C8 C7 120.2(5) C29 C28 C27 119.5(5) 
C8 C9 C10 121.3(4) C28 C29 O2 117.8(4) 
C8 C9 O1 118.3(4) C28 C29 C30 121.8(4) 
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C10 C9 O1 120.3(4) O2 C29 C30 120.4(4) 
N1 C10 C9 119.9(4) C25 C30 N21 122.7(4) 
N1 C10 C5 121.8(4) C25 C30 C29 118.0(5) 
C9 C10 C5 118.2(5) N21 C30 C29 119.2(4) 
C12 C11 S1 113.5(5) C32 C31 S2 114.3(4) 
 
Table 6 Hydrogen Bonds for 09srv155.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
N1 H1N N2 0.86(4) 2.15(4) 2.983(5) 163(4) 
N21 H2N N22 0.78(5) 2.25(5) 2.997(5) 158(6) 
 
Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for 09srv155.  
Atom x y z U(eq) 
H5A 7394 4841 3160 29 
H6A 6974 1639 2730 36 
H7A 5305 1500 2440 40 
H8A 3984 4389 2627 36 
H11A 6569 8115 4252 53 
H11B 7348 9690 4526 53 
H12A 5075 9777 4576 99 
H12B 5833 11481 4841 99 
H12C 5850 8417 4877 99 
H1N 6730(3) 8740(9) 3496(13) 21(11) 
H25A 4792 10238 6500 25 
H26A 4475 13315 6977 33 
H27A 2780 13547 7258 38 
H28A 1461 10586 7081 37 
H31A 4083 6813 5467 36 
H31B 4869 5236 5196 36 
H32B 3419 6665 4850 59 
H32C 2624 5207 5133 59 
H32A 3405 3593 4864 59 
H2N 4140(4) 6400(11) 6184(16) 48(16) 
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A.4) 4-Ethylsulfanyl-3-fluoro-8-methyl-1,2,4b,9-tetraaza-fluorene 43 
 
Table 1 Crystal data and structure refinement for s125  
Identification code  s125 
Empirical formula  C12H11N4SF 
Formula weight  262.31 
Temperature  120(2) 
Crystal system  Monoclinic 
Space group  P21/c 
a/Å, b/Å, c/Å  3.91740(10), 16.8084(2), 17.1269(2) 
α/°, β/°, γ/°,  90.00, 92.580(10), 90.00 
Volume/Å3  1126.58(3) 
Z  4 
ρcalcmg/mm3  1.547 
m/mm-1  0.286 
F(000)  544 
Crystal size  0.42 × 0.22 × 0.16 
Theta range for data collection  1.70 to 29.49° 
Index ranges  -5 ≤ h ≤ 5, -23 ≤ k ≤ 23, -23 ≤ l ≤ 23 
Reflections collected  15223 
Independent reflections  3149[R(int) = 0.0487] 
Data/restraints/parameters  3149/0/207 
Goodness-of-fit on F2  1.069 
Final R indexes [I>2σ (I)]  R1 = 0.0340, wR2 = 0.1121 
Final R indexes [all data]  R1 = 0.0372, wR2 = 0.1154 
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Largest diff. peak/hole  0.473/-0.271 
 
Table 2 Atomic Coordinates (Å×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for s125. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
S1 4800.4(7) 9260.61(15) 1188.52(14) 18.33(11) 
F1 3010.7(19) 9186.9(4) 2892.2(4) 23.84(18) 
N1 5038(3) 7981.5(6) 3202.9(5) 20.9(2) 
N2 6493(3) 7282.2(6) 3041.4(5) 20.8(2) 
N3 9018(2) 6511(6) 2041.9(5) 18.5(2) 
N4 8539(2) 7444.6(5) 1070.8(5) 15.13(19) 
C1 7473(3) 7185.3(6) 2311.2(6) 17.2(2) 
C2 7108(3) 7776.8(6) 1717.5(6) 15.4(2) 
C3 5591(3) 8502.2(6) 1876.2(6) 16(2) 
C4 4615(3) 8527.2(6) 2654.2(6) 18.1(2) 
C5 9633(3) 6679.6(6) 1303.7(6) 16(2) 
C6 11249(3) 6188.8(6) 749.5(6) 17.4(2) 
C7 11702(3) 6499.7(6) 22.1(6) 18.7(2) 
C8 10610(3) 7284(7) -187.4(6) 19.5(2) 
C9 9025(3) 7748.4(6) 331.6(6) 17.4(2) 
C10 12374(3) 5373.3(7) 1003.7(7) 22(2) 
C11 6482(3) 10150.9(6) 1689.9(6) 19.8(2) 
C12 7578(3) 10735.4(7) 1074.6(7) 23.3(2) 
 
Table 3 Anisotropic Displacement Parameters (Å2×103) for s125. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12
S1 21.8(17) 15.88(17) 17.09(16) -1.03(8) -1.51(11) 1.85(9) 
F1 26.7(4) 22.6(3) 22.7(3) -5.2(2) 7(3) 3.9(3) 
N1 23.4(5) 22.3(5) 17.2(4) -0.8(3) 4.4(3) -1.7(4) 
N2 25(5) 20.2(4) 17.4(4) 0.2(3) 3.4(3) -0.7(4) 
N3 21(4) 17.4(4) 17.2(4) 1.2(3) 1.6(3) -0.6(3) 
N4 16.8(4) 14.4(4) 14.2(4) -0.6(3) 1(3) -0.2(3) 
C1 18.3(5) 16.9(5) 16.3(5) 1.3(4) 0.3(4) -2.9(4) 
C2 15.5(4) 16.8(5) 14.1(4) -0.7(3) 1.1(3) -2.2(4) 
C3 16.4(4) 16.2(5) 15.6(4) -1.2(3) 0.9(3) -1.3(4) 
C4 18.6(5) 18(5) 17.9(5) -3.4(4) 3.1(4) -1.1(4) 
C5 16.3(4) 14.3(4) 17.3(4) 1.2(3) -0.6(4) -1(3) 
C6 17.7(5) 15.7(4) 18.8(5) -0.8(4) 1.7(4) -0.3(4) 
C7 20.1(5) 17.9(5) 18.3(5) -2.2(4) 3.2(4) 0.3(4) 
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C8 23.2(5) 19.5(5) 16.1(4) 0.3(4) 3(4) -0.4(4) 
C9 20.6(5) 17.5(5) 14.2(4) 1.6(3) 1.4(4) 0.4(4) 
C10 25(5) 16.3(5) 25(5) 1.4(4) 4.4(4) 4(4) 
C11 24.2(5) 16.2(5) 19(5) -1.8(4) 0.4(4) -0.2(4) 
C12 27.3(6) 18.2(5) 24.4(5) 2.1(4) 0.6(5) -0.1(4) 
 
Table 4 Bond Lengths for s125. 
Atom Atom Length/Å Atom Atom Length/Å 
S1 C3 1.7536(11) N4 C5 1.4073(13) 
S1 C11 1.8330(11) C1 C2 1.4247(14) 
F1 C4 1.3467(12) C2 C3 1.3887(14) 
N1 C4 1.3184(14) C3 C4 1.4033(14) 
N1 N2 1.3408(13) C5 C6 1.4270(14) 
N2 C1 1.3346(13) C6 C7 1.3698(15) 
N3 C5 1.3284(13) C6 C10 1.4985(15) 
N3 C1 1.3742(14) C7 C8 1.4268(15) 
N4 C2 1.3815(12) C8 C9 1.3545(15) 
N4 C9 1.3861(12) C11 C12 1.5169(16) 
 
Table 5 Bond Angles for s125. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C3 S1 C11 103.29(5) C4 C3 S1 124.64(8) 
C4 N1 N2 120.26(9) N1 C4 F1 113.73(9) 
C1 N2 N1 116.31(9) N1 C4 C3 128.70(10) 
C5 N3 C1 104.18(9) F1 C4 C3 117.58(9) 
C2 N4 C9 131.35(9) N3 C5 N4 113.50(9) 
C2 N4 C5 105.74(8) N3 C5 C6 127.93(10) 
C9 N4 C5 122.88(8) N4 C5 C6 118.57(9) 
N2 C1 N3 124.38(10) C7 C6 C5 117.64(9) 
N2 C1 C2 124.05(10) C7 C6 C10 124.38(10) 
N3 C1 C2 111.57(9) C5 C6 C10 117.98(9) 
N4 C2 C3 134.78(9) C6 C7 C8 122.11(10) 
N4 C2 C1 105.01(9) C9 C8 C7 120.56(10) 
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C3 C2 C1 120.21(9) C8 C9 N4 118.23(10) 
C2 C3 C4 110.45(9) C12 C11 S1 108.07(8) 
C2 C3 S1 124.83(8)     
 
Table 6 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for s125.  
Atom x y z U(eq) 
H7 12810(4) 6177(9) -359(8) 24(4) 
H8 10950(4) 7474(9) -705(8) 18(3) 
H9 8210(3) 8272(9) 247(8) 16(3) 
H101 14240(5) 5429(11) 1422(11) 39(4) 
H102 10420(4) 5052(10) 1181(9) 27(4) 
H103 13240(6) 5081(12) 585(13) 51(5) 
H111 4620(4) 10356(9) 2018(8) 19(3) 
H112 8350(4) 9997(9) 2010(9) 22(4) 
H121 8650(5) 11215(10) 1329(10) 38(4) 
H122 5530(6) 10958(11) 747(12) 48(5) 
H123 9140(4) 10486(11) 719(10) 31(4) 
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A.5) 2,3,4-Tribromo-5-methylthiophene 53 
 
Table 1: Crystal data and structure refinement for 10srv123  
Identification code  10srv123 
Empirical formula  C5H3SBr3
Formula weight  334.86 
Temperature / K  120 
Crystal system  Monoclinic 
Space group  P21/c 
a / Å, b / Å, c / Å  15.5475(5), 3.97300(10), 13.8532(5) 
α/°, β/°, γ/°  90.00, 111.420(10), 90.00 
Volume / Å3  796.61(4) 
Z  4 
ρcalc / mg mm-3  2.792 
μ / mm‑1  15.361 
F(000)  616 
Crystal size / mm3  0.37 × 0.12 × 0.05 
Theta range for data collection  1.41 to 30.48° 
Index ranges  -22 ≤ h ≤ 22, -5 ≤ k ≤ 5, -19 ≤ l ≤ 19 
Reflections collected  10157 
Independent reflections  2430[R(int) = 0.0332] 
Data/restraints/parameters  2430/2/90 
Goodness-of-fit on F2  1.066 
Final R indexes [I>2σ (I)]  R1 = 0.0226, wR2 = 0.0468 
Final R indexes [all data]  R1 = 0.0313, wR2 = 0.0493 
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Largest diff. peak/hole / e Å-3  0.540/-0.628 
 
Table 2 Atomic Coordinates (Å×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for 10srv123. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
Br1 1116.5(8) 1848(4) 98.0(7) 21.11(19) 
Br1A 4775.2(3) 1196.1(19) 3634.1(5) 18.54(11) 
Br2 880.92(16) -2020.1(6) 2285.99(19) 19.29(7) 
Br3 3016.47(16) -2486.7(5) 4327.78(17) 17.62(6) 
S1 3161.4(4) 2221.1(14) 1537.9(4) 15.27(11) 
C1 2038.2(15) 1048(5) 1331.1(17) 15.8(4) 
C2 1987.2(15) -419(5) 2192.6(17) 15.5(4) 
C3 2854.4(15) -612(5) 3030.5(16) 14.1(4) 
C4 3555.7(15) 726(5) 2795.0(17) 15.4(4) 
C5 4577(6) 1110.0(4) 3509(11) 20 
C5A 1260(6) 1760.0(2) 284(6) 20 
 
Table 3 Anisotropic Displacement Parameters (Å2×103) for 10srv123. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12
Br1 17.2(5) 27.2(3) 16.1(5) 2.4(4) 2.7(3) 1.5(4) 
Br1A 13.2(2) 25.2(2) 15.8(2) 0.21(18) 3.6(2) -1.5(2) 
Br2 15.21(12) 20.91(11) 24.51(13) -0.19(9) 10.52(10) -1.74(8) 
Br3 22.02(13) 18.88(11) 14.10(11) 1.58(8) 9.12(10) -0.51(9) 
S1 15.6(3) 17.7(3) 13.8(3) 0.7(2) 6.9(2) -1.5(2) 
C1 13.4(10) 16.4(10) 18.1(11) -0.4(9) 6.3(9) -0.1(8) 
C2 13.6(10) 17.3(10) 17.6(11) -3.1(8) 8.0(9) -1.8(8) 
C3 18.3(11) 12.7(9) 13(1) -1.2(8) 7.8(9) -0.2(8) 
C4 15.0(11) 16.7(10) 14.1(10) -0.5(8) 5.0(9) 0.5(8) 
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Table 4 Bond Lengths for 10srv123. 
Atom Atom Length/Å Atom Atom Length/Å 
Br1 C1 1.812(2) C1 C2 1.356(3) 
Br1A C4 1.836(2) C1 C5A 1.538(7) 
Br2 C2 1.882(2) C2 C3 1.424(3) 
Br3 C3 1.876(2) C3 C4 1.356(3) 
S1 C1 1.727(2) C4 C5 1.542(9) 
S1 C4 1.727(2)    
 
Table 5 Bond Angles for 10srv123. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
S1 C1 Br1 120.83(13) C3 C4 S1 110.92(17) 
S1 C4 Br1A 120.51(13) C3 C4 C5 128.0(6) 
C1 C2 Br2 123.66(18) C4 S1 C1 92.27(11) 
C1 C2 C3 113.5(2) C4 C3 Br3 123.23(17) 
C2 C1 Br1 128.65(18) C4 C3 C2 112.84(19) 
C2 C1 S1 110.51(17) C5 C4 Br1A 0.6(6) 
C2 C1 C5A 129.0(4) C5 C4 S1 121.1(6) 
C2 C3 Br3 123.94(16) C5A C1 Br1 0.5(4) 
C3 C2 Br2 122.88(16) C5A C1 S1 120.4(4) 
C3 C4 Br1A 128.53(18)     
 
Table 6 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for 10srv123.  
Atom x y z U(eq) 
H5C 4800 -1015 3875 30 
H5B 4635 2902 4014 30 
H5A 4947 1678 3091 30 
H5AA 759 2980 401 30 
H5AB 1022 -377 -67 30 
H5AC 1502 3119 -150 30 
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